Compositions and methods for ovarian cancer therapy and diagnosis

Abstract

Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.

Description

TECHNICAL FIELD

The present invention relates generally to ovarian cancer therapy. The invention is more specifically related to polypeptides comprising at least a portion of an ovarian carcinoma protein, and to polynucleotides encoding such polypeptides, as well as antibodies and immune system cells that specifically recognize such polypeptides. Such polypeptides, polynucleotides, antibodies and cells may be used in vaccines and pharmaceutical compositions for treatment of ovarian cancer.

BACKGROUND OF THE INVENTION

Ovarian cancer is a significant health problem for women in the United States and throughout the world. Although advances have been made in detection and therapy of this cancer, no vaccine or other universally successful method for prevention or treatment is currently available. Management of the disease currently relies on a combination of early diagnosis and aggressive treatment, which may include one or more of a variety of treatments such as surgery, radiotherapy, chemotherapy and hormone therapy. The course of treatment for a particular cancer is often selected based on a variety of prognostic parameters, including an analysis of specific tumor markers. However, the use of established markers often leads to a result that is difficult to interpret, and high mortality continues to be observed in many cancer patients.

Immunotherapies have the potential to substantially improve cancer treatment and survival. Such therapies may involve the generation or enhancement of an immune response to an ovarian carcinoma antigen. However, to date, relatively few ovarian carcinoma antigens are known and the generation of an immune response against such antigens has not been shown to be therapeutically beneficial.

Accordingly, there is a need in the art for improved methods for identifying ovarian tumor antigens and for using such antigens in the therapy of ovarian cancer. The present invention fulfills these needs and further provides other related advantages.

SUMMARY OF THE INVENTION

Briefly stated, this invention provides compositions and methods for the therapy of cancer, such as ovarian cancer. In one aspect, the present invention provides polypeptides comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished. Within certain embodiments, the ovarian carcinoma protein comprises a sequence that is encoded by a polynucleotide sequence selected from the group consisting of sequences recited in FIGS. 5 , 8 , 13 , 16 A- 16 I and 17 A- 17 C (SEQ ID NOs:5, 8, 13, 19-68 and 69-85), SEQ ID NOs:130, 133, 135, 137, 138, 140, 142, 144-146, 148, 153, 155, 158, 159, 161, 163, 170, 174, 177, 178, 179, 180-182, 184, 187, 189, 190, 192, 195, 196, 198, 200, 207, 214-216, 220, 221, 222, 227, 228, 230, 231, 232, 234, 240-242, 243, 244-246, 250, 251, 253, 254, 256, 259, 261, 262, 264, 265, 272-275, 276, 278, 280, 281, 282, 283, 287, 288, 291, 292, 296, 297, 299, 301, 304-309, 311, 313, 314, 317, 323, 325 and 333, and complements of such polynucleotides.

The present invention further provides polynucleotides that encode a polypeptide as described above or a portion thereof, expression vectors comprising such polynucleotides and host cells transformed or transfected with such expression vectors.

Within other aspects, the present invention provides pharmaceutical compositions and vaccines. Pharmaceutical compositions may comprise a physiologically acceptable carrier in combination with one or more of: (i) a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence encoded by a polynucleotide that comprises a sequence recited in any one of FIGS. 5 , 8 , 13 , 16 A- 16 I and 17 A- 17 C (SEQ ID NOs: 5, 8, 13, 19-68 and 69-85), SEQ ID NOs:130, 133, 135, 137, 138, 140, 142, 144-146, 148, 153, 155, 158, 159, 161, 163, 170, 174, 177, 178, 179, 180-182, 184, 187, 189, 190, 192, 195, 196, 198, 200, 207, 214-216, 220, 221, 222, 227, 228, 230, 231, 232, 234, 240-242, 243, 244-246, 250, 251, 253, 254, 256, 259, 261, 262, 264, 265, 272-275, 276, 278, 280, 281, 282, 283, 287, 288, 291, 292, 296, 297, 299, 301, 304-309, 311, 313, 314, 317, 323, 325 or 333, or a complement of any of the foregoing sequences; (ii) a polynucleotide encoding at least 5 amino acid residues of such an ovarian carcinoma protein; (iii) an antibody that specifically binds to such an ovarian carcinoma protein; (iv) an antigen-presenting cell that expresses a polypeptide as described above and/or (v) a T cell that specifically reacts with such a polypeptide. Vaccines may comprise a non-specific immune response enhancer in combination with one or more of: (i) a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence encoded by a polynucleotide that comprises a sequence recited in any one of FIGS. 5 , 8 , 13 , 16 A- 16 I and 17 A- 17 C (SEQ ID NOs: 5, 8, 13, 19-68 and 69-85), SEQ ID NOs:130, 133, 135, 137, 138, 140, 142, 144-146, 148, 153, 155, 158, 159, 161, 163, 170, 174, 177, 178, 179, 180-182, 184, 187, 189, 190, 192, 195, 196, 198, 200, 207, 214-216, 220, 221, 222, 227, 228, 230, 231, 232, 234, 240-242, 243, 244-246, 250, 251, 253, 254, 256, 259, 261, 262, 264, 265, 272-275, 276, 278, 280, 281, 282, 283, 287, 288, 291, 292, 296, 297, 299, 301, 304-309, 311, 313, 314, 317, 323, 325 or 333, or a complement of any of the foregoing sequences; (ii) a polynucleotide encoding at least 5 amino acid residues of such an ovarian carcinoma protein; (iii) an anti-idiotypic antibody that is specifically bound by an antibody that specifically binds to such a polypeptide; (iv) an antigen-presenting cell that expresses such a polypeptide and/or (v) a T cell that specifically reacts with such a polypeptide.

The present invention further provides, in other aspects, fusion proteins that comprise at least one polypeptide as described above, as well as polynucleotides encoding such fusion proteins.

Within related aspects, pharmaceutical compositions comprising a fusion protein or polynucleotide encoding a fusion protein in combination with a physiologically acceptable carrier are provided.

Vaccines are further provided, within other aspects, comprising a fusion protein or polynucleotide encoding a fusion protein in combination with a non-specific immune response enhancer.

Within further aspects, the present invention provides methods for inhibiting the development of a cancer in a patient, comprising administering to a patient a pharmaceutical composition or vaccine as recited above.

The present invention further provides, within other aspects, methods for stimulating and/or expanding T cells, comprising contacting T cells with (a) a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence encoded by a polynucleotide that comprises a sequence recited in any one of SEQ ID NOs: 1-334; (b) a polynucleotide encoding such a polypeptide and/or (c) an antigen presenting cell that expresses such a polypeptide under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. Such polypeptide, polynucleotide and/or antigen presenting cell(s) may be present within a pharmaceutical composition or vaccine, for use in stimulating and/or expanding T cells in a mammal.

Within other aspects, the present invention provides methods for inhibiting the development of ovarian cancer in a patient, comprising administering to a patient T cells prepared as described above.

Within further aspects, the present invention provides methods for inhibiting the development of ovarian cancer in a patient, comprising the steps of: (a) incubating CD4 + and/or CD8 + T cells isolated from a patient with one or more of: (i) a polypeptide comprising an immunogenic portion of an ovarian carcinoma protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with ovarian carcinoma protein-specific antisera is not substantially diminished, wherein the ovarian carcinoma protein comprises an amino acid sequence encoded by a polynucleotide that comprises a sequence recited in any one of SEQ ID NOs:1-334; (ii) a polynucleotide encoding such a polypeptide; or (iii) an antigen-presenting cell that expresses such a polypeptide; such that T cells proliferate; and (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of ovarian cancer in the patient. The proliferated cells may be cloned prior to administration to the patient.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV2 (SEQ ID NO:1), and the amino acid sequence of the encoded polypeptide (SEQ ID NO:16).

FIG. 2 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV3 (SEQ ID NO:2), and the amino acid sequence of the encoded polypeptide (SEQ ID NO:17).

FIG. 3 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV6 (SEQ ID NO:3), and the amino acid sequence of the encoded polypeptide (SEQ ID NO:18).

FIG. 4 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV9 (SEQ ID NO:4).

FIG. 5 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV10 (SEQ ID NO:5).

FIG. 6 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV12 (SEQ ID NO:6).

FIG. 7 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV14 (SEQ ID NO:7).

FIG. 8 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV17 (SEQ ID NO:8).

FIG. 9 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV18 (SEQ ID NO:9).

FIG. 10 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV23 (SEQ ID NO:10).

FIG. 11 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV24 (SEQ ID NO:11).

FIG. 12 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV27 (SEQ ID NO:12).

FIG. 13 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV41 (SEQ ID NO:13).

FIG. 14 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV54 (SEQ ID NO:14).

FIG. 15 depicts a partial sequence of a polynucleotide encoding a ovarian carcinoma antigen designated OV57 (SEQ ID NO:15).

FIGS. 16A-16I depict partial sequences of polynucleotides (SEQ ID NOs: 19-68) encoding further representative ovarian carcinoma antigens.

FIGS. 17A-17C depict partial sequences of polynucleotides (SEQ ID NOs: 69-85) encoding further representative ovarian carcinoma antigens.

FIGS. 18A-18F depict partial sequences of polynucleotides (SEQ ID NOs: 86-129) encoding further representative ovarian carcinoma antigens.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for the detection and therapy of cancer, such as ovarian cancer. The compositions described herein may include immunogenic polypeptides, polynucleotides encoding such polypeptides, binding agents such as antibodies that bind to a polypeptide, antigen presenting cells (APCs) and/or immune system cells (e.g., T cells).

Polypeptides of the present invention generally comprise at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof. Certain ovarian carcinoma proteins have been identified using an immunoassay technique, and are referred to herein as ovarian carcinoma antigens. An “ovarian carcinoma antigen” is a protein that is expressed by ovarian tumor cells (preferably human cells) at a level that is at least two fold higher than the level in normal ovarian cells. Certain ovarian carcinoma antigens react detectably (within an immunoassay, such as an ELISA or Western blot) with antisera generated against serum from an immunodeficient animal implanted with a human ovarian tumor. Such ovarian carcinoma antigens are shed or secreted from an ovarian tumor into the sera of the immunodeficient animal. Accordingly, certain ovarian carcinoma antigens provided herein are secreted antigens. Certain nucleic acid sequences of the subject invention generally comprise a DNA or RNA sequence that encodes all or a portion of such a polypeptide, or that is complementary to such a sequence.

The present invention further provides ovarian carcinoma sequences that are identified using techniques to evaluate altered expression within an ovarian tumor. Such sequences may be polynucleotide or protein sequences. Ovarian carcinoma sequences are generally expressed in an ovarian tumor at a level that is at least two fold, and preferably at least five fold, greater than the level of expression in normal ovarian tissue, as determined using a representative assay provided herein. Certain partial ovarian carcinoma polynucleotide sequences are presented herein. Proteins encoded by genes comprising such polynucleotide sequences (or complements thereof) are also considered ovarian carcinoma proteins.

Antibodies are generally immune system proteins, or antigen-binding fragments thereof, that are capable of binding to at least a portion of an ovarian carcinoma polypeptide as described herein. T cells that may be employed within the compositions provided herein are generally T cells (e.g., CD4 + and/or CD8 + ) that are specific for such a polypeptide. Certain methods described herein further employ antigen-presenting cells (such as dendritic cells or macrophages) that express an ovarian carcinoma polypeptide as provided herein.

Ovarian Carcinoma Polynucleotides

Any polynucleotide that encodes an ovarian carcinoma protein or a portion or other variant thereof as described herein is encompassed by the present invention. Preferred polynucleotides comprise at least 15 consecutive nucleotides, preferably at least 30 consecutive nucleotides, and more preferably at least 45 consecutive nucleotides, that encode a portion of an ovarian carcinoma protein. More preferably, a polynucleotide encodes an immunogenic portion of an ovarian carcinoma protein, such as an ovarian carcinoma antigen. Polynucleotides complementary to any such sequences are also encompassed by the present invention. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present invention, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.

Polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes an ovarian carcinoma protein or a portion thereof) or may comprise a variant of such a sequence. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the immunogenicity of the encoded polypeptide is not diminished, relative to a native ovarian carcinoma protein. The effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein. Variants preferably exhibit at least about 70% identity, more preferably at least about 80% identity and most preferably at least about 90% identity to a polynucleotide sequence that encodes a native ovarian carcinoma protein or a portion thereof.

The percent identity for two polynucleotide or polypeptide sequences may be readily determined by comparing sequences using computer algorithms well known to those of ordinary skill in the art, such as Megalign, using default parameters. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, or 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Optimal alignment of sequences for comparison may be conducted, for example, using the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, Wis.), using default parameters. Preferably, the percentage of sequence identity is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the window may comprise additions or deletions (i.e., gaps) of 20% or less, usually 5 to 15%, or 10 to 12%, relative to the reference sequence (which does not contain additions or deletions). The percent identity may be calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.

Variants may also, or alternatively, be substantially homologous to a native gene, or a portion or complement thereof. Such polynucleotide variants are capable of hybridizing under moderately stringent conditions to a naturally occurring DNA sequence encoding a native ovarian carcinoma protein (or a complementary sequence). Suitable moderately stringent conditions include prewashing in a solution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C.-65° C., 5×SSC, overnight; followed by washing twice at 65° C. for 20 minutes with each of 2×, 0.5× and 0.2×SSC containing 0.1% SDS.

It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present invention. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).

Polynucleotides may be prepared using any of a variety of techniques. For example, an ovarian carcinoma polynucleotide may be identified, as described in more detail below, by screening a late passage ovarian tumor expression library with antisera generated against sera of immunocompetent mice after injection of such mice with sera from SCID mice implanted with late passage ovarian tumors. Ovarian carcinoma polynucleotides may also be identified using any of a variety of techniques designed to evaluate differential gene expression. Alternatively, polynucleotides may be amplified from cDNA prepared from ovarian tumor cells. Such polynucleotides may be amplified via polymerase chain reaction (PCR). For this approach, sequence-specific primers may be designed based on the sequences provided herein, and may be purchased or synthesized.

An amplified portion may be used to isolate a full length gene from a suitable library (e.g., an ovarian carcinoma cDNA library) using well known techniques. Within such techniques, a library (cDNA or genomic) is screened using one or more polynucleotide probes or primers suitable for amplification. Preferably, a library is size-selected to include larger molecules. Random primed libraries may also be preferred for identifying 5′ and upstream regions of genes. Genomic libraries are preferred for obtaining introns and extending 5′ sequences.

For hybridization techniques, a partial sequence may be labeled (e.g., by nick-translation or end-labeling with 32 P) using well known techniques. A bacterial or bacteriophage library is then screened by hybridizing filters containing denatured bacterial colonies (or lawns containing phage plaques) with the labeled probe (see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989). Hybridizing colonies or plaques are selected and expanded, and the DNA is isolated for further analysis. cDNA clones may be analyzed to determine the amount of additional sequence by, for example, PCR using a primer from the partial sequence and a primer from the vector. Restriction maps and partial sequences may be generated to identify one or more overlapping clones. The complete sequence may then be determined using standard techniques, which may involve generating a series of deletion clones. The resulting overlapping sequences are then assembled into a single contiguous sequence. A full length cDNA molecule can be generated by ligating suitable fragments, using well known techniques.

Alternatively, there are numerous amplification techniques for obtaining a full length coding sequence from a partial cDNA sequence. Within such techniques, amplification is generally performed via PCR. Any of a variety of commercially available kits may be used to perform the amplification step. Primers may be designed using, for example, software well known in the art. Primers are preferably 22-30 nucleotides in length, have a GC content of at least 50% and anneal to the target sequence at temperatures of about 68° C. to 72° C. The amplified region may be sequenced as described above, and overlapping sequences assembled into a contiguous sequence.

One such amplification technique is inverse PCR (see Triglia et al., Nucl. Acids Res. 16:8186, 1988), which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591. Additional techniques include capture PCR (Lagerstrom et al., PCR Methods Applic. 1:111-19, 1991) and walking PCR (Parker et al., Nucl Acids. Res. 19:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (e.g., NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence.

Certain nucleic acid sequences of cDNA molecules encoding portions of ovarian carcinoma proteins are provided in FIGS. 1-15 , 16 A- 16 I, 17 A- 17 C and 18 A- 18 F (SEQ ID NOs:1-15, 19-68, 69-85 and 86-129). Other such nucleic acid sequences are provided in SEQ ID NOs:130-334. These polynucleotides were isolated by serological screening of an ovarian tumor cDNA expression library. The library was prepared from unamplified cDNA derived from a human ovarian tumor OV9334 grown in a SCID mouse, in the vector pScreen. Sera from human patients with ovarian cancer were pooled for the screen.

The polynucleotides recited herein, as well as full length polynucleotides comprising such sequences, other portions of such full length polynucleotides, and sequences complementary to all or a portion of such full length molecules, are specifically encompassed by the present invention. It will be apparent to those of ordinary skill in the art that this technique can also be applied to the identification of antigens that are secreted from other types of tumors.

Any of a variety of well known techniques may be used to evaluate tumor-associated expression of a cDNA. For example, hybridization techniques using labeled polynucleotide probes may be employed. Alternatively, or in addition, amplification techniques such as real-time PCR may be used (see Gibson et al., Genome Research 6:995-1001, 1996; Heid et al., Genome Research 6:986-994, 1996). Real-time PCR is a technique that evaluates the level of PCR product accumulation during amplification. This technique permits quantitative evaluation of mRNA levels in multiple samples. Briefly, mRNA is extracted from tumor and normal tissue and cDNA is prepared using standard techniques. Real-time PCR may be performed, for example, using a Perkin Elmer/Applied Biosystems (Foster City, Calif.) 7700 Prism instrument. Matching primers and fluorescent probes may be designed for genes of interest using, for example, the primer express program provided by Perkin Elmer/Applied Biosystems (Foster City, Calif.). Optimal concentrations of primers and probes may be initially determined by those of ordinary skill in the art, and control (e.g., β-actin) primers and probes may be obtained commercially from, for example, Perkin Elmer/Applied Biosystems (Foster City, Calif.). To quantitate the amount of specific RNA in a sample, a standard curve is generated alongside using a plasmid containing the gene of interest. Standard curves may be generated using the Ct values determined in the real-time PCR, which are related to the initial cDNA concentration used in the assay. Standard dilutions ranging from 10-10 6 copies of the gene of interest are generally sufficient. In addition, a standard curve is generated for the control sequence. This permits standardization of initial RNA content of a tissue sample to the amount of control for comparison purposes.

Polynucleotide variants may generally be prepared by any method known in the art, including chemical synthesis by, for example, solid phase phosphoramidite chemical synthesis. Modifications in a polynucleotide sequence may also be introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis (see Adelman et al., DNA 2:183, 1983). Alternatively, RNA molecules may be generated by in vitro or in vivo transcription of DNA sequences encoding an ovarian carcinoma antigen, or portion thereof, provided that the DNA is incorporated into a vector with a suitable RNA polymerase promoter (such as T7 or SP6). Certain portions may be used to prepare an encoded polypeptide, as described herein. In addition, or alternatively, a portion may be administered to a patient such that the encoded polypeptide is generated in vivo.

A portion of a sequence complementary to a coding sequence (i.e., an antisense polynucleotide) may also be used as a probe or to modulate gene expression. cDNA constructs that can be transcribed into antisense RNA may also be introduced into cells or tissues to facilitate the production of antisense RNA. An antisense polynucleotide may be used, as described herein, to inhibit expression of an ovarian carcinoma protein. Antisense technology can be used to control gene expression through triple-helix formation, which compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules (see Gee et al., In Huber and Carr, Molecular and Immunologic Approaches, Futura Publishing Co. (Mt. Kisco, N.Y.; 1994). Alternatively, an antisense molecule may be designed to hybridize with a control region of a gene (e.g., promoter, enhancer or transcription initiation site), and block transcription of the gene; or to block translation by inhibiting binding of a transcript to ribosomes.

Any polynucleotide may be further modified to increase stability in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends; the use of phosphorothioate or 2′ O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

Nucleotide sequences as described herein may be joined to a variety of other nucleotide sequences using established recombinant DNA techniques. For example, a polynucleotide may be cloned into any of a variety of cloning vectors, including plasmids, phagemids, lambda phage derivatives and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors. In general, a vector will contain an origin of replication functional in at least one organism, convenient restriction endonuclease sites and one or more selectable markers. Other elements will depend upon the desired use, and will be apparent to those of ordinary skill in the art.

Within certain embodiments, polynucleotides may be formulated so as to permit entry into a cell of a mammal, and expression therein. Such formulations are particularly useful for therapeutic purposes, as described below. Those of ordinary skill in the art will appreciate that there are many ways to achieve expression of a polynucleotide in a target cell, and any suitable method may be employed. For example, a polynucleotide may be incorporated into a viral vector such as, but not limited to, adenovirus, adeno-associated virus, retrovirus, or vaccinia or other pox virus (e.g., avian pox virus). Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a targeting moiety, such as a gene that encodes a ligand for a receptor on a specific target cell, to render the vector target specific. Targeting may also be accomplished using an antibody, by methods known to those of ordinary skill in the art.

Other formulations for therapeutic purposes include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (i.e., an artificial membrane vesicle). The preparation and use of such systems is well known in the art.

Ovarian Carcinoma Polypeptides

Within the context of the present invention, polypeptides may comprise at least an immunogenic portion of an ovarian carcinoma protein or a variant thereof, as described herein. Certain ovarian carcinoma proteins are ovarian carcinoma antigens that are expressed by ovarian tumor cells and react detectably within an immunoassay (such as an ELISA) with antisera generated against serum from an immunodeficient animal implanted with an ovarian tumor. Other ovarian carcinoma proteins are encoded by ovarian carcinoma polynucleotides recited herein. Polypeptides as described herein may be of any length. Additional sequences derived from the native protein and/or heterologous sequences may be present, and such sequences may (but need not) possess further immunogenic or antigenic properties.

An “immunogenic portion,” as used herein is a portion of an antigen that is recognized (i.e., specifically bound) by a B-cell and/or T-cell surface antigen receptor. Such immunogenic portions generally comprise at least 5 amino acid residues, more preferably at least 10, and still more preferably at least 20 amino acid residues of an ovarian carcinoma protein or a variant thereof. Preferred immunogenic portions are encoded by cDNA molecules isolated as described herein. Further immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with ovarian carcinoma protein-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are “ovarian carcinoma protein-specific” if they specifically bind to an ovarian carcinoma protein (i.e., they react with the ovarian carcinoma protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera, antibodies and T cells may be prepared as described herein, and using well known techniques. An immunogenic portion of a native ovarian carcinoma protein is a portion that reacts with such antisera, antibodies and/or T-cells at a level that is not substantially less than the reactivity of the full length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Such immunogenic portions may react within such assays at a level that is similar to or greater than the reactivity of the full length protein. Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. For example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, 125 I-labeled Protein A.

As noted above, a composition may comprise a variant of a native ovarian carcinoma protein. A polypeptide “variant,” as used herein, is a polypeptide that differs from a native ovarian carcinoma protein in one or more substitutions, deletions, additions and/or insertions, such that the immunogenicity of the polypeptide is not substantially diminished. In other words, the ability of a variant to react with ovarian carcinoma protein-specific antisera may be enhanced or unchanged, relative to the native ovarian carcinoma protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native ovarian carcinoma protein. Such variants may generally be identified by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with ovarian carcinoma protein-specific antibodies or antisera as described herein. Preferred variants include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other preferred variants include variants in which a small portion (e.g. 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% identity to the native polypeptide. Preferably, a variant contains conservative substitutions. A “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. Amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydropathic nature of the polypeptide.

As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

Polypeptides may be prepared using any of a variety of well known techniques. Recombinant polypeptides encoded by DNA sequences as described above may be readily prepared from the DNA sequences using any of a variety of expression vectors known to those of ordinary skill in the art. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are E. coli, yeast or a mammalian cell line such as COS or CHO. Supernatants from suitable host/vector systems which secrete recombinant protein or polypeptide into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix or an ion exchange resin. Finally, one or more reverse phase HPLC steps can be employed to further purify a recombinant polypeptide.

Portions and other variants having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, J Am. Chem. Soc. 85:2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Applied BioSystems, Inc. (Foster City, Calif.), and may be operated according to the manufacturer's instructions.

Within certain specific embodiments, a polypeptide may be a fusion protein that comprises multiple polypeptides as described herein, or that comprises one polypeptide as described herein and a known tumor antigen, such as an ovarian carcinoma protein or a variant of such a protein. A fusion partner may, for example, assist in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or may assist in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners are both immunological and expression enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, which facilitate purification of the protein.

Fusion proteins may generally be prepared using standard techniques, including chemical conjugation. Preferably, a fusion protein is expressed as a recombinant protein, allowing the production of increased levels, relative to a non-fused protein, in an expression system. Briefly, DNA sequences encoding the polypeptide components may be assembled separately, and ligated into an appropriate expression vector. The 3′ end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5′ end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in phase. This permits translation into a single fusion protein that retains the biological activity of both component polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Pat. Nos. 4,935,233 and 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5′ to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3′ to the DNA sequence encoding the second polypeptide.

Fusion proteins are also provided that comprise a polypeptide of the present invention together with an unrelated immunogenic protein. Preferably the immunogenic protein is capable of eliciting a recall response. Examples of such proteins include tetanus, tuberculosis and hepatitis proteins (see, for example, Stoute et al. New Engl. J. Med., 336:86-91, 1997).

Within preferred embodiments, an immunological fusion partner is derived from protein D, a surface protein of the gram-negative bacterium Haemophilus influenza B (WO 91/18926). Preferably, a protein D derivative comprises approximately the first third of the protein (e.g., the first N-terminal 100-110 amino acids), and a protein D derivative may be lipidated. Within certain preferred embodiments, the first 109 residues of a Lipoprotein D fusion partner is included on the N-terminus to provide the polypeptide with additional exogenous T-cell epitopes and to increase the expression level in E. coli (thus functioning as an expression enhancer). The lipid tail ensures optimal presentation of the antigen to antigen present cells. Other fusion partners include the non-structural protein from influenzae virus, NS1 (hemaglutinin). Typically, the N-terminal 81 amino acids are used, although different fragments that include T-helper epitopes may be used.

In another embodiment, the immunological fusion partner is the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from Streptococcus pneumoniae, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytA gene; Gene 43:265-292, 1986). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E. coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see Biotechnology 10:795-798, 1992). Within a preferred embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A particularly preferred repeat portion incorporates residues 188-305.

In general, polypeptides (including fusion proteins) and polynucleotides as described herein are isolated. An “isolated” polypeptide or polynucleotide is one that is removed from its original environment. For example, a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. A polynucleotide is considered to be isolated if, for example, it is cloned into a vector that is not a part of the natural environment.

Binding Agents

The present invention further provides agents, such as antibodies and antigen-binding fragments thereof, that specifically bind to an ovarian carcinoma protein. As used herein, an antibody, or antigen-binding fragment thereof, is said to “specifically bind” to an ovarian carcinoma protein if it reacts at a detectable level (within, for example, an ELISA) with an ovarian carcinoma protein, and does not react detectably with unrelated proteins under similar conditions. As used herein, “binding” refers to a noncovalent association between two separate molecules such that a “complex” is formed. The ability to bind may be evaluated by, for example, determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In general, two compounds are said to “bind,” in the context of the present invention, when the binding constant for complex formation exceeds about 10 3 L/mol. The binding constant maybe determined using methods well known in the art.

Binding agents may be further capable of differentiating between patients with and without a cancer, such as ovarian cancer, using the representative assays provided herein. In other words, antibodies or other binding agents that bind to a ovarian carcinoma antigen will generate a signal indicating the presence of a cancer in at least about 20% of patients with the disease, and will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without the cancer. To determine whether a binding agent satisfies this requirement, biological samples (e.g., blood, sera, leukophoresis, urine and/or tumor biopsies) from patients with and without a cancer (as determined using standard clinical tests) may be assayed as described herein for the presence of polypeptides that bind to the binding agent. It will be apparent that a statistically significant number of samples with and without the disease should be assayed. Each binding agent should satisfy the above criteria; however, those of ordinary skill in the art will recognize that binding agents may be used in combination to improve sensitivity.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome, with or without a peptide component, an RNA molecule or a polypeptide. In a preferred embodiment, a binding agent is an antibody or an antigen-binding fragment thereof. Antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In general, antibodies can be produced by cell culture techniques, including the generation of monoclonal antibodies as described herein, or via transfection of antibody genes into suitable bacterial or mammalian cell hosts, in order to allow for the production of recombinant antibodies. In one technique, an immunogen comprising the polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep or goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for an antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and their culture supernatants tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Within certain embodiments, the use of antigen-binding fragments of antibodies may be preferred. Such fragments include Fab fragments, which may be prepared using standard techniques. Briefly, immunoglobulins may be purified from rabbit serum by affinity chromatography on Protein A bead columns (Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988) and digested by papain to yield Fab and Fc fragments. The Fab and Fc fragments may be separated by affinity chromatography on protein A bead columns.

Monoclonal antibodies of the present invention may be coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include 90 Y, 123 I, 125 I, 131 I, 186 Re, 188 Re, 211 At, and 212 Bi. Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (e.g., covalently bonded) to a suitable monoclonal antibody either directly or indirectly (e.g., via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the catalog of the Pierce Chemical Co., Rockford, Ill.), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Pat. No. 4,489,710, to Spitler), by irradiation of a photolabile bond (e.g., U.S. Pat. No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Pat. No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Pat. No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Pat. No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (e.g., U.S. Pat. No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g., U.S. Pat. Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Pat. No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Pat. No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.

Also provided herein are anti-idiotypic antibodies that mimic an immunogenic portion of an ovarian carcinoma protein. Such antibodies may be raised against an antibody, or antigen-binding fragment thereof, that specifically binds to an immunogenic portion of an ovarian carcinoma protein, using well known techniques. Anti-idiotypic antibodies that mimic an immunogenic portion of an ovarian carcinoma protein are those antibodies that bind to an antibody, or antigen-binding fragment thereof, that specifically binds to an immunogenic portion of an ovarian carcinoma protein, as described herein.

T Cells

Immunotherapeutic compositions may also, or alternatively, comprise T cells specific for an ovarian carcinoma protein. Such cells may generally be prepared in vitro or ex vivo, using standard procedures. For example, T cells may be present within (or isolated from) bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood of a mammal, such as a patient, using a commercially available cell separation system, such as the CEPRATE™ system, available from CellPro Inc., Bothell Wash. (see also U.S. Pat. Nos. 5,240,856; 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). Alternatively, T cells may be derived from related or unrelated humans, non-human animals, cell lines or cultures.

T cells may be stimulated with an ovarian carcinoma polypeptide, polynucleotide encoding an ovarian carcinoma polypeptide and/or an antigen presenting cell (APC) that expresses such a polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide. Preferably, an ovarian carcinoma polypeptide or polynucleotide is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.

T cells are considered to be specific for an ovarian carcinoma polypeptide if the T cells kill target cells coated with an ovarian carcinoma polypeptide or expressing a gene encoding such a polypeptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., Cancer Res. 54:1065-1070, 1994. Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with an ovarian carcinoma polypeptide (200 ng/ml-100 μg/ml, preferably 100 ng/ml-25 μg/ml) for 3-7 days should result in at least a two fold increase in proliferation of the T cells and/or contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN-γ) is indicative of T cell activation (see Coligan et al., Current Protocols in Immunology, vol. 1, Wiley Interscience (Greene 1998). T cells that have been activated in response to an ovarian carcinoma polypeptide, polynucleotide or ovarian carcinoma polypeptide-expressing APC may be CD4 − and/or CD8 + . Ovarian carcinoma polypeptide-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient or a related or unrelated donor and are administered to the patient following stimulation and expansion.

For therapeutic purposes, CD4 + or CD8 + T cells that proliferate in response to an ovarian carcinoma polypeptide, polynucleotide or APC can be expanded in number either in vitro or in vivo. Proliferation of such T cells in vitro may be accomplished in a variety of ways. For example, the T cells can be re-exposed to an ovarian carcinoma polypeptide, with or without the addition of T cell growth factors, such as interleukin-2, and/or stimulator cells that synthesize an ovarian carcinoma polypeptide. Alternatively, one or more T cells that proliferate in the presence of an ovarian carcinoma polypeptide can be expanded in number by cloning. Methods for cloning cells are well known in the art, and include limiting dilution. Following expansion, the cells may be administered back to the patient as described, for example, by Chang et al., Crit. Rev. Oncol. Hematol. 22:213, 1996.

Pharmaceutical Compositions and Vaccines

Within certain aspects, polypeptides, polynucleotides, binding agents and/or immune system cells as described herein may be incorporated into pharmaceutical compositions or vaccines. Pharmaceutical compositions comprise one or more such compounds or cells and a physiologically acceptable carrier. Vaccines may comprise one or more such compounds or cells and a non-specific immune response enhancer. A non-specific immune response enhancer may be any substance that enhances an immune response to an exogenous antigen. Examples of non-specific immune response enhancers include adjuvants, biodegradable microspheres (e.g., polylactic galactide) and liposomes (into which the compound is incorporated; see e.g., Fullerton, U.S. Pat. No. 4,235,877). Vaccine preparation is generally described in, for example, M. F. Powell and M. J. Newman, eds., “Vaccine Design (the subunit and adjuvant approach),” Plenum Press (NY, 1995). Pharmaceutical compositions and vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive. For example, one or more immunogenic portions of other tumor antigens may be present, either incorporated into a fusion polypeptide or as a separate compound within the composition or vaccine.

A pharmaceutical composition or vaccine may contain DNA encoding one or more of the polypeptides as described above, such that the polypeptide is generated in situ. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch et al., PNAS 86:317-321, 1989; Flexner et al., Ann. N.Y. Acad. Sci. 569:86-103, 1989; Flexner et al., Vaccine 8:17-21, 1990; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Pat. No.4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, Biotechniques 6:616-627, 1988; Rosenfeld et al., Science 252:431-434, 1991; Kolls et al., PNAS 91:215-219, 1994; Kass-Eisler et al., PNAS 90:11498-11502, 1993; Guzman et al., Circulation 88:2838-2848, 1993; and Guzman et al., Cir. Res. 73:1202-1207, 1993. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be “naked,” as described, for example, in Ulmer et al., Science 259:1745-1749, 1993 and reviewed by Cohen, Science 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. Compositions of the present invention may be formulated for any appropriate manner of administration, including for example, topical, oral, nasal, intravenous, intracranial, intraperitoneal, subcutaneous or intramuscular administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a fat, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactate polyglycolate) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268 and 5,075,109.

Such compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide) and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate. Compounds may also be encapsulated within liposomes using well known technology.

Any of a variety of non-specific immune response enhancers may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis or Mycobacterium tuberculosis derived proteins. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.), Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.), alum, biodegradable microspheres, monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.

Within the vaccines provided herein, the adjuvant composition is preferably designed to induce an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN-γ, IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6, IL-10 and TNF-β) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, Ann. Rev. Immunol. 7:145-173, 1989.

Preferred adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL), together with an aluminum salt. MPL adjuvants are available from Ribi ImmunoChem Research Inc. (Hamilton, Mont.; see U.S. Pat. Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094). Also preferred is AS-2 (SmithKline Beecham). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555. Another preferred adjuvant is a saponin, preferably QS21, which may be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprises an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210. Any vaccine provided herein may be prepared using well known methods that result in a combination of antigen, immune response enhancer and a suitable carrier or excipient.

The compositions described herein may be administered as part of a sustained release formulation (i.e., a formulation such as a capsule or sponge that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane. Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

Any of a variety of delivery vehicles may be employed within pharmaceutical compositions and vaccines to facilitate production of an antigen-specific immune response that targets tumor cells. Delivery vehicles include antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-tumor effects per se and/or to be immunologically compatible with the receiver (i.e., matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, including tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells.

Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as antigen-presenting cells. Dendritic cells are highly potent APCs (Banchereau and Steinman, Nature 392:245-251, 1998) and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic antitumor immunity (see Timmerman and Levy, Ann. Rev. Med. 50:507-529, 1999). In general, dendritic cells may be identified based on their typical shape (stellate in situ, with marked cytoplasmic processes (dendrites) visible in vitro) and based on the lack of differentiation markers of B cells (CD19 and CD20), T cells (CD3), monocytes (CD14) and natural killer cells (CD56), as determined using standard assays. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells in vivo or ex vivo, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel et al., Nature Med. 4:594-600, 1998).

Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, tumor-infiltrating cells, peritumoral tissues-infiltrating cells, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated ex vivo by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNFα to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to the culture medium combinations of GM-CSF, IL-3, TNFα, CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce maturation and proliferation of dendritic cells.

Dendritic cells are conveniently categorized as “immature” and “mature” cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fcγ receptor, mannose receptor and DEC-205 marker. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MIHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80 and CD86).

APCs may generally be transfected with a polynucleotide encoding a ovarian carcinoma antigen (or portion or other variant thereof) such that the antigen, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place ex vivo, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs in vivo. In vivo and ex vivo transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., Immunology and cell Biology 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the polypeptide, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

Cancer Therapy

In further aspects of the present invention, the compositions described herein may be used for immunotherapy of cancer, such as ovarian cancer. Within such methods, pharmaceutical compositions and vaccines are typically administered to a patient. As used herein, a “patient” refers to any warm-blooded animal, preferably a human. A patient may or may not be afflicted with cancer. Accordingly, the above pharmaceutical compositions and vaccines may be used to prevent the development of a cancer or to treat a patient afflicted with a cancer. Within certain preferred embodiments, a patient is afflicted with ovarian cancer. Such cancer may be diagnosed using criteria generally accepted in the art, including the presence of a malignant tumor. Pharmaceutical compositions and vaccines may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs.

Within certain embodiments, immunotherapy may be active immunotherapy, in which treatment relies on the in vivo stimulation of the endogenous host immune system to react against tumors with the administration of immuno response-modifying agents (such as tumor vaccines, bacterial adjuvants and/or cytokines).

Within other embodiments, immunotherapy may be passive immunotherapy, in which treatment involves the delivery of agents with established tumor-immune reactivity (such as effector cells or antibodies) that can directly or indirectly mediate antitumor effects and does not necessarily depend on an intact host immune system. Examples of effector cells include T lymphocytes (such as CD8 + cytotoxic T lymphocytes and CD4 − T-helper tumor-infiltrating lymphocytes), killer cells (such as Natural Killer cells and lymphokine-activated killer cells), B cells and antigen-presenting cells (such as dendritic cells and macrophages) expressing a polypeptide provided herein. T cell receptors and antibody receptors specific for the polypeptides recited herein may be cloned, expressed and transferred into other vectors or effector cells for adoptive immunotherapy. The polypeptides provided herein may also be used to generate antibodies or anti-idiotypic antibodies (as described above and in U.S. Pat. No. 4,918,164) for passive immunotherapy.

Effector cells may generally be obtained in sufficient quantities for adoptive immunotherapy by growth in vitro, as described herein. Culture conditions for expanding single antigen-specific effector cells to several billion in number with retention of antigen recognition in vivo are well known in the art. Such in vitro culture conditions typically use intermittent stimulation with antigen, often in the presence of cytokines (such as IL-2) and non-dividing feeder cells. As noted above, immunoreactive polypeptides as provided herein may be used to rapidly expand antigen-specific T cell cultures in order to generate a sufficient number of cells for immunotherapy. In particular, antigen-presenting cells, such as dendritic, macrophage or B cells, may be pulsed with immunoreactive polypeptides or transfected with one or more polynucleotides using standard techniques well known in the art. For example, antigen-presenting cells can be transfected with a polynucleotide having a promoter appropriate for increasing expression in a recombinant virus or other expression system. Cultured effector cells for use in therapy must be able to grow and distribute widely, and to survive long term in vivo. Studies have shown that cultured effector cells can be induced to grow in vivo and to survive long term in substantial numbers by repeated stimulation with antigen supplemented with IL-2 (see, for example, Cheever et al., Immunological Reviews 157:177, 1997).

Alternatively, a vector expressing a polypeptide recited herein may be introduced into stem cells taken from a patient and clonally propagated in vitro for autologous transplant back into the same patient.

Routes and frequency of administration, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration), orally or in the bed of a resected tumor. Preferably, between 1 and 10 doses may be administered over a 52 week period. Preferably, 6 doses are administered, at intervals of 1 month, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting an anti-tumor immune response, and is at least 10-50% above the basal (i.e., untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic effector cells capable of killing the patient's tumor cells in vitro. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (e.g. more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. In general, for pharmaceutical compositions and vaccines comprising one or more polypeptides, the amount of each polypeptide present in a dose ranges from about 100 μg to 5 mg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.

In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome (e.g., more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Increases in preexisting immune responses to an ovarian carcinoma antigen generally correlate with an improved clinical outcome. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays, which may be performed using samples obtained from a patient before and after treatment.

Methods for Detecting Cancer

In general, a cancer may be detected in a patient based on the presence of one or more ovarian carcinoma proteins and/or polynucleotides encoding such proteins in a biological sample (such as blood, sera, urine and/or tumor biopsies) obtained from the patient. In other words, such proteins may be used as markers to indicate the presence or absence of a cancer such as ovarian cancer. In addition, such proteins may be useful for the detection of other cancers. The binding agents provided herein generally permit detection of the level of protein that binds to the agent in the biological sample. Polynucleotide primers and probes may be used to detect the level of mRNA encoding a tumor protein, which is also indicative of the presence or absence of a cancer. In general, an ovarian carcinoma-associated sequence should be present at a level that is at least three fold higher in tumor tissue than in normal tissue.

There are a variety of assay formats known to those of ordinary skill in the art for using a binding agent to detect polypeptide markers in a sample. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. In general, the presence or absence of a cancer in a patient may be determined by (a) contacting a biological sample obtained from a patient with a binding agent; (b) detecting in the sample a level of polypeptide that binds to the binding agent; and (c) comparing the level of polypeptide with a predetermined cut-off value.

In a preferred embodiment, the assay involves the use of binding agent immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a detection reagent that contains a reporter group and specifically binds to the binding agent/polypeptide complex. Such detection reagents may comprise, for example, a binding agent that specifically binds to the polypeptide or an antibody or other agent that specifically binds to the binding agent, such as an anti-immunoglobulin, protein G, protein A or a lectin. Alternatively, a competitive assay may be utilized, in which a polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding agent after incubation of the binding agent with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding agent is indicative of the reactivity of the sample with the immobilized binding agent. Suitable polypeptides for use within such assays include full length ovarian carcinoma proteins and portions thereof to which the binding agent binds, as described above.

The solid support may be any material known to those of ordinary skill in the art to which the tumor protein may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term “immobilization” refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the agent and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μg, and preferably about 100 ng to about 1 μg, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (see, e.g., Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a detection reagent (preferably a second antibody capable of binding to a different site on the polypeptide) containing a reporter group is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, Mo.). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is a period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with ovarian cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include those groups recited above.

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

To determine the presence or absence of a cancer, such as ovarian cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value for the detection of a cancer is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without the cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for the cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for a cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the binding agent is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized binding agent as the sample passes through the membrane. A second, labeled binding agent then binds to the binding agent-polypeptide complex as a solution containing the second binding agent flows through the membrane. The detection of bound second binding agent may then be performed as described above. In the strip test format, one end of the membrane to which binding agent is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second binding agent and to the area of immobilized binding agent. Concentration of second binding agent at the area of immobilized antibody indicates the presence of a cancer. Typically, the concentration of second binding agent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of binding agent immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferred binding agents for use in such assays are antibodies and antigen-binding fragments thereof. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μg, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the tumor proteins or binding agents of the present invention. The above descriptions are intended to be exemplary only. For example, it will be apparent to those of ordinary skill in the art that the above protocols may be readily modified to use ovarian carcinoma polypeptides to detect antibodies that bind to such polypeptides in a biological sample. The detection of such ovarian carcinoma protein specific antibodies may correlate with the presence of a cancer.

A cancer may also, or alternatively, be detected based on the presence of T cells that specifically react with an ovarian carcinoma protein in a biological sample. Within certain methods, a biological sample comprising CD4 + and/or CD8 + T cells isolated from a patient is incubated with an ovarian carcinoma protein, a polynucleotide encoding such a polypeptide and/or an APC that expresses at least an immunogenic portion of such a polypeptide, and the presence or absence of specific activation of the T cells is detected. Suitable biological samples include, but are not limited to, isolated T cells. For example, T cells may be isolated from a patient by routine techniques (such as by Ficoll/Hypaque density gradient centrifugation of peripheral blood lymphocytes). T cells may be incubated in vitro for 2-9 days (typically 4 days) at 37° C. with an ovarian carcinoma protein (e.g., 5-25 μg/ml). It may be desirable to incubate another aliquot of a T cell sample in the absence of ovarian carcinoma protein to serve as a control. For CD4 + T cells, activation is preferably detected by evaluating proliferation of the T cells. For CD8 + T cells, activation is preferably detected by evaluating cytolytic activity. A level of proliferation that is at least two fold greater and/or a level of cytolytic activity that is at least 20% greater than in disease-free patients indicates the presence of a cancer in the patient.

As noted above, a cancer may also, or alternatively, be detected based on the level of mRNA encoding an ovarian carcinoma protein in a biological sample. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify a portion of an ovarian carcinoma protein cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for (i.e., hybridizes to) a polynucleotide encoding the ovarian carcinoma protein. The amplified cDNA is then separated and detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes that specifically hybridize to a polynucleotide encoding an ovarian carcinoma protein may be used in a hybridization assay to detect the presence of polynucleotide encoding the tumor protein in a biological sample.

To permit hybridization under assay conditions, oligonucleotide primers and probes should comprise an oligonucleotide sequence that has at least about 60%, preferably at least about 75% and more preferably at least about 90%, identity to a portion of a polynucleotide encoding an ovarian carcinoma protein that is at least 10 nucleotides, and preferably at least 20 nucleotides, in length. Preferably, oligonucleotide primers and/or probes hybridize to a polynucleotide encoding a polypeptide described herein under moderately stringent conditions, as defined above. Oligonucleotide primers and/or probes which may be usefully employed in the diagnostic methods described herein preferably are at least 10-40 nucleotides in length. In a preferred embodiment, the oligonucleotide primers comprise at least 10 contiguous nucleotides, more preferably at least 15 contiguous nucleotides, of a DNA molecule having a sequence provided herein. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51:263, 1987; Erlich ed., PCR Technology, Stockton Press, N.Y., 1989).

One preferred assay employs RT-PCR, in which PCR is applied in conjunction with reverse transcription. Typically, RNA is extracted from a biological sample such as a biopsy tissue and is reverse transcribed to produce cDNA molecules. PCR amplification using at least one specific primer generates a cDNA molecule, which may be separated and visualized using, for example, gel electrophoresis. Amplification may be performed on biological samples taken from a test patient and from an individual who is not afflicted with a cancer. The amplification reaction may be performed on several dilutions of cDNA spanning two orders of magnitude. A two-fold or greater increase in expression in several dilutions of the test patient sample as compared to the same dilutions of the non-cancerous sample is typically considered positive.

In another embodiment, ovarian carcinoma proteins and polynucleotides encoding such proteins may be used as markers for monitoring the progression of cancer. In this embodiment, assays as described above for the diagnosis of a cancer may be performed over time, and the change in the level of reactive polypeptide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, a cancer is progressing in those patients in whom the level of polypeptide detected by the binding agent increases over time. In contrast, the cancer is not progressing when the level of reactive polypeptide either remains constant or decreases with time.

Certain in vivo diagnostic assays may be performed directly on a tumor. One such assay involves contacting tumor cells with a binding agent. The bound binding agent may then be detected directly or indirectly via a reporter group. Such binding agents may also be used in histological applications. Alternatively, polynucleotide probes may be used within such applications.

As noted above, to improve sensitivity, multiple ovarian carcinoma protein markers may be assayed within a given sample. It will be apparent that binding agents specific for different proteins provided herein may be combined within a single assay. Further, multiple primers or probes may be used concurrently. The selection of tumor protein markers may be based on routine experiments to determine combinations that results in optimal sensitivity. In addition, or alternatively, assays for tumor proteins provided herein may be combined with assays for other known tumor antigens.

Diagnostic Kits

The present invention further provides kits for use within any of the above diagnostic methods. Such kits typically comprise two or more components necessary for performing a diagnostic assay. Components may be compounds, reagents, containers and/or equipment. For example, one container within a kit may contain a monoclonal antibody or fragment thereof that specifically binds to an ovarian carcinoma protein. Such antibodies or fragments may be provided attached to a support material, as described above. One or more additional containers may enclose elements, such as reagents or buffers, to be used in the assay. Such kits may also, or alternatively, contain a detection reagent as described above that contains a reporter group suitable for direct or indirect detection of antibody binding.

Alternatively, a kit may be designed to detect the level of mRNA encoding an ovarian carcinoma protein in a biological sample. Such kits generally comprise at least one oligonucleotide probe or primer, as described above, that hybridizes to a polynucleotide encoding an ovarian carcinoma protein. Such an oligonucleotide may be used, for example, within a PCR or hybridization assay. Additional components that may be present within such kits include a second oligonucleotide and/or a diagnostic reagent or container to facilitate the detection of a polynucleotide encoding an ovarian carcinoma protein.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLES

Example 1

Identification of Ovarian Tumor Antigen cDNAs

This Example illustrates the identification of cDNA molecules encoding ovarian tumor antigens.

Patient sera (from two human patients with ovarian cancer) was adsorbed against E. coli and used at a 1:200 dilution in a serological expression screen performed as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y., 1989. The library screened was made from a SCID-derived human ovarian tumor (OV9334) using a directional RH oligo(dT) priming cDNA library construction kit and the λScreen vector (Novagen). Approximately 600,000 pfu of the amplified OV9334 library were screened.

In a first screen, three novel clones were identified (OV10, OV17 and OV41), and the partial sequences are provided in FIGS. 5 , 8 and 13 (SEQ ID NOs: 5, 8 and 13), respectively. Additional sequences matched previously identified genes, which were not previously known to be associated with ovarian carcinoma. These sequences are identified in Table I.

TABLE 1
Additional Ovarian Carcinoma Antigen Partial Sequences
Sequence            Match
OV6 (SEQ ID NO:3)   High Mobility Group Protein 14
OV2 (SEQ ID NO:1)   Hypothetical 33.4 kD Protein
OV3 (SEQ ID NO:2)   High Mobility Group Protein 17
OV9 (SEQ ID NO:4)   Integrin Alpha-3
OV12 (SEQ ID NO:6)  Filamental Protein
OV14 (SEQ ID NO:7)  Ubiquitin-Conjugating Enzyme
OV18 (SEQ ID NO:9)  Alpha-Glucosidase I
OV23 (SEQ ID NO:10) Ribosomal Protein L10
OV24 (SEQ ID NO:11) Mitochondrial Gene
OV27 (SEQ ID NO:12) Ribonucleoprotein
OV54 (SEQ ID NO:14) Ribosomal Protein L18
OV57 (SEQ ID NO:15) Ribosomal Protein S10

Within a second screens further clones were identified. Homologies for these clones are provided in Table II. Sequences of novel clones are provided in FIGS. 16A-16I (SEQ ID NOs:19-68). Those clones for which homology was found in the DNA sequence, but not the protein sequence, are provided in FIGS. 17A-17C (SEQ ID NOs:69-85), and those that matched previously identified DNA and protein sequences, which were not previously known to be associated with ovarian carcinoma, are provided in FIGS. 18A-18F (SEQ ID NOs:86-129).

TABLE II
Further Ovarian Carcinoma Antigen Partial Sequences
	SEQ
Sequence	ID	DNA Homology	Protein Homology
OVp2-1	86	AND-1	AND-1
OVp2-2	19	Novel	Novel
OVp2-4	87	Topoisom. II	Topoisom. II
OVp2-5	88	cAMP phosphodiesterase	cAMP phosphodiesterase
OVp2-6	89	P1	P1
OVp2-9	90	kinase PRKAR1A	kinase PRKAR1A
OVp2-10	91	Human RNA polym. II	Human RNA polym. II
OVp2-11	92	Mu. p162	Mu. p162
OVp2-13	20	Novel	Novel
OVp2-14	21	Novel	Novel
OVp2-15	69	Hu. BAC G5541B18	Novel
OVp2-16	93	Hu. fanconi anemia mRNA	FAA
OVp2-17	94	Hu. histone H1	Histone H1
OVp2-20	22	Novel	Novel
OVp2-21	23	Novel	Novel
OVp2-22	70	Hu K1AA0642 mRNA	Novel
OVp2-23	95	Hu. lysophospholipase mRNA	Hu. lysophospholipase mRNA
OVp2-24	71	Hu. Chrom 16 cosmid clone	Novel
		400D1
OVp2-25	24	Novel	Novel; similar to PHD finger
			protein
OVp2-27	25	Novel	Novel
OVp2-28	26	Novel	Novel
OVp2-29	27	Novel	Novel
OVp2-31	28	Novel	Novel
OVp2-37	29	Novel	Novel
OVp2-38	30	Novel	Novel
OVp2-39	96	Human Tumor protein	Human Tumor protein
OVp2-40	31	Novel	Novel
OVp2-42	32	Novel	Novel
OVp2-43	97	nucleophosmin	nucleophosmin
OVp2-47	72	Hu PAC DJ0751H13	Novel; zinc finger-like
OVp2-48	98	Human Carbonyl Reductase	Carbonyl Reductase
OVp2-52	33	Novel	Novel
OVp2-54	99	Mu., Hu. chromatin structrl pro.	Mu., Hu. chromatin structrl pro.
OVp2-55	73	Hu. mRNA clone A33187	Novel; similar to laminin
OVp2-56	34	Novel	Novel
OVp2-58	100	H3.3 Histone	H3.3 Histone
OVp2-59	101	cyt.C oxidase subunit	cyt.C oxidase subunit
OVp2-60	35	Novel	Novel
OVp2-66	102	alpha-CP1; rnp-assoc.	alpha-CP1; rnp-assoc.
OVp2-69	36	Novel	Novel
OVp2-71	37	Novel	Novel
OVp2-81	74	HuCpG DNA clone 11B11	Novel
OVp2-82	103	Human KIAA0111 gene	Euk Init'n Factor 4A-like
OVp2-83	38	Novel	Novel
OVp2-84	39	Novel	Novel
OVp2-85	40	Novel	Novel
OVp2-87	41	Novel	Novel
OVp2-88	42	Novel	Novel
OVp2-90	43	Novel	Novel
OVp2-91	104	Mu, Hu cathepsinC	Mu, Hu cathepsinC
OVp2-93	44	Novel	Novel
OVp2-94	45	Novel	Novel
OVp2-98	46	Novel; Carbonyl Reductase (pig)	Novel
OVp2-99	47	Novel	Novel
OVp2-100	75	Human K1AA0788	Novel
OVp2-103	105	Human tra gp96	tra gp96
OVp2-104	76	Hu BAC clone 78c6	Novel
OVp2-106	106	Ubiq-conj. enz; carcinoma	Ubiquitin-conjugating enzyme
OVp2-108	77	KIAA0249	Novel
OVp2-109	107	Mu.p162	Mu.p162
OVp2-110	48	Novel	Novel
OVp3-2	108	Mu. Acyl-CoA dehydrog.	Mu. Acyl-CoA dehydrog.
OVp3-3	78	Hu. Chrom 17, hRPC.117	Novel
OVp3-4	49	Novel	Novel
OVp3-5	79	Unkn. Hu. DNA;	Novel
OVp3-6	109	Mu. retrotranspsn.	Mu. ORF; carcinoma
OVp3-7	110	Hu. glypican4	Glypican precursor
OVp3-8	50	Novel	Novel
OVp3-9	80	Mu. entactin	Novel
OVp3-11	51	Novel	Novel
OVp3-17	111	Elongation Factor 1 alpha	EF-1 alpha
OVp3-19	52	Novel	Novel
OVp3-23	81	Hu. RES4-4 (brain)	Novel
OVp3-24	112	Hu. P8; mitogen	Hu. P8
OVp3-26	113	Hu ribosomal. L18	Hu ribosomal. L18
OVp3-28	114	Hu KS/14 antigen	Tumor-assoc. glycoprotein
OVp3-29	115	Hu. Actin-binding	Hu. Actin-binding
OVp3-31	53	Novel	Novel
OVp3-34	116	Hu DPM1	Hu DPM1
OVp3-36	117	Hu PAC DJ269O05	Hu. Line-1 homolog; putative p150
OVp3-37	118	Mu. fibronectin/precursor (Hu)	fibronectin
OVp3-38	54	Novel	Novel
OVp3-40	55	Novel	Novel
OVp3-41	56	Novel	Novel
OVp3-44	57	Novel	Novel
OVp3-47	58	Novel	Novel
OVp3-50	82	Chrom.; PAC	Novel; similar to p40, 40 kD
OVp3-51	59	Novel; 86% Mu. oncogene ect2	Novel; Mu ect2
OVp3-52	119	RAC3 (Hu Rac3)	Ras-like; G protein; Rac3
OVp3-53	120	(Hu) alpha-enolase	alpha-enolase; carbonate
			hydratase(Hu)
OVp3-54	121	Hu. Nuclr. NP220	NP220
OVp3-64	60	Novel	Novel
OVp3-66	83	Hu. mitochond. DNA	Novel; similar to cyt.C oxidase
			subunit
OVp3-70	61	Novel	Novel
OVp3-71	62	Novel	Novel
OVp3-81	63	Novel	Novel
OVp3-83	122	RNA binding factor	Unknown
OVp3-84	84	Hu PAC RPC13-197B17	Novel
OVp3-86	123	Cathepsin C	Cathepsin C
OVp3-87	64	Novel	Novel
OVp3-88	65	Novel	Novel
OVp3-90	124	Human EF-1 alpha	Human EF-1 alpha
OVp3-91	125	Human nuclear factor NF-IL6	similar to Hu. nuclear factor NF-
			IL6
OVp3-94	126	Hu. polyadenylate-binding	polyadenylate-binding
		PAIP1
OVp3-95	127	Human TAK1-binding	Unknown
OVp3-97	128	Hu ribosomal L27	Hu ribosomal L27
OVp3-101	129	Human cytoskeletal g-actin	Unknown
OVp3-104	85	mitochondrial; Hu. clone 23884	Novel
OVp3-107	66	Novel	Novel
OVp3-110	67	Novel	Novel
OVp3-127	68	Novel	Novel; 50% homology to human
			hepatoma-derived growth factor

Still further ovarian carcinoma sequences are presented in Table III and SEQ ID NOs: 130-334.

TABLE III
Further Ovarian Carcinoma Antigen Partial Sequences
Clone No.	Sequence	SEQ ID NO	Homology
OVp2-3	15674.2	130	Novel
OVp2-8	15679.2	131	A.t BAC F21E10; ESTs
OVp2-26	20045.1	132	Human 1-mf; ETS
OVp2-33	20047.1	133	Novel; ESTs
OVp2-34	20056.1	134	BiP, GRP; ESTs
OVp2-45	17295.1	135	Human Chrom 16; ESTs
OVp2-49	20209.1	136	Human C90RF3 short isoform; ESTs
OVp2-53	16111.2	137	Novel; ESTs
OVp2-61	22421.1	138	Novel
OVp2-62	22422.1	139	TNF-α stimulated ATP-binding; ESTs
OVp2-63	22423.1	140	Human.DNA from phage pTELchrom.
			16p13.3; ESTs
OVp2-64	22424.1	141	Human mRNA for fibronectin; ESTs
OVp2-65	22425.1	142	Novel; ESTs
OVp2-74	22428.1	143	Human deoxyhypusine synthase mRNA;
			ESTs
OVp2-75	22430.1	144	Novel
OVp2-76	22431.1	145	Novel; ESTs
OVp2-77	22432.1	146	Novel; ESTs
OVp2-78	22433.1	147	Human.cDNA DKFZp586E0518; ESTs
OVp2-79	22434.1	148	Human DNA cosmid U131B10
OVp2-95	20213.1	149	Hu. Protective protein; ESTs
OVp2-97	20214.1	150	Plasma protein S; ESTs
OVp2-107	20216.1	151	Human epiderm al carcinoma mRNA for
			E2; ESTs
OVp2-113	20496.1	152	Human Histone H1′; ESTs
OVp2-114	20497.1	153	Novel
OVp2-116	18077.1	154	Human Pyruvate dehydrogenase kinase;
			EST
OVp2-119	18078.1	155	Human K1AA0803, BAC clone; ESTs
OVp2-121	20498.1	156	Murine DNA-binding, Zn Finger; ESTs
OVp2-122	18085.1	157	Rat trg
OVp2-124	20500.1	158	Novel; ESTs
OVp2-127	18084.1	159	Human Cosmid F23149
OVp2-128	20501.1	160	Human GlcNac 1-P transferase; ESTs
OVp2-129	20502.1	161	Novel; EST
OVp2-131	18573.2	162	Human laminin alpha 5 chain; ESTs
OVp2-133	18574.1	163	Novel
OVp2-134	18345.1	164	Human tazarotene-induced gene 2; ESTs
OVp2-135	18575.1	165	Actin-binding P57, coronin-like; ESTs
OVp2-139	18728.1	166	Human clone 1033D10; includes BING5;
			ESTs
OVp2-141	18577.1	167	Human cosmid F23149; EST
OVp2-143	18881.1	168	c-myc proto-oncogene; ESTs
OVp2-144	18882.1	169	Murine, Human nucleic acid-binding
			protein; ESTs
OVp2-146	18884.1	170	Novel; ESTs
OVp2-147	18885.1	171	Human B23 nucleophosmin; ESTs
OVp2-148	18886.1	172	cation-dependent Human, Murine MP-6R;
			ESTs
OVp2-150	18889.1	173	Human FXR1; ESTs
OVp2-152	18891.1	174	Human KIAA0465; ESTs
OVp2-153	18892.1	175	Human α-2macroglobin receptor assoc;
			ESTs
OVp2-158	20027.1	176	Topoisomerase II; ESTs
OVp2-160	20028.1	177	Novel
OVp2-162	20029.1	178	Novel
OVp2-167	20035.1	179	K1AA0630; ESTs
OVp2-169	20037.1	180	Novel
OVp2-171	20039.1	181	Novel; ESTs
OVp2-172	20072.1	182	Novel
OVp2-174	20031.1	183	mig-2; ESTs
OVp2-179	20040.1	184	Novel; ESTs
OVp2-180	20041.1	185	Antiquin; turgor protein; ESTs
OVp2-184	20044.1	186	Human ribosomal P1; ESTs
OVp2-185	20057.1	187	Novel; ESTs
OVp2-187	20074.1	188	MuLV env
OVp2-188	20075.1	189	Novel; EST
OVp2-189	20058.1	190	Novel; EST
OVp2-190	20059.1	191	Gonadotropin-Reg Hormone Producing;
			ESTs
OVp2-191	21502.1	192	Novel; ESTs
OVp2-192	21503.1	193	18S rRNA, DNA; ESTs
OVp2-193	21504.1	194	Arg-rich Nuclear Protein; ESTs
OVp2-194	21505.1	195	Novel; ESTs
OVp2-195	21506.1	196	Novel; ESTs
OVp2-196	21507.1	197	Human Clone 406A7; ESTs
OVp2-197	21508.1	198	Novel; ESTs
OVp2-204	22128.1	199	Human Mitochondrial DNA; ESTs
OVp2-206	22129.1	200	Human chrom. DNA for RAD23A; ESTs
OVp2-207	22130.1	201	Human clone 24921 mRNA; ESTs
OVp2-208	22131.1	202	Human 4F5rel mRNA; ESTs
OVp2-209	22133.1	203	Human ribosomal pro. S6
			kinase.SW1/SNF related; ESTs
OVp2-211	22134.1	204	Human beta-glucuronidase (BG) mRNA;
			ESTs
OVp2-212	22135.1	205	Human DNA for hnRNP protein A2/B1;
			ESTs
OVp2-215	22137.1	206	Human translocation protein 1; ESTs
OVp2-216	22138.1	207	Human chromosone X orf5; ESTs
OVp2-217	22139.1	208	Human ribosomal protein S19; ESTs
OVp2-218	22140.1	209	Murine mRNA for histone H3.3A; ESTs
OVp2-220	22141.1	210	Human PAC 434P1; ESTs
OVp2-221	22142.1	211	Human AKAP450.K1AA0803.Hyperion;
			ESTs
OVp2-222	22144.1	212	Human HRFX2 mRNA, DNA binding
OVp2-223	22145.1	213	Human NF-kappa-B transcrip'n factor
			p65; ESTs
OVp2-225	22146.1	214	Novel
OVp2-226	22147.1	215	Novel
OVp2-228	22148.1	216	Novel; ESTs
OVp2-229	22149.1	217	Human mitochondrial genes; ESTs
OVp2-230	22150.1	218	O. cuniculus endooligopeptidase A related
			protein; ESTs
OVp2-232	22152.1	219	Human clone A9A2BR11; Mu Zfr
OVp2-233	22153.1	220	Human KIAA0098; Murine chaperonin
			containg TCP-1; ESTs
OVp2-238	22154.1	221	human DNA seq. from PAC 93H18; ESTs
OVp2-239	22155.1	222	Novel
OVp2-241	22156.1	223	Human glutathione S-transferase theta 1;
			ESTs
OVp2-243	22157.1	224	Human TCB.OIP3, pyruvate kinase; ESTs
OVp2-244	22158.1	225	Human mRNA for KIAA0250 gene; EST
OVp2-250	22160.1	226	Human complement component C4A
			mRNA; EST
OVp2-251	22161.1	227	Novel; EST
OVp2-252	22162.1	228	Novel; EST
OVp2-253	22163.1	229	Human. G protein Golf alpha gene; ESTs
OVp2-254	22164.1	230	Novel; ESTs
OVp2-257	22897.1	231	Novel; ESTs
OVp2-258	22440.1	232	Human chrom 16. cosmid clone 399H11;
			ESTs
OVp2-259	22441.1	233	human cDNA DKFZp564B112; ESTs
OVp2-260	22898.1	234	Novel; ESTs
OVp2-262	22442.1	235	Human mRNA for ribosomal protein L31;
			ESTs
OVp2-265	22899.1	236	Human TNF receptor mRNA; ESTs
OVp2-266	22445.1	237	Human 12q13.1 PAC RPC11-228P16
OVp2-270	22447.1	238	Hu. cDNA DKFZp586F1523; ESTs
OVp2-273	22450.1	239	Homo sapiens cytochrome b-245; ESTs
OVp2-276	22451.1	240	Novel; ESTs
OVp2-279	22454.1	241	Novel; ESTs
OVp2-282	22903.1	242	Novel; ESTs
OVp2-283	22904.1	243	Human K1AA9001 mRNA,R1N63; ESTs
OVp2-284	22905.1	244	Novel; ESTs
OVp2-285	22906.1	245	Novel; ESTs
OVp2-287	22907.1	246	Novel
OVp3-15	20048.1	247	JM26; ESTs
OVp3-27	20049.1	248	mult. Human BAC; Linel; ESTs
OVp3-42	20050.1	249	Tyrosine phosphatase; ESTs
OVp3-58	20052.1	250	Novel; ESTs
OVp3-61	20060.1	251	Novel; ESTs
OVp3-73	20064.1	252	glypican-4
OVp3-74	20065.1	253	Novel; ESTs
OVp3-78	20069.1	254	Novel
OVp3-80	20053.1	255	MLN 50 RNA; EST
OVp3-89	20217.1	256	Novel
OVp3-108	20222.1	257	Human parathymosin; ESTs
OVp3-109	20223.1	258	Human eryth/α-adductin; ESTs
OVp3-114	18080.1	259	Novel
OVp3-115	20225.1	260	Human JM26; ESTs
OVp3-116	20226.1	261	Novel; ESTs
OVp3-120	20503.1	262	Human K1AA0875; ESTs
OVp3-121	20227.1	263	Human Guanine-binding; ESTs
OVp3-122	20228.1	264	Novel; ESTs
OVp3-123	18086.1	265	Novel
OVp3-124	18087.1	266	Human transposon L1.2; ESTs
OVp3-127	18089.1	267	low sim. to Mu. Hepatoma GF; ESTs
OVp3-129	20504.1	268	Human β spectrin (actin-binding); ESTs
OVp3-130	18347.1	269	BAC GS083B20; Linel, p150; ESTs
OVp3-131	18348.1	270	glutathione S-transferase; ESTs
OVp3-132	18349.1	271	Human mRNA KIAA0710; EST
OVp3-136	20506.1	272	Novel; ESTs
OVp3-137	18731.1	273	Novel; ESTs
OVp3-142	20508.1	274	Novel
OVp3-144	18735.1	275	Novel; EST
OVp3-147	18738.1	276	K1AA0941, PGEMEX; ESTs
OVp3-148	20510.1	277	Polyubiquitin; ESTs
OVp3-149	18894.1	278	Novel; ESTs
OVp3-150	18895.1	279	Human SWI/SNF; ESTs
OVp4-1	20017.1	280	Novel; EST
OVp4-2	20018.1	281	Human KIAA0241; ESTs
OVp4-4	20019.1	282	Novel; ESTs
OVp4-6	20020.1	283	Novel; ESTs
OVp4-7	20021.1	284	laminin-binding; ESTs
OVp4-8	20022.1	285	okadaic-acid-inducible; ESTs
OVp4-10	20023.1	286	MAC25; ESTs
OVp4-13	20054.1	287	Novel; ESTs
OVp4-14	20055.1	288	Novel
OVp4-15	20076.1	289	Human HSP; ESTs
OVp4-16	20077.1	290	Clathrin; δ3A (AP-3 complex); ESTs
OVp4-18	20078.1	291	Novel; ESTs
OVp4-20	20070.1	292	Novel
OVp4-22	20229.1	293	Human β-Catenin; ESTs
OVp4-22A	20511.1	294	llPPL1 (51C); DNA repair; ESTs
OVp4-23	20230.1	295	Transcrp'n Fact. AP-1, JUN A, C-JUN;
			ESTs
OVp4-24	20231.1	296	Novel; ESTs
OVp4-25	20512.1	297	Novel; ESTs
OVp4-26	20232.1	298	ribosomal P0; ESTs
OVp4-26A	20538.1	299	Novel; ESTs
OVp4-28	20234.1	300	Transcrp'n Factor S-II; ESTs
OVp4-29	20235.1	301	Novel; ESTs
OVp4-30	20236.1	302	Human AHNAK; neuroblast diff'n.; ESTs
OVp4-31	20237.1	303	CD81(TAPA-1) cell surface; ESTs
OVp4-33	20545.1	304	Novel; ESTs
OVp4-34	20546.1	305	Novel
OVp4-35	20547.1	306	Novel; ESTs
OVp4-36	21510.1	307	Novel
OVp4-37	20548.1	308	Novel; ESTs
OVp4-38	22166.1	309	Novel; ESTs
OVp4-40	20549.1	310	Human Profilin; EST
OVp4-43	20551.1	311	Novel
OVp4-44	20552.1	312	Human 30M3; ESTs
OVp4-45	20553.1	313	Chrom. 14 specific cosmid
OVp4-46	20554.1	314	Novel; ESTs
OVp4-47	20555.1	315	EF-1 α; ESTs
OVp4-48	20556.1	316	B-CAM mRNA; EST
OVp4-49	20557.1	317	Novel
OVp4-51	20559.1	318	Human N-cadherin; ESTs
OVp4-52	20560.1	319	Human p16INK4/MTS1; ESTs
OVp4-53	20561.1	320	Human RNA helicase
OVp4-54	20562.1	321	Murine Fibronectin; ESTs
OVp4-55	20778.1	322	RibosomalS6(kinase substrate); ESTs
OVp4-56	20779.1	323	Novel; ESTs
OVp4-58	20781.1	324	CPG island DNA; EST
OVp4-59	20782.1	325	Human KIAA 0241; ESTs
OVp4-61	20784.1	326	Human PAC; EST
OVp4-62	20785.1	327	Na/H reg. factor; ESTs
OVp4-63	20786.1	328	Ferritin Heavy Chain; ESTs
OVp4-64	20787.1	329	MHC -1 H2; ESTs
OVp4-66	20789.1	330	RNA Helicase-related; ESTs
OVp4-70	20793.1	331	BC-2protein RNA; ESTs
OVp4-72	20795.1	332	Phosphorylase Kinase; ESTs
OVp4-73	20796.1	333	Novel
OVp4-74	20797.1	334	Human clone 327J16; ESTs

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

334 1 514 DNA Homo sapien 1ctccttctcg tcacacacca ggtccccgcg gaagccgcgg tgtcggcgcc atggcggagc 60tgacggctct tgagagtctc atcgagatgg gcttccccag gggacgcgcg gagaaggctc 120tggccctcac agggaaccag ggcatcgagg ctgcgatgga ctggctgatg gagcacgaag 180acgaccccga tgtggacgag cctttagaga ctccccttgg acatatcctg ggacgggagc 240ccacttcctc agagcaaggc ggccttgaag gatctggttc tgctgccgga gaaggcaaac 300ccgctttgag tgaagaggaa agacaggaac aaactaagag gatgttggag ctggtggccc 360agaagcagcg ggagcgtgaa gaaagagagg aacgggaggc attggaacgg gaacggcagc 420gcaggagaca agggcaagag ttgtcagcag cacgacagcg gctacaggaa gatgagatgc 480gccgggctgc tgaggagagg cggagggaaa aggc 514 2 461 DNA Homo sapien 2gagaacgacc cccggaccga ccaaagcccg cgcgccgctg catcccgcgt ccagcaccta 60cgtcccgctg ccgtcgccgc cgccaccatg cccaagagaa aggctgaagg ggatgctaag 120ggagataaag caaaggtgaa ggacgaacca cagagaagat ccgcgaggtt gtctgctaaa 180cctgctcctc caaagccaga gcccaagcct aaaaaggccc ctgcaaagaa gggagagaag 240gtacccaaag ggaaaaaggg aaaagctgat gctggcaagg aggggaataa ccctgcagaa 300aatggagatg ccaaaacaga ccaggcacag aaagctgaag gtgctggaga tgccaagtga 360agtgtgtgca tttttgataa ctgtgtactt ctggtgactg tacagtttga aatactattt 420tttatcaagt tttataaaaa tgcagaattt tggtttactt t 461 3 436 DNA Homo sapien 3gaggagtggc agcggcaagg cagcccagtt tcgcgaaggc tgtcggcgcg ccgcggcccg 60caggcacccg gcacgcgcct tccccgcagg cacccggcac gcgccttccc cgccgccacg 120atgcccaaga ggaaggtcag ctccgccgaa ggcgccgcca aggaagagcc caagaggaga 180tcggcgcggt tgtcagctaa acctcctgca aaagtggaag cgaagccgaa aaaggcagca 240gcgaaggata aatcttcaga caaaaaagtg caaacaaaag ggaaaagggg agcaaaggga 300aaacaggccg aagtggctaa ccaagaaact aaagaagact tacctgcgga aaacggggaa 360acgaagactg aggagagtcc agcctctgat gaagcaggag agaaagaagc caagtctgat 420taataaccat atacca 436 4 75 DNA Homo sapien 4ggaattccct ccccctcctt gtgccttctt tgtatatagg cttctcacgg cgaccaataa 60acagctccca gtttg 75 5 222 DNA Homo sapien 5ccggggctga aaacggtggc agaaagtgag caacttaggg agacagaaag agcgcagaac 60tcgaaattcc gaggcagaga gagcggaggg caagccgtgg gtagaaacgc gccgaggcga 120ggacgaaggc cttggcccgc ggagacgcag gcacccgcgg agaacgcttc ggatccgtca 180cggttttgcc tcatttggaa gatattactt cgcccctgaa aa 222 6 147 DNA Homo sapien 6cctgaaagga ccttgggtgg taaagctgta cttggtggga gtgagggcgt ggggaggaac 60catgcaaatc gccttccatg gtttttaaat gcagtaaata acatttctgg atgagacttg 120tttccaaaat aaaccagcta tatctgt 147 7 952 DNA Homo sapien 7ggggagcgga gcggggccgc cggggcctct ccagggccgc agcggcagca gttgggcccc 60ccgccccggc cggcggaccg aagaacgcag gaagggggcc ggggggaccc gcccccggcc 120ggccgcagcc atgaactcca acgtggagaa cctacccccg cacatcatcc gcctggtgta 180caaggaggtg acgacactga ccgcagaccc acccgatggc atcaaggtct ttcccaacga 240ggaggacctc accgacctcc aggtcaccat cgagggccct gaggggaccc catatgctgg 300aggtctgttc cgcatgaaac tcctgctggg gaaggacttc cctgcctccc cacccaaggg 360ctacttcctg accaagatct tccacccgaa cgtgggcgcc aatggcgaga tctgcgtcaa 420cgtgctcaag agggactgga cggctgagct gggcatccga cacgtactgc tgaccatcaa 480gtgcctgctg atccacccta accccgagtc tgcactcaac gaggaggcgg gccgcctgct 540cttggagaac tacgaggagt atgcggctcg ggcccgtctg ctcacagaga tccacggggg 600cgccggcggg cccagcggca gggccgaagc cggtcgggcc ctggccagtg gcactgaagc 660ttcctccacc gaccctgggg ccccaggggg cccgggaggg gctgagggtc ccatggccaa 720gaagcatgct ggcgagcscg ataagaagct ggcggccaac aaaaacacgg acaacaagcg 780ggcgctgcgg cggctgtagt gggctctctt cctccttcca ccgtgacccc aacctytcct 840gtcccctccc tccaactctg tctytaagtt atttaaatta tggctggggt cggggagggt 900acagggggca ctgggacctg gatttgtttt tctaaataaa gttggaaaag ca 952 8 859 DNA Homo sapien 8ctcatgcctg taatcccagc actttggaag gcaggagcca ccaagcgcag ccatgattta 60ttagatcact tctaaaagcc ctctctccat ctccaagcca gcaagtgctt ctttgcaccc 120cagctctaaa acaaagccct tggggacaca atcaaagaca gtagttgcca agaggaatag 180ggagcatgga aagaaggtgc tggatgtgca tacagctaac ctggtaactc caaactggat 240gagctcattc cttgagactg gaattacaaa attggaacag ctcactaata attgaagatg 300atttgggaaa accattatcc ttcctcaggt tttacaaggt ttttatgact catttataag 360gtcctacagc taaaaaaaat catgctgtat ttcagagaag tttaacttga aaatattttt 420ttcactaatt aaaaattccc attatacctt atagttgcaa ttgtatcctt attgctgaaa 480gatatccata ctacctacca cttctttaaa atttaaaaaa ttctataaat aaaaaatata 540acaattgcaa atatgtaaat aacttccaac ataaaacaaa atttatagta attataagaa 600gttcttttat actaaaaatt aagttgtaat tatgatagaa ataatctgta aaaggtattt 660ttagcaaaat ttattaatac gggtagcaat aataataccc aattatatat gcatattgtt 720tgtattttag aacctgtgac aaatgaaaat ggttttccta gataagaacg aaactgtgtt 780gggtggctaa caagatygaa actcatctga ctttgagaaa taaatcaatt tggtttgttt 840atttaaaaaa aaaaagctt 859 9 289 DNA Homo sapien 9gaggcatggg ctgccgccct ttccacggct ggaccagcct tgtcttactg gccatggctg 60aagactactg aagggaggga gaggagggga gccaagacac tcatgccact ctggctctga 120agggacaaag gcttctggct tttgccccca gccccttgga taccagtaat tcaaaccttc 180ctcatttcat ctcaggtgtc tccttgctgt catcccacat agccctgggg tgaatgtgaa 240tccagagtct atttttctaa ataaattgga aaaaacaaaa aaaaagctt 289 10 328 DNA Homo sapien 10tgggttggtg aagattccac atacaaattt tttgaggtta tcctcattga tccattccat 60aaagctatca gaagaaatcc tgacacccag tggatcacca aaccagtcca caagcacagg 120gagatgcgtg ggctgacatc tgcaggccga aagagccgtg gccttggaaa gggccacaag 180ttccaccaca ctattggtgg ctctcgccgg gcagcttgga gaaggcgcaa tactctccag 240ctccaccgtt accgctaata taagtaaagt ttgtaaaatt catacttaat aaacaattta 300ggacagtcaa aaaaaaaaaa aaagcttg 328 11 386 DNA Homo sapien 11gcagtacatg ctaagacttc accagtcaaa gcgaactact atactcaatt gatccaataa 60cttgaccaac ggaacaagtt accctaggga taacagcgca atcctattct agagtccata 120tcaacaatag ggtttacgac ctcgatgttg gatcaggaca tcccgatggt gcagccgcta 180ttaaaggttc gtttgttcaa cgattaaagt cctacgtgat ctgagttcag accggagtaa 240tccaggtcgg tttctatcta cttcaaattc ctccctgtac gaaaggacaa gagaaataag 300gcctacttca caaagcgcct tcccccgtaa atgatatcat ctcaacttag tattataccc 360acacccaccc aagaacaggg tttgtt 386 12 231 DNA Homo sapien 12gacggctacc tggctccgga gaatgggtat ttgatggagg ctgcgccgga gtgaagaggt 60cgtcctctcc atctgctgtg tttggacgcg ttcctgccca gccccttgct gtcatcccct 120cccccaacct tggccacttg agtttgtcct ccaagggtag gtgtctcatt tgttctggcc 180ccttggattt aaaaataaaa ttaatttcct gtaaaaaaaa aaaaaaagct t 231 13 84 DNA Homo sapien 13ctacacacca aatctgctag ttccttgatc tccgacctct caagctctag aactgctaga 60aataaatttc tatttttata agct 84 14 91 DNA Homo sapien 14ccacgcttca ccaccaagag gcccaacacc ttcttctagg tgcagggccc tcgtccgggt 60gtgccccaaa taaactcagg aacgccccgg t 91 15 168 DNA Homo sapien 15gctgacagag atacctacag acggagtgct gtgccacctg gtgccgacaa gaaagccgag 60gctggggctg ggtcagcaac cgaattccag tttagaggcg gatttggtcg tggacgtggt 120cagccacctc agtaaaattg gagaggattc ttttgcattg aataaact 168 16 154 PRT Homo sapien 16Met Ala Glu Leu Thr Ala Leu Glu Ser Leu Ile Glu Met Gly Phe Pro 1 5 10 15Arg Gly Arg Ala Glu Lys Ala Leu Ala Leu Thr Gly Asn Gln Gly Ile 20 25 30Glu Ala Ala Met Asp Trp Leu Met Glu His Glu Asp Asp Pro Asp Val 35 40 45Asp Glu Pro Leu Glu Thr Pro Leu Gly His Ile Leu Gly Arg Glu Pro 50 55 60Thr Ser Ser Glu Gln Gly Gly Leu Glu Gly Ser Gly Ser Ala Ala Gly65 70 75 80Glu Gly Lys Pro Ala Leu Ser Glu Glu Glu Arg Gln Glu Gln Thr Lys 85 90 95Arg Met Leu Glu Leu Val Ala Gln Lys Gln Arg Glu Arg Glu Glu Arg 100 105 110Glu Glu Arg Glu Ala Leu Glu Arg Glu Arg Gln Arg Arg Arg Gln Gly 115 120 125Gln Glu Leu Ser Ala Ala Arg Gln Arg Leu Gln Glu Asp Glu Met Arg 130 135 140Arg Ala Ala Glu Glu Arg Arg Arg Glu Lys145 150 17 90 PRT Homo sapien 17Met Pro Lys Arg Lys Ala Glu Gly Asp Ala Lys Gly Asp Lys Ala Lys 1 5 10 15Val Lys Asp Glu Pro Gln Arg Arg Ser Ala Arg Leu Ser Ala Lys Pro 20 25 30Ala Pro Pro Lys Pro Glu Pro Lys Pro Lys Lys Ala Pro Ala Lys Lys 35 40 45Gly Glu Lys Val Pro Lys Gly Lys Lys Gly Lys Ala Asp Ala Gly Lys 50 55 60Glu Gly Asn Asn Pro Ala Glu Asn Gly Asp Ala Lys Thr Asp Gln Ala65 70 75 80Gln Lys Ala Glu Gly Ala Gly Asp Ala Lys 85 90 18 100 PRT Homo sapien 18Met Pro Lys Arg Lys Val Ser Ser Ala Glu Gly Ala Ala Lys Glu Glu 1 5 10 15Pro Lys Arg Arg Ser Ala Arg Leu Ser Ala Lys Pro Pro Ala Lys Val 20 25 30Glu Ala Lys Pro Lys Lys Ala Ala Ala Lys Asp Lys Ser Ser Asp Lys 35 40 45Lys Val Gln Thr Lys Gly Lys Arg Gly Ala Lys Gly Lys Gln Ala Glu 50 55 60Val Ala Asn Gln Glu Thr Lys Glu Asp Leu Pro Ala Glu Asn Gly Glu65 70 75 80Thr Lys Thr Glu Glu Ser Pro Ala Ser Asp Glu Ala Gly Glu Lys Glu 85 90 95Ala Lys Ser Asp 100 19 244 DNA Homo sapien 19caaacaatac tatcttataa aatagtactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctaaaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttac 244 20 241 DNA Homo sapien 20tcaacctcct cctccaagcc ctttctcagt acaagctttc aataaagggg caagttgcag 60tgcccaagga tttgactatg gcctgggaaa taacaaacgt gacagaggaa ctatctcaac 120atcttcaaga ccagtgtcca catcagggaa gtcagagctg ccctctaagc acagcaggtc 180agttaaaccc gacgggcatg tgagccggac tcctgctgac cagaagaagc cacgggggac 240a 241 21 220 DNA Homo sapien 21caaaattcta acctgtatca gaggagtgaa atgccccgtg aattgaggca actgtagata 60ttcgaaatgc ttctaaaaag gctgtgaggt tatgtccttt actgcatgtc attggtaggt 120catctcaaaa tggcactcga gctttggaag ggtgagaact attgctagat ttggtagggg 180gtctgcatct atgggcccga gtcctccatc tccacaagct 220 22 240 DNA Homo sapien 22atctgcttta agtaactaca tgaaatatct caagccccaa gtaactatac ccagaaccag 60caccaaccga ggcttctgaa caaaaacaac ctcacaaagc aatttaccca gaaagcaaca 120tttctaagac aggagactgc ctcctccaaa tggctcactc cattgaaaaa acgccatctg 180ccagaggcag acaccaaata aaaggcactt ggacatcagg atttgtaaaa aaacaagtac 240 23 221 DNA Homo sapien 23ggattttttt atacaacctt agaccacctt ctttagcttt aggcgtctgc ggttgccctt 60ggatctgttc tcaatcctca gtgtgtgtgg cagcatgtga tcatagagag ctgggcaaag 120ttcactttct ctttgctgac agtctcacct tttctcactg ggaagctgca caggagcctt 180tgggctggtt cagcccagag gcccctgttc tcctgccttc c 221 24 248 DNA Homo sapien 24atggcgcccc gcgcccggag ggccccttct gagcgccccg gcccctccct ccgcgctccc 60cctcctcccc gcggcgcccc cgccccgccc cgcccccgcc gagaccccga ccccggcccc 120acgggcggac actcggccgg gcagccgcgg gccgagcgca gccgctccgc accgatgcgc 180ctggtggcag actccaagtg ggaccggcgg acacgcagcc tcgcgtgtca ggggaagctg 240atggagaa 248 25 248 DNA Homo sapien 25tgccggggag gctgaacagg agggttagga ataaaatcag ggcttaagca gagctggtcc 60attcctcagt cctctcacgc ccctgttttc tgagcacggg cgttctgact cagttttaac 120tttgaattta ggagataaca caacatttgt tccttgccca ttaaaaaaaa aaaaaaacaa 180gtaacttttt ttgctccagc tgtactcaac ctggttgact aatgctcact gtagagctag 240aaaaccaa 248 26 248 DNA Homo sapien 26gaataggaac taaaatgtaa atctgtctta aacatctgtg aaaaagatgg tacttttgac 60aacatttatc tgcatgtcca gatcagcaat gagtcggcaa ttgacttcta caggaagttt 120ggcctttgag attattgaga caaagaagaa ctactataag aggatagagc ccgcagatgc 180tcatgtgctg cagaaaaacc tcaaagttcc ttctggtcag aatgcagatg tgcaaaagac 240agacaact 248 27 178 DNA Homo sapien 27aaaaagatgg tacttttgac aacatttatc tgcatgtcca gatcagcaat gagtcggcaa 60ttgacttcta caggaagttt ggctttgaga ttattgagac aaagaagaac tactataaga 120ggatagagcc cgcagatgct catgtgctgc agaaaaacct caaagttcct tctggtca 178 28 240 DNA Homo sapien 28ccgaggggct gcaagcccgg gagggcccct gtaggagccc agcgcgtggc ggggactgca 60gcaggaactc ctgcctggcg tggcatcgcg gggcgcccgc tggggagacg ccacccgtgt 120gtgacccctg tccggagcgg atccagaacc acccccggac tcaactgtgt gaggtccaca 180cggactgttg gccgtgccaa ccagggactg gcgctccgac ctgcccgagg accccaaagc 240 29 443 DNA Homo sapien 29ctgtttcaaa caaaaccaaa aacctaagta gagcattaca ggcctctgtg gctgctgcgt 60ttctgtagaa agcaacttat tttattgact tttttttttt aaggaaaaga aataaaaaga 120ccccagcaag caaaaacatt taaaaaatga ttttttttcc tcctacttaa gtggttcttt 180ctccctttgc tctacttttg gagaatgaac ttaacatccc ggcttctttt gttaagccat 240agctgacctt aatctgtggt tagtttatta aaataattaa aaatactttc taagaagaga 300tatttttgat attaggactg atgttgaaac atataggggc aatttataaa aaggtagtta 360gagaaatata ttttagtgaa ctataaccac agagcacaga tgactcccaa tgagctgatc 420tgtctttagg tttctccctt tcc 443 30 451 DNA Homo sapien 30ttgccgaacc gctttcttac cctccgcacc cgttaagttc tccggtcggg cggcagtctc 60tgaacactta gccgcgccat ccggggtcac accgcctgga aggaggtgac gggggcggcg 120cggggcgcgg acactccccg ctgagagtcc gcctgccatg gactcggaat attacagcgg 180cgaccagtca gatgatggtg gtgctacccc agtacaggat gaacgggatt cagggtcaga 240cggtgaggat gatgtaaatg agcaacactc cggatcagac actggaagtg tagaacgtca 300ttcagagaat gaaactagtg atcgagaaga tggcctcccc aaaggacatc atgtgacaga 360ctctgagaac gatgagccct taaatcttaa tgctagtgac tctgaaagtg aggagcttca 420caggcaaaag gacagcgact ctgaatctga g 451 31 444 DNA Homo sapien 31aaacaatact atcttataaa atagtactgt tgaattattc caagcctccc taggtttgct 60ctcaaatgtc atttacagat tgggctaacg acctagaatc tatatataaa gactttctga 120agaactctgt attatagcaa taccaaacga gtgctgtgtg tgcaaacagt ctggcgttgc 180tttttatgtt gatatttatc ctagaacact gaaagagaat atgccagtga taactcactt 240tacttcagtc atttcaacac agaaaatgct tctctagcat ttttcttttg tagtgttaac 300attttgaaat tcatgtttca gaggcttcat catcacagaa tttactcttg ctccatgaaa 360aaaaattaaa taccttcaga ggaatattta agttgtaaac tatgaaactt gagaaatcct 420cttgagataa aaggctgcca aatc 444 32 451 DNA Homo sapien 32gatccaattc caacaatcta tcttataaaa tagactgttg aattattcca agcctcccta 60ggtttgctct caaatgtcat ttacagattg ggctaacgac ctaaaatcta tatataaaga 120ctttctgaag aactctgtat tatagcaata ccaaacgagt gctgtgtgtg caaacagtct 180ggcgttgctt tttatgttga tatttatcct agaacactga aagagaatat gccagtgata 240actcacttta cttcagtcat ttcaacacag aaaatgcttc tctagcattt ttcttttgta 300gtgttaacat tttgaaattc atgtttcaga ggcttcatca tcacagaatt tactcttgct 360ccatgaaaaa aaattaaata ccttcagagg aatatttaag ttgtaaacta tgaaacttga 420gaaatcctct tgagataaaa ggctgccaaa t 451 33 224 DNA Homo sapien 33cgcgagtgct gtctccgcag ccgcgcggta gacggccgcg ttccagccct gctggcgacc 60cccggagttg agcctgcgag ttgggtgcgg gaacaccggc cctgggtggc cgggaaccct 120aaggccacca ccgcgatccg caggtcaaac gtgacggggc tccctcctgg atagggtcgg 180tcgggaagtt gatggagact cgacaggcct aagtgtccac catc 224 34 1231 DNA Homo sapien 34atccgcggcc aaccagagcg cgcgcgcggc acaacctcat cccaggctcg cgtgcgcagc 60agctggagca gatccgcagg gacatccgag acttccggtc tagcgcgggg ctggacaaag 120tcatagtgct gtggacggcg aacacggagc gcttctgtga ggtgattcca ggcctcaacg 180acacagccga gaacctgctg cgcaccattg agctcggtct ggaggtgtcg ccctccacgc 240tcttcgccgt ggccagcatc ctggagggct gtgccttcct caatgggtct ccgcagaaca 300ccctggtgcc cggagctctt gagctcgcgt ggcagcaccg ggtttttgtg ggcggagatg 360acttcaagtc aggccagacc aaagtcaagt ccgtgcttgt ggacttcctc attggctccg 420gcctcaagac catgtccatc gtgagttaca accacctggg caacaacgat ggggagaacc 480ctatcggcgc cattgcagtt ccgctctaag gaggtgtcca agagcaacgt ggtggacgac 540atggtgcaga gcaacccagt gctctatacg cccggcgaag agcctgacca ctgcgtggtc 600atcaagtatg tgccgtacgt gggtgacagc aagcgcgcgc tggatgagta tacctcggag 660ctgatgctgg gcggaaccaa cacactggtg ctgcacaaca cgtgtgagga ctcgctgctg 720gccgcaccca tcatgctgga cctagcgctg ctgaccgagc tgtgccagcg cgtgagcttc 780tgcactgaca tggaccccga gccgcagacc ttccaccccg tgctgtccct gctcagcttc 840ctcttcaagg cgccactagt gccgcccggc agcccggtgg tcaatgcgct tttccgccag 900cgcagctgca tcgagaacat cctcagggcc tgcgtggggc tcccgccaca gaaccacatg 960ctcctggaac acaaaatgga gcgcccaggg cccagcctca agcgagttgg acccgtggct 1020gccacctacc ctatgttgaa caagaaagga ccggtacccg ctgccaccaa tggctgcacc 1080ggtgatgcca atgggcatct gcaagaggag cccccaatgc ccaccacctg aggccccggt 1140cacacagttt ctcggctctt cctccccgct gccccccacg accctacctt gaaggccccc 1200acaaataaag gcgctgccac tcaaaaaaaa a 1231 35 234 DNA Homo sapien misc_feature (1)...(234) n = A,T,C or G 35actgacccca cccaggatca aggctcanga tgcaatgaca aataacgcta ccactaggca 60gaacttgacc cgtgtgtagg aggatagtgg gaaaagcact tagaggccgg ggtcagtaac 120aacatcagcc aacagggatg accacgcccg ctgggcttca gcatggaggt gaaacaagca 180gccctggctc ctgccctgcg ggcacctctg tctgggaggg gcaggagggg cttc 234 36 234 DNA Homo sapien 36tcagagccca cccggcatgt acaactgtga aaggccttgg aaaactggag cgatgagagc 60ggtgaatcgt gttggtctca ttggagaccc gcagattggg agattctgga accaggacga 120ccttgcccct cacctgcagc agaagccccc ggaaacgccc ggccccgacc cggacctgag 180ccgcctgggg gcccaaggga agctgaacgc ccggtgggct cccgcgatgg ttct 234 37 246 DNA Homo sapien 37gattcgagag agggaaatct cacttccacc ttattttcac taaattttct gaaacagaca 60aaatgtgtag tgttgacagg gccaatctcc gtgacttttg ttcatatgct tttatttatc 120catgatttcc aagacactgg gcttcccatt ctcacttccc ctcatcaatc cctttccttt 180ctttagaagg gggcttatgt atgagactgg tgaagtccag tgaagctaag taaaggggca 240agatgg 246 38 244 DNA Homo sapien 38agcagaggag gttcgattaa aactggaaga gaccagagag gtacagaact tgaggaagag 60gcccaacggg gtgagtgctg tggccttgct ggtgggagag aaggtacaag aggagaccac 120tctagtggat gatccctttc agatgaagac aggtggtatg gtggatatga agaaactgaa 180ggaaaggggc aaagataaga tcagtgagga ggaggacctg cacctgggga catcgttttc 240tgca 244 39 242 DNA Homo sapien misc_feature (1)...(242) n = A,T,C or G 39caacaatctt ctntaaaata gactgttgaa ttattccaag cctccctagg tttgctctca 60aatgtcattt acagattggg ctaacgacct agaatctata tataaagact ttctgaagaa 120ctctgtatta tagcaatacc aaacgagtgc tgtgtgtgca aacagtctgg cgttgctttt 180tatgttgata tttatcctag aacactgaaa gagaatatgc cagtgataac tcactttact 240tc 242 40 241 DNA Homo sapien misc_feature (1)...(241) n = A,T,C or G 40accagaactg aaacagagga ctgtgctgaa tctctaaatc atgttgatag tgatgtacca 60ccttctaata ccatgagtgn ttttaacacc tctgattacc gctttgagtg tatatgtggt 120gaacttgatc agatagatcg taagcctcgt gttcaatgcc tgaagtgtca cctgtggcaa 180catgcaaagt gtgtgaatta tgatgagaaa aatctgaaga tcaagccttt ttactgcccc 240c 241 41 245 DNA Homo sapien 41agcgagagga agagaggaga agaaagagaa accagggggg cgaggcgccg tccaatgaca 60aagcccaggg gtgggcgccg gccgccatct tgtaccgggc agcaggatat tcgcccgcgt 120cctccgccct cggaggggga ggggcggcgg cggaggcgag aaaagtagcg agagacgcca 180gcagcagccg ccgccgcgga gccaacgcgg actgggacgg cggcggcagt agtgggaccc 240ggcga 245 42 241 DNA Homo sapien misc_feature (1)...(241) n = A,T,C or G 42agccnagact ttagattgcc cggaggaagc aaactcttcg tataaaaaaa agcaggccat 60ctgcttaacc cttggctcca ccataaggca ctgggactcg gatttctcta tctgatagag 120gtattttctg tggccctggg agctgtctgt ctttccccta cccccaagga tgccaggaag 180acgtccacca ttagccatgt ggcaaccttt acttctatgc ctcacaagtg cctttcagag 240a 241 43 245 DNA Homo sapien 43gcatgcccct tggagtggaa ggaagctgga cagggcaggc ctctggggac gggacacagg 60gaagcccgaa ggggcgcctt ggccaggtct gccatctcct ccagcgaggc tctggccagc 120actgggtgag agtggggagg gggcactggc ctttgcagca cagtaaaaca tggtccagac 180aacctgtggc cccggcctca tgagcacccc ctgcacaggc ccagcccaag ccaggcgcta 240gaagg 245 44 238 DNA Homo sapien 44gatgcccctt ggagtggaag gaagctggac agggcaggcc tctggggacg ggacacaggg 60aagcccgaag gggcgccttg gccaggtctg ccatctcctc cagcgaggct ctggccagca 120ctgggtgaga gtggggaggg ggcactggcc tttgcagcac agtaaaacat ggtccagaca 180acctgtggcc ccggcctcat gagcaccccc tgcacaggcc cagcccaagc caggcgct 238 45 247 DNA Homo sapien 45gcctttgcgc accgtttctt ccctccgcac ccgttaagtt ctccggtcgg gcggcagtct 60ctgaacactt agccgcgcca tccggggtca caccgcctgg aaggaggtga cgggggcggc 120gcggggcgcg gacactcccc gctgagagtc cgcctgccat ggactcggaa tattacagcg 180gcgaccagtc agatgatggt ggtgctaccc cagtacagga tgaacgggat tcagggtcag 240acggtga 247 46 225 DNA Homo sapien 46gcccgcgcac cctctctcgg ggctggtggc ctgcgtgggc ggccgggtgg tcggcagagc 60cgccggggcc cccgggctca gaaagaggcc gaaatggctg cgaagcaggc cccgggcagg 120agtcgctcgg gcgcagggag gaagtgaacc ggccggaggt agcgcccggc tgctggcccc 180acagtcccga caccttcgga actcctaact cctttacttg tccgg 225 47 227 DNA Homo sapien 47caaacaatac tatcttataa aatagtactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctaaaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgcca 227 48 537 DNA Homo sapien 48gccgcccggg ccctggatcc tgcaccgagg ccgcaaaaag gccacaggca gcgcagtgtc 60catcttcgtg tatgatgtga aaccgggagc tgaagagcag acccaggtgg ccaaagctgc 120cttcaaacgc ctcaaaactc tccgacaccc caacatcctg gcctatatcg atgggttgga 180gacagaaaag tgcctccaca tcgtgacaga ggctgtgacc cccctgggaa catacctcaa 240gggctggcga gtggaaactt gggggtctgg actacatgta ctcggcacag ggcaacggcg 300ggggaccacc cagcaagggg atcccggagc tcgagcagta tgatcccccg gagctggctg 360acagcagtag cagagcagtc agagagaagt ggtcagcaga catgtggcgc ttgggctgcc 420tcatctggga agttttcaat gggtctctac ctcgggcagc tgccctgcgc aaccctggga 480agatccccaa atccctggtg acccattact gtgaactggt gggagctaac ccaaaag 537 49 336 DNA Homo sapien 49aagcgtctct tttccactgt tgcagtgagc tgagaccatg ccactgtact ctagcctggg 60taacagccag accctgtctc aaaaaaaaaa acaatttttt tcataacata attcccattt 120ttatttattt tgagtcactc ataattaatt gccaaaaaag cattttatac attgagttgg 180ggggtagtgg atcttagtgt ggtgttgcat ggaggggcga gattttatat ttataatcaa 240cacgtgggtt aacatgtttt tttgaaatcc aagcaataca caggaaattt aagtagaata 300aaaattgcag cccatttttg aaatgtcagc atgtgc 336 50 247 DNA Homo sapien misc_feature (1)...(247) n = A,T,C or G 50cagctgngaa tctgactggt cctgnacttt ttttggctgg ngggctatta antatatcct 60cagtttcaga gcctgttatt ggtctattca nggattcaac ttcttccttg nttantcttg 120ggagggggta tgtgtccang aatttatcca tttcttctan attttctagc ttatttgtgt 180acagatgttt atagtattca ttctctgatg ggagnttgta tttctgtggg atcagnggtg 240atatccc 247 51 243 DNA Homo sapien misc_feature (1)...(243) n = A,T,C or G 51ctggctgctt ttttgctgng ggtagatggt gggaatactt ctggtctaga tataacttac 60cactaagaaa cccccagtat gtcaccactg cctaaatcta actagaccag ggtccaaatg 120ccatccaggc caggcaggaa atatacctca tgtgaaagac agtaaggagt tgtgggcagt 180gtaacaaaca ggagagctat gccccaacta aaaggagcag ctgctactgc ttagtttcag 240cca 243 52 944 DNA Homo sapien 52ccaaacaccc gaaagacaca aaccagaatt gagccctact ccccaaaatg tacaaacaga 60tgatacgctt aactttttgg acacctgtga tttgcatact gagcatataa agccatcttt 120acgcacgtcc atcggtgaaa gaaaacggtc tctttcacca ctaattaagt tttctccagt 180ggaacaaaga ttgagaacca caatagcatg tagtcttgga gaactaccta atttaaagga 240agaagacatt ttgaataaga gccttgatgc aaaagaacca ccgtctgact tgacaagatg 300aagacgtacc catttaatat aactatgatg cacttaaatt gaagctatgc cacaggatag 360aaaatgaatt acaacttaaa tacatgttgg aagtgtaaca ctgtttttca agggttaaaa 420aaattcctaa tgccttttag ccttctttaa tatttttagg taaggaaagt atgtttggat 480tttttcctct ttgtaggtat atgagattga aatgtgaagt atttggacaa caaacgtcaa 540gcaatgggaa gccattttga tttcttgagt aatcttgtaa gcattaagtg aatgacaaag 600tagtagtgta acttatttct tatgttataa cttcagtcaa ttaatataag gatagttttt 660gttgtatgtt cactaaatgg ttaatataat agccattgaa tatactaatc tttcatctta 720gagaactata caacttttat tgtttcttaa tggaacattc tggctaacca gaaaaagtga 780gaaaagtagt acccttggga tgtgtagtca agatgacaaa ttttaagact ggaaaagctc 840taaacaggct taatgattct tcaggtagaa tgatcctgag aaggtgatgt ttgatggaat 900aaagtgcatg tgatgattaa gtgaagactg gggcagaatg attt 944 53 230 DNA Homo sapien 53taaagataat gattgataag ctagaacttt ctgatgtagt cattacatga aaccccttgt 60cactggtttg tgtgttcaga ggaagccatg gccgagatag ctttcctgaa ataaaccagt 120agcttttcag attgacgttc ttgctacaat tgtaccatct ggtaattcct gaaaatgtca 180atttttttgt gttaatattt ttggtttcaa acaataacaa atgtctctag 230 54 242 DNA Homo sapien 54ggaagaagga gaagcaattc tattccaagg ccaagaccta ctggaaacaa atcccaccca 60cggtggacgg catgcttggg gggtatggcc acatctccag catcgacatc aacagctccc 120ggaagtttct gcagaggttt ttgagggaag gcccgaacaa gacaggaacg tcctgtgccc 180tggactgtgg agctggcatt gggaggatca ccaagcggct gctcctgccg ctgttcagag 240ag 242 55 246 DNA Homo sapien 55ccaaacaccc gaaagacaca aaccagaatt gagccctact ccccaaaatg tacaaacaga 60tgatacgctt aactttttgg acacctgtga tttgcatact gagcatataa agccatcttt 120acgcacgtcc atcggtgaaa gaaaacggtc tctttcacca ctaattaagt tttctccagt 180ggaacaaaga ttgagaacca caatagcatg tagtcttgga gaactaccta atttaaagga 240agaaga 246 56 241 DNA Homo sapien 56tttggagctt caaagaggca aagtgactaa ggaggaaatt agtaaagagt ttatgttaag 60cgcagattgt cttctctttt taagatgcct tgtgaatatc tctccttgga tgcaatggag 120aaatggatca tctgtaagta accgagctag ctagggctgt ctcttgtgtt taagctttaa 180tgagggaatg cctgtttctg ccttagctct gcccttcacc ctgcaatgac acctgtgtgc 240t 241 57 246 DNA Homo sapien 57ccaaacaccc gaaagacaca aaccagaatt gagccctact ccccaaaatg tacaaacaga 60tgatacgctt aactttttgg acacctgtga tttgcatact gagcatataa agccatcttt 120acgcacgtcc atcggtgaaa gaaaacggtc tctttcacca ctaattaagt tttctccagt 180ggaacaaaga ttgagaacca caatagcatg tagtcttgga gaactaccta atttaaagga 240agaaga 246 58 244 DNA Homo sapien 58attgcatcgt tttccaacat acttttagat ttacaaagta aaaccaacca tggatctgcc 60tatcttggtg tgtcgatctt gtaattttat ctttgtgtgt gtgtgtgtgt gtgtgtgtgc 120actcactggg gcctaagctc agaacctcac acaggcagag tatacacacg ccctgcaact 180aaactgcatc tctagtccct atacatgtgt cctactcatc cttcaaagtg agtccctagg 240ggat 244 59 1737 DNA Homo sapien 59cggtatttgt gagaggagtc ggcgtttgaa gaggtggaac tcctagggct tttttgagag 60tgctgattta gaagaataca aatcatggct gaaaatagtg tattaacatc cactactggg 120aggactagct tggcagactc ttccattttt gattctaaag ttactgagat ttccaaggaa 180aacttactta ttggatctac ttcatatgta gaagaagaga tgcctcagat tgaaacaaga 240gtgatattgg ttcaagaagc tggaaaacaa gaagaactta taaaagcctt aaaggacatt 300aaagtgggct ttgtaaagat ggagtcagtg gaagaatttg aaggtttgga ttctccggaa 360tttgaaaatg tatttgtagt cacggacttt caggattctg tctttaatga cctctacaag 420gctgattgta gagttattga cacagttgta ttaaattgtt cacaaaaagg agagcctttg 480ccattttcat gtcgcccgtt gtattgtaca agtatgatga atctagtact atgctttact 540ggatttagga aaaaagaaga actagtcagg ttggtgacat tggtccatca catgggtgga 600gttattcgaa aagactttaa ttcaaaagtt acacatttgg tggcaaattg tacacaagga 660gaaaaattca gggttgctgt gagtctaggt actccaatta tgaagccaga atggatttat 720aaagcttggg aaaggcggaa tgaacaggat ttctatgcag cagttgatga ctttagaaat 780gaatttaaag ttcctccatt tcaagattgt attttaagtt tcctgggatt ttcagatgaa 840gagaaaacca atatatggaa gaaatgactg aaatgcaagg aggtaaatat ttaccgcttg 900gagatgaaag atgcactcac cttgtagttg aagagaatat agtaaaagat cttccctttg 960aaccttcaaa gaaactttat gttgtcaagc aagagtggtt ctggggaagc attcaaatgg 1020atgcccgagc tggagaaact atgtatttat atgaaaaggc aaatactcct gagctcaaga 1080aatcagtgtc aatgctttct ctaaataccc ctaacagcaa tcgcaaacga cgtcgtttaa 1140aagaaacact tgctcagctt tcaagagaga cagacgtgtc accatttcca ccccgtaagc 1200gcccatcagc tgagcattcc ctttccatag ggtcactcct agatatctcc aacacaccag 1260agtctagcat taactatgga gacaccccaa agtcttgtac taagtcttct aaaagctcca 1320ctccagttcc ttcaaagcag tcagcaaggt ggcaagttgc aaaagagctt tatcaaactg 1380aaagtaatta tgttaatata ttggcaacaa ttattcagtt atttcaagta ccattggaag 1440aggaaggaca acgtggtgga cctatccttg caccagagga gattaagact atttttggta 1500gcatcccaga tatctttgat gtacacacta agataaagga tgatcttgaa gaccttatag 1560ttaattggga tgagagcaaa agcattggtg acatttttct gaaatattca aaagatttgg 1620taaaaaccta ccctcccttt gtaaacttct ttgaaatgag caaggaaaca attattaaat 1680gtgaaaaaca gaaaccaaga tttcatgctt ttctcaagat aaaccaagca aaaccag 1737 60 249 DNA Homo sapien 60tcaaaagcaa caagattaaa aagattagaa tgcagtggaa ttgtagcttt aagacgctga 60atgtgattct gtatcattta agagagaaag tagaattaac acatgttcac acacagaaag 120aatctactct ttgtacaacc tttgctgaaa gaactttgaa agacttcagt aaaaacaaag 180ttaaatccag aaaagacaag atcaaacaag caatggtgag caaaaaacct agcaaacgtg 240gcactaaac 249 61 243 DNA Homo sapien 61ttgtttatca tggagctaat aatcctaaag gattgctgga agttcgggaa gccctggaaa 60aggtacacaa agtagaagac cttcttccga ttatgaagtt taatactaaa acgaaggatg 120ggttcaccgt gaacacaaaa gttcccagcc ttaaagacca agggaaggaa tatgatggat 180tcacaatcac gattacagga gacaaagttg gcaatatatt attttctgtg gaaactcaaa 240cca 243 62 240 DNA Homo sapien 62gttgttgccc tgtgattagt tctgcttttt aacccactcc ctggatgcat ttttccctcc 60ttgcatttcc ctcttttcct ggagttcata ctagagaatc tgcactatgt ttttcccttt 120ttgtcttgag atgaaagttt taaaataatc cacctctgtc atttccactc tctgaacatc 180ccaagctgta tccctggcct cttttctcag actatgtttc tttacttggg acctagaact 240 63 245 DNA Homo sapien misc_feature (1)...(245) n = A,T,C or G 63agcccncctg aagcgccgcg gcgccgctat cgagcttcct gcantggtgg ccacccgagc 60aagtgccgtg gcgggggcgg agagcggcca cggcggcggc gcctccccaa gtggcccgtt 120gcgtccgacc ccgcgtgaaa gatatcaagt tattctagta caaccatata aataaataat 180acctgaagtc tcagtgtaac atggacaatt aacagtgatg acagataaat acagacgcat 240gggga 245 64 299 DNA Homo sapien 64tgccagagca gctgggaagg tgtggaagga gcagttccgg gtgaggtggc cttcccttat 60gaaacactac agccccaccg actacgtcaa ttggttggaa gagtataaag ttcggcaaaa 120agctgggtta gaagcgcgga agattgtagc ctcgttctca aagaggttct tttcagagca 180cgttccttgt aatggcttca gtgacattga gaaccttgaa ggaccagaga ttttttttga 240ggatgaactg gtgtgtatcc taaatatgga aggaagaaaa gctttgacct ggaaatact 299 65 246 DNA Homo sapien 65agccgggccc gagctgggct ctgcgaggtg caagaaagcc tttgaggtga aggtgtatga 60aagtcatcat aacagatgtt ttccaaaaac ttgtagaagg ttgtgaaaaa actactagga 120tcacgcggca tgtattgagg tgtggcatgc agcattttgg aaggaaaatt gaagacgtgt 180tcaagaaaac atgaacagaa gcaaatgatg aaaatcagca ttttacttga tgttgataac 240atcaca 246 66 528 DNA Homo sapien 66agtccctaaa tacatgaggc tgggtgagca gatgaaaccg gtagccactg tgctgatgca 60tgtgactcca ttcagttggg gattttggtt ccatgtggat ccatactaag tattcttcag 120tcagtggatt ttagcaaggg gaggtaggag tggaagagag gtgtgaagaa acctctccga 180acaaatgaac cagcagtaag tttctaaaaa tcagaatcta gatagaagtt ctgcaatatg 240aaatgagcac attctttgat aaggcgtatc tattcatgct tttgtaccac tgttttgtac 300ctgactccct gaccgatttg tattttttat atacaactag aaggaagtca caagattgcc 360ttctacagtg tgccatttcc aaatggatct gttgttggag gaaactggtt gctagtcaat 420gttctatatt taatgaatgt gtgataaatc atcctgtaat cagtatggag taacctgttt 480ttgtagtttg gatgaatatg tcctgagaaa tttccatcca ctttggtt 528 67 536 DNA Homo sapien 67gttctgcatc ctccaggctc tggttcccat gcagcagctg tcagcgttca gacaacccct 60cagaacgtgc ccagccggtc aggcctgccc cacatgcact cccagctgga gcatcgcccc 120agccagagga gcagctcccc tgtgggcctt gccaaatggt ttggctcaga tgtgctacag 180caacccctgc cctccatgcc cgccaaagtt atcagtgtag atgaattgga ataccgacag 240tgagcagggc aggcagactc aactaagccc ggacctgtgg tggcacactg ggcaggaccc 300tgcttcatct cgggttggtt tatgggcttt tactttggag cactctgtgt gaagctgttt 360ggtggaaccc atgcatctgg tgtggtccgc attatgatgg aaggatctta accagtcgag 420tggagtgtac attgtctgaa tacaggatgc acaatgttgt caatcctgga aatggtcttt 480cttttttgta agatatgtga atgaagtgtt ggtgtcctca ccaagaggtg gcacct 536 68 1664 DNA Homo sapien 68attgatgaac tcccagaggg ccggccagtg cgggtagccc ggattgatga actcccagag 60ggcgctgtga agcctccagc aaacaagtat cctatcttct tttttggcac ccatgaaact 120gcatttctag gtcccaaaga cctttttcca tataaggagt acaaagacaa gtttggaaag 180tcaaacaaac ggaaaggatt taacgaagga ttgtgggaaa tagaaaataa cccaggagta 240aagtttactg gctaccaggc aattcagcaa cagagctctt cagaaactga gggagaaggt 300ggaaatactg cagatgcaag cagtgaggaa gaaggtgata gagtagaaga agatggaaaa 360ggcaaaagaa agaatgaaaa agcaggctca aaacggaaaa agtcatatac ttcaaagaaa 420tcctctaaac agtcccggaa atctccagga gatgaagatg acaaagactg caaagaagag 480gaaaacaaaa gcagctctga gggtggagat gcgggcaacg acacaagaaa cacaacttca 540gacttgcaga aaaccagtga agggacctaa ctaccataat gaatgctgca tattaagaga 600aaccacaaga aggttatatg tttggttgtc taatattctt ggatttgata tgaaccaaca 660catagtcctt gttgtcattg acagaacccc agtttgtatg tacattattc atattcctct 720ctgttgtgtt tcggggggaa aagacatttt agcctttttt aaaagttact gatttaattt 780catgttattt ggttgcatga agttgccctt aaccactaag gattatcaag atttttgcgc 840agacttatac atgtctagga tccttttatc aaggcagtta tgatcatcgt tttcctgcct 900tgaccccacc atcatcaaac actcagttaa atataaatta acatttttta gatgaccact 960caacataatg cttaagaatg gaatttcctc tctgtgacag aacccaggaa ttaattccta 1020aatacataac gttggtatat tgaagacgaa attaaaattg tccttcagtt ttgaggccat 1080gtgtaaagtt tacccatatt gtaaaatatc tattccggta ttagaaatag ctagttgaca 1140gcttatactt ctcaaaattc atattgttat gtacacaaac taagtttcta tatgtgaagt 1200tagtgagtct ttttgtgtta ctccaaaata aaggcaatga tttatttttt tcccagtgcc 1260aatacaattt tgagctaagc actcaaggtg gatactttac attttaaagc tggaatcagc 1320aacagcccta tgggaaacca gacaaagcat tgacttttaa atgtagactt ttaaaataaa 1380ctgttttctt ttggaactac aattagaata gttaatattc atccttaaac cattattatg 1440tgtacattat tgttgctatt gtgataatag agaattttat ttatttttat gccagcttat 1500attgtgagaa cacatttagt cagtttgggt tttatcaatc ctgttaatgc ttgtccttgg 1560aacatctttc gcgtattcac ggtttgtagt tgaaaagttt actgtaaaaa aatcaaaaac 1620aaaaaaatgt attgttttta cagaataaat ttattggaat gtgt 1664 69 218 DNA Homo sapien 69taatgagcca accacgtggg agcttaacca gtgatagaac tagaaattgg gttcttcaac 60agaaaataga agggagaaac aaaagaatca aactacgcta aattgattga aatgaatgga 120ggaggaaccg gctgtaatca tgaattagaa atgatcagac aaaagcttca atgtgtagct 180tcaaaactac aggttctacc ccagaaagcc tctgagag 218 70 241 DNA Homo sapien 70aacaaataaa aaataaaaac aacgccagtc tcagtaaatc tgtaggtgtg tctaaccggc 60agaataagaa agtagaagaa gaagaaaagt tgctgaagct ctttcaggga gtaaataaag 120cccaagatgg atttacgcag tgggtgtgaa cagatgcttc atgcccttaa tacggcaaat 180aacttggatg ttcccacatt tgtttctttc ctgaaagaag tagaatctcc ttatgaggtc 240c 241 71 224 DNA Homo sapien 71agactgacca ccggcctccc gcctgcaggt cagaggctct gacactgtct ggtttccaat 60gcttctggag acttcctgcc taggcctcat cctcctcttt gccagtcacc tgattaacca 120attctccagc attaggactt acctccttct ttttgtaagg tctcttgtat gttgttaaat 180gtttggctta aacaatttat aaaagccttt ctagaaggca gact 224 72 250 DNA Homo sapien misc_feature (1)...(250) n = A,T,C or G 72gcgatgagtg cgcccccaaa ggggcaccct cgctgcggtg canacactgg tgcgtggcga 60ggttctcccc tttgggtgcg atgagtgcgc actgggcgcc accgtggatg cccccgccgc 120caagcccctg gccagcgcgc ctggcggacc gggctgcggc ccaggatccg atcccgtggt 180gccccagcgc gccccctcgg gcgagcggtc cttcttctgc ccggactgcg ggcgcggctt 240ctcccatggg 250 73 227 DNA Homo sapien 73tacttcactc acctaattgt gatgttcaag tcccccaggc cggctgccat ggtgctggac 60cgctcccagg actttgggaa aacatggaag ccttataagt actttgcgac taactgctcc 120gctacatttg gcctggaaga tgatgttgtc aagaagggcg ctatttgtac ttctaaatac 180tccagtcctt ttccatgcac tggaggagag gttattttca aagcttt 227 74 260 DNA Homo sapien misc_feature (1)...(260) n = A,T,C or G 74atgcgtnttc ggcggccgcg gcggaccatg gccctggccc ggcgtcgctg ggctttcctc 60acggcgtccc cgagcagcgt cgcagagcgg gccgacttcc gggaaggaac tgaccagcga 120ctgagcggcg gccggcgcgc ttagcgccct gaacatgcgg cagtccctgc gggcgacccc 180gggctccgga caggcggcgg cggaggcggc ggctcgggag ggaaggaggc ggcggcgccg 240gcggaggtgg cggcggagac 260 75 204 DNA Homo sapien 75gtggggacca ggtctgtggg cctcaggtct ggccagccag ggctggtgct gtccccgcct 60acctccactt cctttccctt gctcactctg gatccagtga cagcaggtgt catgggtcaa 120gcataaatca tatatagcat tttcaggcat gttcctggta gttcttttga gtctgacatt 180ctaataaaat aatttgtaga aacc 204 76 227 DNA Homo sapien 76aaccacacat tggaaaaatc agtttaccct agaatctagt tattgttgtg gtacagttta 60atttttgtca aataattctt tctaaaattt ctaatgtaag tctttaattt tcaagatatt 120ttgcttagaa gatgatatgg tttggctgtg tccccaccca aatctcacct tgaattccca 180cgtgttgtag ggggcaggtc tttcctgtgc tgttcttgtg aaagtga 227 77 528 DNA Homo sapien 77tagtacagca gccatgcagc caccttattt catagatgcc atctgtgtgt cctcttgact 60accttctatt tagaggaaga atgagagctt tgtgtgttta actgagctta tagtaggact 120tctttgcata tgtatggtac tgaaaaatct taatatacat ctttaatcct ttttaggttg 180tcctttaaag agtttttgac tagtttcttt ttcttgacag ctcttctctt tggacacatg 240ggccttctta gagggttcag tctaggaccc ggctctcctg gccctgtgtt gagggtagct 300ggtccctctg tccctgtgtc tgctagcact agactttgtt gctgcagatt gatccagtgg 360gtacataggc taattaatgt gagtcttttt ccttgtttaa aggagtccct cttgctgaaa 420gtagagtgat tactattgct gtagtgctag gaaagtatta agtttgtgct gaaaatccat 480tgccatttgg tacaaatgac attgttcttt ctgtgaaaga gatgccct 528 78 241 DNA Homo sapien misc_feature (1)...(241) n = A,T,C or G 78aatgcgggcc gcgtgcgtgc tgtgcggggc ngccggcggt cgcccagagc ggagcatccg 60gcccccggca ctcccttccc cagcaggcct agggagctgc gcgcgggggc agtgcgtgac 120ctggagaccc gggccctggt ggattgggag tcgggcnggg gggagcaggt catgctaggg 180tggtctccgg ccaagggagc gatgaaggtc aggcgcggcg agcggggctg ggaggcgggg 240c 241 79 247 DNA Homo sapien 79agaatattaa gaaaatgaag taactgattt tctaaaaaaa aaaaaaaaaa aatttctaca 60ttataactca cagcattgtt ccattgcagg ttttgcaatg tttgggggta aagacagtag 120aaatattatt cagtaaacaa taatgtgtga acttttaaga tggataatag ggcatggact 180gagtgctgct atcttgaaat gtgcacaggt acacttacct tttttttttt tttttttaac 240tttttcc 247 80 246 DNA Homo sapien misc_feature (1)...(246) n = A,T,C or G 80cttgttccct ctccaagtat ttcatagtaa cactctactt gaagtgactt gatccagact 60gaaaagtgtc ctgcagtgga atgaccacca ggcccagatc tagcctagcc tgagctctca 120caacctctcc ttaaccttcc ctagaacaat tacctttagc tcagtaatgg gaaaatctct 180accctaacat gagggcagga cacacacaca cacacacaca ccctttgatc tcagtcttta 240nacaag 246 81 223 DNA Homo sapien 81ggctcagggc tccttccatt ctaaccttga gccacagtgt cactcttcag ggctctgctc 60ctggctctat tttgttaagg tgtcatcagc cttcaacctc catttatata tttttataat 120gttaagccac tgaccaactt tttcatagaa acaactatca gattcgaggg ctccctttgt 180ccccctgacc tgggcacagg catgggcgat ggctccctct tcc 223 82 235 DNA Homo sapien 82caccatcatc aaagaccaaa ggtagataaa accacaaaga tgggaaaaaa aacagagcag 60aaaagctgaa aattctaaaa atcagagcgc ctctcctcct ccaaaggaac acagctcctt 120gccagcaatg gaacaaagct ggacagagaa tgactttgac aagttgagag aagaaggctt 180gagatgatca aacttctccg agctaaagga ggaagtttga acccatagca aagaa 235 83 245 DNA Homo sapien 83tccgtttatc acagtccact taaaaaatga tgatgatgat aaaaaccatg acccaccaat 60cacatgccta tcatatagta aaacccagcc catgacccct aacaggggcc ctctcagccc 120tcctaatgac ctccggccta accatgtgat ttcacttcca ctccataacg ctcctcatac 180taggcctact aaccaacaca ctaaccatat accaatgatg gcgcgatgta acacgagaaa 240gcaca 245 84 244 DNA Homo sapien 84agccagatga cctttttccc caagtgatac tccaagagca aaagtattga aaatagaaga 60agtcagtgat acttcatccc tgcaacctca agccagtttg aagcaggatg tatgtcagtc 120ttacagcgag aaaatgccca tagagataga acaaaaacct gctcagtttg ccacaactgt 180tcttcctcca attcctgcaa actcgttcca gctcgaatct gatttcagac aattgaaaag 240ttct 244 85 219 DNA Homo sapien 85gtcactgagc ctgccaacca cgctgtggca ggtacctcca gccccagaca cctgcagcct 60ccactgaaag ctcaatggca gcctcatgag accctggacc ggaaccaccc actacctaaa 120aaatcccaaa catataactg aactccttat acccaattgg accaatctat caccctatag 180aagaactaat gttagtataa gtaacatgaa aacattctc 219 86 241 DNA Homo sapien 86agcacgttca actaatattt tagacaatat gggcaaatca tccaagaaat ccactgcact 60tagtcgaact acaaataatg aaaagtctcc cattataaag cctctgattc caaagccgaa 120gcctaagcag gcatctgcag catcctattt ccagaaaaga aattctcaaa ctaataaaac 180tgaggaagtg aaagaagaaa atcttaaaaa tgtattatct gaaaccccag ctatatgtcc 240t 241 87 224 DNA Homo sapien 87cctgccaaaa ccaagaatcg ccgcagaagg aagccatcca cttctgatga ttctgactct 60aattttgaga aaattgtttc gaaagcagtc acaagcacta aatccaacgg ggagagtgat 120gacttccata tggactttga ctcagctgtg gctcctcggg caaaatctgt acgggcaaag 180aaacctataa agtacctgga agagtcagat gaagatgatc tgtt 224 88 241 DNA Homo sapien 88aattcttcca tcaaggagat atagaaaaaa aatatcattt gggtgtgagt ccactttgcg 60atcagtcaca ctgaatctat tgccaacatc cagattggtt ttatgactta cctagtggag 120cctttattta cagaatgggc caggttttcc aatacaaggc tatcccagac aatgcttgga 180cacgtggggc tgaataaagc cagctggaag ggactgcaga gagaacagtc gagcagtgag 240g 241 89 237 DNA Homo sapien 89gtccttccga ggaagctaag gctgcgttgg ggtgaggccc tcacttcatc cggcgactag 60caccgcgtcc ggcagcgcca gccctacact cgcccgcgcc atggcctctg tctccgagct 120cgcctgcatc tactcggccc tcattctgca cgacgatgag gtgacagtca cggaggataa 180gatcaatgcc ctcattaaag cagccggtgt aaatgttgag cctttttggc ctggctt 237 90 242 DNA Homo sapien misc_feature (1)...(242) n = A,T,C or G 90aatgcaaaat gcttgcangt cactcccaaa tataacccta cattacctta tatataaatc 60acaatgaaaa taaaagtgcc tacattacag aactgtgaaa ttttgtttaa aaaaataata 120aaaataaact gttgggtatc attggaataa tgtaacacat aaggctggaa aatactgaaa 180tacagttaag actcaataca caagtttact ttaaaaaaga aaagaaagaa aagtttgcca 240ga 242 91 239 DNA Homo sapien 91acaagatcat cattcgtgtg cagaccaccc cagactacag tccccaggag gctttcacca 60acgccatcac agacctcatc agcgagctct cccttctgga ggagcgattc cgggtggcca 120tcaaggacaa gcaagaagga attgagtagc agctgaaaga agcgttgctt agtggctgga 180aggctggcac atactcctca gggcccttca gtttaccaca tggcgacagc cactctcag 239 92 242 DNA Homo sapien 92tttaatgttg tctcaccata acacaaaaag catgaacttg tattaatcat atataataga 60ttgatcatgc actgtattca caggaggttg gaaaaccatg ccattttctg gaacttaagg 120tgttgcatta tttcatcaat catttgttaa aaaaaaccaa aaaaataaaa atgtgaaccc 180ttcaggtgta aacaccttat cttggtatac aattgatctt tttgttttgt tttgaagtat 240ca 242 93 221 DNA Homo sapien 93gggagaatgt gcacctgcag gtaccgggga gactcacaag gcacgagttc tgacaagaac 60gtaaacagga agaccagggc cttcttgctg cagccatggt agcctcgtgt gctcccaaag 120gaggccttga accagtctgc atatgacagg aacgcagagg ggccctccag tgctgcctgg 180cgcacaacca ggaacgcagt gaccatgctg tccagctggc a 221 94 229 DNA Homo sapien 94cacgtccgcc cctgcggcca agcccaagcg ggccaagggc ctccaagaag tccacagacc 60accccaagta ttcagacatg atcgtggctg ccatccaggc cgagaagaac cgcgctggct 120cctcgcgcca gtccattcag aagtatatca agagccacta caaggtgggt gagaacgctg 180actcgcagat caagttgtcc atcaagcgcc tggtcaccac cggtgtcct 229 95 224 DNA Homo sapien 95gctagtcaga accctatacc atgaagtgta gttaccatac agattaatat gtagcaaaaa 60tgtatgcttg atatttctca actgtgttaa tttttctgct gtattccagc tgaccaaaac 120aatattaaga atgcatcttt ataaatgggt gctaattgat aatggaaata atttagtaat 180ggactataca ggatgttaat aatgaagcca tatgtttatg tctg 224 96 446 DNA Homo sapien 96agctcaagat acatgaaatc aatcaaaggg aaacttgaag aacagagacc agaaagagta 60aaacctttta tgacaggggc tgcagaacaa atcaagcaca tccctgctaa tttcaaaaac 120taccagttct ttattggtga aaacatgaat ccagatggca tggttgctct attggactac 180cgtgaggatg gtgtgacccc atatatgatt ttctttaagg atggtttaga aatggaaaaa 240tgttaacaaa tgtggcaatt attttggatc tatcacctgt catcataact ggcttctgct 300tgtcatccac acaacaccag gacttaagac aaatgggact gatgtcatct tgagctcttc 360atttattttg actgtgattt atttggagtg gaggcattgt ttttaagaaa aacatgtcat 420gtaggttgtc taaaaataaa atgcat 446 97 352 DNA Homo sapien 97aattcagcct tcctccctgc cagagatctc tttaagaaaa tagtttaaac aatttgttaa 60aaaattttcc gtcttatttc atttctgtaa cagttgatat ctggctgtcc tttttataat 120gcagagtgag aactttccct accgtgtttg ataaatgttg tccaggttct attgccaaga 180atgtgttgtc caaaatgcct gtttagtttt taaagatgga actccaccct ttgcttggtt 240ttaagtatgt atggaatgtt atgataggac atagtagtag cggtggtcag acatggaaat 300ggtggggaga caaaaatata catgtgaaat aaaactcagt attttaataa ag 352 98 248 DNA Homo sapien misc_feature (1)...(248) n = A,T,C or G 98cggccgacag anctgaggcg gagggcctga gcccgcgctt ccaccagctg gacatcgacg 60atctgcagag catccgcgcc ctgcgcgact tcctgcgcaa ggagtacggg ggcctggacg 120tgctggtcaa caacgcgggc atcgccttca aggttgctga tcccacaccc tttcatattc 180aagctgaagt gacgatgaaa acaaatttct ttggtacccg agatgtgtgc acagaattac 240tccctcta 248 99 224 DNA Homo sapien misc_feature (1)...(224) n = A,T,C or G 99agnaagagac aatgaactca taggccagac tgtgcgtatc tcccagggac cctacaaagg 60ctacattggt gtggtgaagg atgccacaga gtccacggcc agagtagaac tgcattctac 120ctgccagacc atctctgtgg atcgccagcg gctcaccacg gtcgactccc agcgtccagg 180tggcatgacc tctacatatg gacggactcc catgtatggc tctc 224 100 236 DNA Homo sapien misc_feature (1)...(236) n = A,T,C or G 100ctgtggcgct ccgtgaaatt agacgttatc agaagtncac tgaacttctg attcgcaaac 60ttcccttcca gcgtctggng cgagaaattg ctcaggactt taaaacagat ctgcgcttcc 120agagcgcagc tatcggtgct ttgcaggagg caagtgaggc ctatctggtt ggcctttttg 180aagacaccaa cctgtgtgct atccatgcca aacgtgtaac aattatgcca aaagac 236 101 243 DNA Homo sapien 101cttcctgacc ttgggctacg gctgaccgtt tttttgtggt gtactccgtg ccatcatgtc 60cgtcctgacg ccgctgctgc tgcggggctt gacaggctcg gcccggcggc tcccagtgcc 120gcgcgccaag atccattcgt tgccgccgga ggggaagctt gggatcatgg aattggccgt 180tgggcttacc tcctgcttcg tgaccttcct cctgccagcg ggctggatcc tgtcacacct 240gga 243 102 234 DNA Homo sapien misc_feature (1)...(234) n = A,T,C or G 102ccgganncgn caccgccgcg cnntcgccca cccgcccgcc cgccgctccc ggccccgctc 60gccccctccg ccgccgccgc ccgcccctgc gactacgctg cggcctcccg cccgctcccg 120ctcgctcccg cggccctcgc tcgcctcgcg ccggcagttt tgggcctaca cctcccctcc 180ccccgccagc cgccaaagac ttgaccacgt aacgagccca actcccccga acgc 234 103 247 DNA Homo sapien 103cagcgccagc gaggtcggag cggacagcga ggtcggcagc ggcacagcga ggtcggcagc 60ggcacagcga ggtcggcagt ggcagcgagg tcggcagcgg cacagcgagg tcggcagcgg 120cagcgaggtc ggcagcggcg cgcgctgtgc tcttccgcgg actctgaatc atggcgacca 180cggccacgat ggcgacctcg ggctcggcgc gaaagcggct gctcaaagag gaagacatga 240ctaaagt 247 104 247 DNA Homo sapien 104gattaaccac aattctcaga cccaatcctg agtcctcagg aggttgtatc ttgcagcccc 60tatgcccaag gttgtgatgg tggattccca tacctcattg cagggaagta tgcccaagat 120tttggggtgg tggaagaaag ctgctttccc tacacagcca aagattctcc atgcaaacca 180agggagaatt gcctccgtta ctattcttct gactactact atgtgggtgg tttctatggt 240ggctgca 247 105 224 DNA Homo sapien 105agagaaagaa gaatctgatg atgaagctgc agtagaggaa gaagaagaag aaaagaaacc 60aaagactaaa aaagttgaaa aaactgtctg ggactgggaa cttatgaatg atatcaaacc 120aatatggcag agaccatcaa aagaagtaga agaagatgaa tacaaagctt tctacaaatc 180attttcaaag gaaagtgatg accccatggc ttatattcac ttta 224 106 522 DNA Homo sapien misc_feature (1)...(522) n = A,T,C or G 106cggagccgga gacaagagca gaggccgaac tcgggatctg acaagatggc cgggctgccc 60cgcangatca tcaaggaaac ccagcgtttg ctggcagaac cagttcctgg cattaaagca 120gaaccagatg agagcaacgc ccgttatttt catgtggtca ttgctggccc ccaggattcc 180ccctttgagg gagggacttt taaacttgaa ctattccttc cagaagaata cccaatggca 240gcacctaaag tacgtttcat gaccaaaatt tatcatccta atgtagacaa gttgggaaga 300atatgtttag atattttgaa aggtaagtgt tgtttgtcac cctgtgcttt attaacgtgt 360cctttttgtc ctaagcattc tacatttaga atgtaagcat tggaatctca ctgtatgcta 420acagccccag agtgtgtggg agggaagtgc agcagttctg ggcctgttgt ccatgcttta 480tcatatactg ggcctgttac cttcatagat aagtggtccc ca 522 107 526 DNA Homo sapien 107tttaatgttg tctcaccata acacaaaaag catgaacttg tattaatcat atataataga 60ttgatcatgc actgtattca caggaggttg gaaaaccatg ccattttctg gaacttaagg 120tgttgcatta tttcatcaat catttgttaa aaaaaaacta aaaaataaaa atgtgaaccc 180ttcaggtgta aacaccttat cttggtatac aattgatctt tttgttttgt tttgaagtat 240cagatattaa tttggaataa ggtaaggttc tcttgaaaca tttgaaaacc ctttaagcca 300actgatctga cagctttccc atcagtagaa gtgggaacat accttcttag gtatttacta 360ttaactacat gtaggcagtt tatagcttct gatcagtgta gtagacatta caaacactgg 420ttgtaatggg gttttctgta gactttactt gagaggtgag tataaagcat tttttagtca 480tcatcatgac gatgctgctc aagtgcagat ccagaacagt acagcg 526 108 243 DNA Homo sapien misc_feature (1)...(243) n = A,T,C or G 108aatgcccatc atggcagcgg cgttccgcag aggctgcagg gtcctgagaa gtgtttctca 60ttttgagtgt cgaacacaac actcgaaagc ggctcacaag caggagcccg gattagggtt 120tagttttgag ttgacnggaa cagcagaaag agtttcaagc aactgcccgc aagtttgcca 180gagaggagat tatccccgtc gccccggaat atgacaaaag cggggaggtg ggtatcgggt 240tgc 243 109 242 DNA Homo sapien misc_feature (1)...(242) n = A,T,C or G 109cgngaacaac gccctanaaa aaacaagaag gtaatccctc aacaaaccta aaagaagaca 60gccacaagaa cagaatgcaa gagatggaag agagaatctc aggtgcagaa gattccatag 120agaacatcgg cacaacaatc aaagaaaatg gaaaatgcaa aaagatccta actcaaaata 180tccaggaaat ccaggacaca ataagaagac caaacgtacg gataatagga gtggatgaga 240ag 242 110 246 DNA Homo sapien 110ttcagataac tacttgaaat atgcagagaa atccctgaat gatatgtttg tgaagacata 60tggccattta tacatgcaaa attctgagct atttaaagat ctcttcgtag agttgaaacg 120ttactacgtg gtgggaaatg tgaacctgga agaaatgcta aatgacttct gggctcgcct 180cctggagcgg atgttccgcc tggtgaactc ccagtaccac tttacagatg agtatctgga 240atgtgt 246 111 238 DNA Homo sapien 111ccaaaatggg aaaggaaaag actcatatca acattgtcgt cattggacac gtagattcgg 60gcaagtccac cactactggc catctgatct ataaatgcgg tggcatcgac aaaagaacca 120ttgaaaaatt tgagaaggag gctgctgaga tgggaaaggg ctccttcaag tatgcctggg 180tcttggataa actgaaagct gagcgtgaac gtggtatcac cattgatatc tccttgtg 238 112 242 DNA Homo sapien misc_feature (1)...(242) n = A,T,C or G 112agagaggaag aagcganggg cacggcgctg agacagagct ggagatgagg ccagaccatg 60gacactacac ccagcaatag agacgggact gcggaggaag gaggacccag gacaggatcc 120aggccggctt gccacacccc ccacccctag gacttattcc cgctgactga gtctctgagg 180ggctaccagg aaagcgcctc caaccctagc aaaagtgcaa gatggggagt gagaggctgg 240ga 242 113 225 DNA Homo sapien 113cgaacgcgga gagcacgcca tgaaggcctc gggcacgcta cgagagtaca aggtagtggg 60tcgctgcctg cccaccccca aatgccacac gccgcccctc taccgcatgc gaatctttgc 120gcctaatcat gtcgtcgcca agtcccgctt ctggtacttt gtatctcagt taaagaagat 180gaagaagtct tcaggggaga ttgtctactg tgggcaggtg tttga 225 114 231 DNA Homo sapien 114tcaatgcagg gtctaaaagc tggtgttatt gctgttattg tggttgtggt gatagcagtt 60gttgctggaa ttgttgtgct ggttatttcc agaaagaaga gaatggcaaa gtatgagaag 120gctgagataa aggagatggg tgagatgcat agggaactca atgcataact atataatttg 180aagattatag aagaagggaa atagcaaatg gacacaaatt acaaatgtgt g 231 115 226 DNA Homo sapien 115gtgcagcggg cagaccctgt ggccgtcacg ccctgccgct ccagggaagg gagccaggct 60gagcctctgc cacgtgggag aggggctgtt tccagccacc acccaaaaaa acaccacaag 120ggtcagtcct agcccacccg acagcttccc ttcccaagca ggggtttcgg ggacagtgca 180ccagggaggg ccactgacag gcttgggaca tgtgcccagc tctcct 226 116 230 DNA Homo sapien 116ttctaagacc cgagagaaaa agttgggact aggaactgca tatattcatg gaatgaaaca 60tgccacagga aactacatca ttattatgga tgctgatctc tcacaccatc caaaatttat 120tcctgaattt attaggaagc aaaaggaggg taattttgat attgtctctg gaactcgcta 180caaaggaaat ggaggtgtat atggctggga tttgaaaaga aaaataatca 230 117 225 DNA Homo sapien 117tggtggtagg gtgtcaattt tagatctctc ctgctttctc ttgtgggcat ttagtgctat 60acatttccct ctacaccctg ctttaaatgt gtcccagaga ttctggtaca ttgtgtcttt 120gttctcattg gtttcaaaga acatctttat ttctgcgttc atttcattat ttacccacta 180gtcattcagg agcaggttgt tcagtttcca tgtagttgtg tggtt 225 118 247 DNA Homo sapien 118aagtgtgatc cccatgaagc aacgtgctat gacgatgggg agacctacca tgtaggagaa 60cagtggcaga aagaatatct cggagccatt tgctcctgca cgtgtttcgg aggccagcgg 120ggctggcgct gtgacaactg ccgtagacct ggggctgctg aacccagtcc cgatggcacc 180accggccaca cctacaacca gtatacacag agatacaatc agagaacaaa cactaacgta 240aattgcc 247 119 227 DNA Homo sapien 119gaccaccacg cacttgatgg cctgcgacgg cgccgtgggg aagacatgct tgctgatcag 60ctacacgacc aacgccttcc ccggagagta catccccacc gtttttgaca actactctgc 120caacgtgatg gtggacggga aaccagtcaa cttggggctg tgggacacag cgggtcagga 180ggactacgat cggctgcggc cactctccta cccccaaact gacgtct 227 120 235 DNA Homo sapien 120ctttgccggc ctgccgggcc tgcagctcct ggacctgtca cagaaccaga tcgccagcct 60gcccagcggg gtcttccagc cactcgccaa cctcaggagc acggagatct cgccggcttt 120acgttcacct cggtgtctgc agcaccctcc gcttcctctc ctaggcgacg agacccagtg 180gctagaagtt caccatgtct attctcaaga tccatgccag ggagatcttt gactc 235 121 226 DNA Homo sapien 121ctttgaggtt cctttcttct gcaaacacac tgtcagatgg taacaatgct gttttagggt 60taataatttc tgcccctttc ttctccaagt cactgttaaa catctgctga tttaaagcac 120actcctcggc attttcagtg aattgttcaa tactgactga agcggatgct acaagaggaa 180tttcttcttt gacctcctct ccttgagttt caagctccaa agtttc 226 122 245 DNA Homo sapien 122agctcccaca acaggtggct aagggaaaag gaggtagatg atggcaaaat aagatttagt 60tgtgttttct cagagccgcc acaagattga acaaaatgtt ttctgtttgg gcatcctgag 120gaagttgtat tagctgttaa tgctctgtga gtttagaaaa agtcttgata gtaaatctag 180tttttgacac agtgcatgaa ctaagtagtt aaatatttac atattcagaa aggaatagtg 240gaaaa 245 123 246 DNA Homo sapien 123gattaaccac aattctcaga cccaatcctg agtcctcagg aggttgtatc ttgcagcccc 60tatgcccaag gttgtgatgg tggattccca tacctcattg cagggaagta tgcccaagat 120tttggggtgg tggaagaaag ctgctttccc tacacagcca aagattctcc atgcaaacca 180agggagaatt gcctccgtta ctattcttct gactactact atgtgggtgg tttctatggt 240ggctgc 246 124 245 DNA Homo sapien 124agcccaaatg gaaaggaaaa gactcatatc aaacattgtc gtcattggac acgtagattc 60gggcaagtcc accactactg gccatctgat ctataaatgc ggtggcatcg acaaaagaac 120cattgaaaaa tttgagaagg aggctgctga gatgggaaag ggctccttca agtatgcctg 180ggtcttggat aaactgaaag ctgagcgtga acgtggtatc accattgata tctccttgtg 240gaaat 245 125 242 DNA Homo sapien 125gttaagcaga aggtggagag ctgtcgcgcg agctcagcac cctgcggaac ttgttcaagc 60agctgcccga gcccctgctc gcctcctccg gccactgcta gcgcggcccc cgcgcgcgtc 120cccctgccgg ccggggctga gactccgggg agcgcccgcg cccgcgccct cgcccccgcc 180cccggcggcg ccggcaaaac tttggcactg gggcacttgg cagcgcgggg agcccgtcgg 240ta 242 126 245 DNA Homo sapien 126agcctggagc ggcgggtgct cgggctgcgt ccgctccgca gaagcaccga gcagccgagc 60cggggcccgc cgccctcctc ctccatgagg cccgagtgag gcgcggcggc tatagccgac 120ccgcggcgcc ttccccccgc gtcctatcgc gagcgcagcg gcagcggccc ctggaggagg 180aggcggagga ggaggagcat gtcggacggt ttcgatcggg ccccagagca aacgaggccc 240ctgag 245 127 246 DNA Homo sapien 127agcccccggt gggctgaggc aggggccgct gtcgtcaggc ctgagccagg gtgagctggt 60gcctgccttg cattttcctt ctggtgctgt gaagaccata ggctggcagg cagctgagat 120gaactgtctt taccactgat gaggggcctc tgccggctga gggtagcaag caggggttgt 180gagtcaggct gggggacttg tttgaaagaa agaggagtgg aaaatggttc caggagggaa 240gaggtt 246 128 224 DNA Homo sapien 128ccgaaatggg caagttcatg aaacctggga aggtggtgct tgtcctggct ggacgctact 60ccggacgcaa agctgtcatc gtgaagaaca ttgatgatgg cacctcagat cgcccctaca 120gccatgctct ggtggctgga attgaccgct acccccgcaa agtgacagct gccatgggca 180agaagaagat cgccaagaga tcaaagataa aatcttttgt gaaa 224 129 228 DNA Homo sapien misc_feature (1)...(228) n = A,T,C or G 129ctttgctttc taaactcttc cagaaaggac tgtgagcaag atgaatttac ttttcttaaa 60aaaaaaaaaa aacagggttg gaaagtccaa gccgtaggac ccagtttcct ttcttagctg 120atgtctttgg ccagaacacc gngggctgtt acttgctttg aggnggaagc ggtttgcatt 180tacgcctgta aatgtattca ttcttaattt atgtaaggtt ttttttgt 228 130 443 DNA Homo sapien 130cagagcaaga ctccgtccca aaaaaaaaaa aaaaaaaaaa tacatatata tatatgtata 60tgtatgtatg tatgtatgtg agtgaaatcc tcatctttta tggtagagag tcaatgacat 120tatctaaaag gtgataaatt tggaaataga tatgtaagca tattatatat tatctagagt 180tactgtcata attcttagta ataatagaga gaaatatgaa agaactaagc aagaattatt 240tagaagagtt tgtctctggg tataaatagg acagatcttg gttctaatca caccactgat 300ttgtcaacca caggcaagta ttaataaaaa ctcataaaaa gtaaatgttc taaaactgct 360ctaaaaaata aagtcttaaa aaaaggtaaa tgttttggaa taaacagaca attacaataa 420caatgacatt aaccccgaag tct 443 131 444 DNA Homo sapien 131caaacaatac tatcttataa aatagtactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctaaaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttacttcagt catttcaaca cagaaaatgc ttctctagca tttttctttt gtagtgttaa 300cattttgaaa ttcatgtttc agaggcttca tcatcacaga atttactctt gctccatgaa 360aaaaaattaa ataccttcag aggaatattt aagttgtaaa ctatgaaact tgagaaatcc 420tcttgagata aaaggctgcc aaat 444 132 424 DNA Homo sapien 132aaggaagggg cgaacggcgt gagctggcgc cgaaatggga gaaagcagcg agtgagatgg 60gaaggggcgc caggcgagca cccgggagcc agcgggacct gggcaggggc gcccggagca 120ggcgcgcatg gcgggccccg cgcggggatc cggctggaag agagcgtagc acggctcgca 180cgagtccggg gccgatgtac caggtgagcg gccagcgccc ctctggctgc gacgcgccct 240atggagcccc cagcgcagcc ccgggcccag gccagcctca ggggaacccc ttgggctgca 300ccccacttct gccgaatgac tctggccacc cctcagagct gggcggcacc agacgggcgg 360ggaatggtgc cctgggtggc cccaaggccc accggaagtt gcagacacac ccatctctcg 420ccag 424 133 424 DNA Homo sapien 133tacagtgcgt gttcaggacc cccgattgca gaatgagggc tcctggaact cttatgtgga 60ttataagata ttcctccata ccaacagcaa agcctttact gccaagactt cctgtgtgcg 120gcgccgctac cgtgagttcg tgtggctgag aaagcagcta cagagaaatg ctggtttggt 180gcctgttcct gaacttcctg ggaagtcaac cttcttcggc acctcagatg agttcattga 240gaagcgacga caaggtctgc agcacttcct tgaaaaggtc ctgcagagtg tggttctcct 300gtcagacagc cagttgcacc tattcctgca aagccagctc tcggtgcctg agatagaagc 360ctgtgtccag ggccgaagta ccatgactgt gtctgatgcc attcttcgat atgctatgtc 420aaac 424 134 426 DNA Homo sapien misc_feature (1)...(426) n = A,T,C or G 134gggaagcgcc gcggcctgta tttctnnacc tgcccttcgc ctggttcgtg gcgccttntg 60accccgggcc cctgccgcct gcaagtcgga aacngcgctg tgctcctgtg ctacggcctg 120tggctggact gcctgctgct gcccaactgg ctggcaagat gaagctctcc ctggtggccg 180cgatgctgct gctgctcagc gcggcgcggg ccgaggagga ggacaagaag gaggacgtgg 240gcacggtggt cggcatcgac ctggggacca cctactcctg cgtcggcgtg ttcaagaacg 300gccgcgtgga gatcatcgcc aacgatcagg gcaaccgcat cacgccgtcc tatgtcgcct 360tcactcctga aggggaacgt ctgattggcg atgccgccaa gaaccagctc acctccaacc 420ccgaga 426 135 422 DNA Homo sapien 135gactcctgtg aggatgcagc actccctggc aggtcagacc tatgccgtgc ccttcatcca 60gccagacctg cggcgagagg aggccgtcca gcagatggcg gatgccctgc agtacctgca 120gaaggtctct ggagacatct tcagcaggta gagcagagcc ggagccaggt gcaggccatt 180ggagagaagg tctccttggc ccaggccaag attgagaaga tcaagggcag caagaaggcc 240atcaaggtgt tctccagtgc caagtaccct gctccagggc gcctgcagga atatggctcc 300atcttcacgg gcgcccagga ccctggcctg cagagacgcc cccgccacag gatccagagc 360aagcaccgcc ccctggacga gcgggccctg caggagaagc tgaaggactt tcctgtgtgc 420gt 422 136 233 DNA Homo sapien misc_feature (1)...(233) n = A,T,C or G 136gctgctctga gattnngagt tcttctgcag agatgattaa atatatccaa gagacattgg 60aaaacnggnt gaacatttta cattggtctg ctcagcacat ggctggatgc ggatatttct 120ataattccag aaagtcacac agctcctctg tatgagacca gtgggcgcca tttaaaagaa 180caggatgaga atctaagata tattattaat aaatgtaatg gatttttttt tgt 233 137 427 DNA Homo sapien misc_feature (1)...(427) n = A,T,C or G 137taaagcataa tgattgataa gctagaactt tctgatgtag tcattacatg aaaccccttg 60tcactggttt gtgtgttcag aggaagccat ggccgagata gctttcctga aataaaccag 120tagcttttca gattgacgtt cttgctacaa ttgtaccatc tggtaattcc tgaaaatgtc 180aatttttttg tgttaatatt tttggtttca aacaataaca aatgtctcta gaaagaaatt 240ttaagaaagc ttaattaata gtaaaaatgc ctttcctgaa ataatcttgg aaaatttttt 300aaatggcaaa aatggatgaa gtcatgctta atacattgan gggttggttt tttggtttgg 360ttnggttggt tnggttttga aaacagaagt tcgctcttgg tgcccangct ggaagtgcaa 420tggcacg 427 138 456 DNA Homo sapien 138taagttcctg aagtgcagaa ctcccagaca aattatgtta gagcctgatt gttagttcag 60gaggagcttc cactgctaac tcccatcctc ctactcagtt ctaggccact ggtacccact 120tgagggtaga gttgtattta caaatacttg gagtgatttt atgcaacaaa ctgcacagag 180gattatagac tcagttaata ggggagtgga gaatgccagc aagcccctga gttagagtga 240atggccttca actgtgctta ccaattgtgg aacaaaagcc agctagaacc ctagcaatat 300agtagggtta tgggatcttt ggagtgttgc ttttctggct ggatacctcc gtggacagtg 360gggcctttgc ctgagttctt gtcctgtgtc caggaagaat gaggtatgca gacaagtgga 420gggtgagcaa gatgaagaga agctttattg agtgtt 456 139 456 DNA Homo sapien misc_feature (1)...(456) n = A,T,C or G 139tancaggagg agagtctaag gcanatgatc cctatgctca tcttagcaaa aaggagaaga 60aaaagctgaa aaaacagatg gagtatgagc gccaagtggc ttcattaaaa gcagccaatg 120cagctgaaaa tgacttctcc gtgtcccagg cggagatgtc ctcccgccaa gccatgttag 180aaaatgcatc tgacatcaag ctggagaagt tcagcatctc cgctcatggc aaggagctgt 240tcgtcaatgc agacctgtac attgtagccg gccgccgcta cgggctggta ggacccaatg 300gcaagggcaa gaccacactc ctcaagcaca ttgccaaccg agccctgagc atccctccca 360acattgatgt gttgctgtgt gagcaggagg tggtagcaga tgagacacca gcagtccagg 420ctgttcttcg agctgacacc aagcgattga agctgc 456 140 452 DNA Homo sapien 140ggagcttccg ggagggcggc tcgcaggcac catgactcct gtgaggatgc agcactccct 60ggcaggtcag acctatgccg tgcccctcat ccagccagac ctgcggcgag aggaggccgt 120ccagcagatg gcggatgccc tgcagtacct gcagaaggtc tctggagaca tcttcagcag 180gtagagcaga gccggagcca ggtgcaggcc attggagaga aggtctcctt ggcccaggcc 240aagattgaga agatcaaggg cagcaagaag gccatcaagg tgttctccag tgccaagtac 300cctgctccag agcgcctgca ggaatatggc tccatcttca cgggcgccca ggaccctggc 360ctgcagagac gcccccgcca caggatccag agcaagcacc gccccctgga cgagcgggcc 420ctgcaggaga agctgacttt cctgtgtgcg tg 452 141 451 DNA Homo sapien misc_feature (1)...(451) n = A,T,C or G 141agggtacacn aatagnctat tcgccatcag tagaaggtag cagcacagaa ctcaaccttc 60ctgaaactgc aaactccgtc accctcagtg acttgcaacc tggtgttcag tataacatca 120ctatctatgc tgtggaagaa aatcaagaaa gtacacctgt tgtcattcaa caagaaacca 180ctggcacccc acgctcagat acagtgccct ctcccaggga cctgcagttt gtggaagtga 240cagacgtgaa ggtcaccatc atgtggacac cgcctgagag tgcagtgacc ggctaccgtg 300tggatgtgat ccccgtcaac ctgcctggcg agcacgggca gaggctgccc atcagcagga 360acacctttgc agaagtcacc gggctgtccc ctggggtcac ctattacttc aaagtctttg 420cagtgagcca tgggagggag agcaagcctc t 451 142 463 DNA Homo sapien 142gaattccaaa caatactatc ttataaaata gtactgttga attattccaa gcctccctag 60gtttgctctc aaatgtcatt tacagattgg gctaacgacc taaaatctat atataaagac 120tttctgaaga actctgtatt atagcaatac caaacgagtg ctgtgtgtgc aaacagtctg 180gcgttgcttt ttatgttgat atttatccta gaacactgaa agagaatatg ccagtgataa 240ctcactttac ttcagtcatt tcaacacaga aaatgcttct ctagcatttt tcttttgtag 300tgttaacatt ttgaaattca tgtttcagag gcttcatcat cacagaattt actcttgctc 360catgaaaaaa aattaaatac cttcagagga atatttaagt tgtaaactat gaaacttgag 420aaatcctctt gagataaaag gctgccaaat ccagtattat aaa 463 143 368 DNA Homo sapien 143caccacattg ccaatgccaa cctcatgcgg aacggggccg actacgctgt ttacatcaac 60acagcccagg agtttgatgg ctctgactca ggtgcccgac cagacgaggc tgtctcctgg 120ggcaagatcc gggtggatgc acagcccgtc aaggtctatg ctgacgcctc cctggtcttc 180cccctgcttg tggctgaaac ctttgcccag aagatggatg ccttcatgca tgagaagaac 240gaggactgag cggctgcggt cccaggaagg tcttaccccc tcttctattt attaatttgc 300agacccagcc cctcccctac tttttggtca gctacgtctc tagaataaga tggtatctga 360agtccttc 368 144 452 DNA Homo sapien 144cttgattcaa aagaatcaaa atgggtattt tgaagagaga cctgtactgc tagtgttcct 60tgcagcactg ttcacaatag ccaagtgaac agataaagaa aatgaagtgt atacctgcag 120taggatgctg tgcgtgcagc ctgaaagaag gaaatcctgc cattcgtgac aacgtgggtg 180accatgaagg agattatgca aaatgaaata agccagacac agaaagaaac tgcatggttc 240cacttaaatg tgatatccag catagactca cagaagtaaa gggtggaatg gcggtcatca 300ggggattggg ggagagggaa atggggagct acttaatcaa tgggatgaaa tttcattaaa 360caagatgaga atgttctaga gatatgccgt actacatggt acctgtagtc aacaataatg 420tagacttaga aatgtgttaa gcggtggctc tc 452 145 456 DNA Homo sapien 145caaacaatac tatcttataa aatagtactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctaaaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttacttcagt catttcaaca cagaaaatgc ttctctagca tttttctttt gtagtgttaa 300cattttgaaa ttcatgtttc agaggcttca tcatcacaga atttactctt gctccatgaa 360aaaaaattaa ataccttcag aggaatattt aagttgtaaa ctatgaaact tgagaaatcc 420tcttgagata aaaggctgcc aaatccagta ttataa 456 146 210 DNA Homo sapien 146ggagagccca agggtctaac ggttaagggg acccacatac cagtgccaag ggggatgtca 60agtggtgatg tcgttgtgct cccctccccc agagcgggtg ggcggggggt gaatatggtt 120ggcctgcatc aggtggcctt cccatttaag tgccttctct gtgactgaga gccctagtgt 180gatgagaact aaagagaaag ccagacccct 210 147 452 DNA Homo sapien 147ataccccaga gcacagtccc agcttcacca acttcagggt cagcacctcg agatcaagca 60ggcagttgat tcctttaaat actgctgaaa gtctctctct ccagcatagt gaatctaaga 120gaagaggcag gaaaagacaa tctacagagt catctcctgt accactgaat cgaagaagtt 180ctggcaggca aggaggtgtc catgaactgt ctgcttttga acaacttgtc gtggaactgg 240tacggcatga tgatagctgg ccctttttga aactggtttc taaaatccag gtcccagact 300actatgacat cattaagaag cccattgcct taaatataat tcgagaaaaa gtaaataaat 360gtgaatataa attagcatct gagtttattg atgatattga gttaatgttt tcaaactgct 420ttgaatacaa ccctcggaac acaagtgaag ca 452 148 453 DNA Homo sapien 148caagaggaga aagggactct ccctggacta catgatgact caatggacaa gctaagagtt 60gaaagcaaca ggaaagttca cgaatcttgg tggtagtaac agtggcagct gtgatgttgg 120ctatataggc ctgagtctag ttctccagtc cagctggtga ttttgtgagc tattcaatat 180gctttcaata tatacgtttt ctgccaccaa gaggagaaag ggactctccc tggactacat 240gatgactcaa tggacaagct aagagttgaa agcaacagga aagttcacga atcttgggcc 300attaccagat cacctcccta gcactagtga gtgcctacca ccaccactct aactgccatc 360agtgttaact cagattctcc aaggagcaga tactaagatg gaattagata tgcaagagat 420tgattgaggg aaatgcccat gacagaaagc gtg 453 149 445 DNA Homo sapien misc_feature (1)...(445) n = A,T,C or G 149ggacactgtt gtggtccagg atttgggcaa catcttcact cgcctgccac tcaagcggat 60gtggcatnag gcactgctgc gctcagggga taaagtgcgc atggaccccc cctgaccaac 120acaacagctg cttccaccta cctcaacaac ccgtacgtgc ggaaggccct caacatcccg 180gagcagctgc cacaatggga catgtgcaac tttctggtaa acttacagta ccgccgtctc 240taccgaagca tgaactccca gtatctgaag ctgcttagct cacagaaata ccagatccta 300ttatataatg gagatgtaga catggcctgc ttgttcagga agcgggagaa catggtgaag 360gcagcgaggg gcttgtcggt gggaaccatg tggccggcgc ccttgatcgt gagaaagctt 420gcggccgcac tcgagcccgg gtgaa 445 150 446 DNA Homo sapien misc_feature (1)...(446) n = A,T,C or G 150tttgtctttt nncaaactga tggacatgag tgagctctaa tatcattatg tttagaaatg 60gcttcatcca gatccaactg tacaccatta atattcactt ccatgcagcc attataaaag 120gcattcactg gtgtggcact gaatggaaca tctggaaggc cacccaggta tgtggccact 180tttgctttca ttgctttgtc caagacggca agttgtcttt gaaggtcttc atgggagatg 240gtttctattt taagtggtgt cgacaactcc agattgtttc tgttgactct aaattccaga 300tgagattgtt gatcggaaca tagacttagg gcctgtatcc gatatattac agtattttca 360acagataaca gaatatcctg tgatttttca gaggtggagt ccaccaagga cacagcaaag 420ggcactgtgt tgttaccaga aaccaa 446 151 444 DNA Homo sapien misc_feature (1)...(444) n = A,T,C or G 151cggagacgag agcagaggcc naactcnnga tctgacaaga tggccgggct gccccgcagg 60atcatcnggg aaacccancg tttgctggca gaaccagttc ctggcattaa agcanaacca 120gatgagagca acgcccgtta ttttcatgtg gtcattgctg gcccccagga ttcccccttt 180gagggaggga cttttaaact tgaactattc cttccagaag aatacccaat ggcagcacct 240aaagtacgtt tcatgaccaa aatttatcat cctaatgtag acaagttggg aagaatntgn 300ttagatnttt ttgaaaggat aagtggtncc cnatnnctgc agatccgcac aggtcttgct 360atcaatcnan gctttnttna gtctcctntt ncanatgatc catngncnaa ccatatngnc 420gcncccttgt antgggcnca nctn 444 152 444 DNA Homo sapien 152ccgtccgccc ctgcggccaa gcccaagcgg gccaaggcct ccaagaagtc cacagaccac 60cccaagtatt cagacatgat cgtggctgcc atccaggccg agaagaaccg cgctggctcc 120tcgcgccagt ccattcagaa gtatatcaag agccactaca aggtgggtga gaacgctgac 180tcgcagatca agttgtccat caagcgcctg gtcaccaccg gtgtcctcaa gcagaccaaa 240ggggtggggg cctcggggtc cttccggcta gccaagagcg acgaacccaa gaagtcagtg 300gccttcaaga agaccaagaa ggaaatcaag aaggtagcca cgccaaagaa ggcatccaag 360cccaagaagg ctgcctccaa agccccaacc aagaaaccca aagccacccc ggtcaagaag 420gccaagaaga agctggctgc cacg 444 153 441 DNA Homo sapien misc_feature (1)...(441) n = A,T,C or G 153tgctggatct ggagtcagga gaaatgtgga taaagtttta gtgataaatt ctgctcaaag 60ttagggtgaa tgcagacatc ctagactgta ctttgggtgg ggtaagaaga aggggggtga 120ctagacatat acttgcatcc agaggccaga ggtcaatgct gggtgtcttt cttgaccgtt 180gtcttgtttt gaatggagtg atggagatta aatttaaggc ttttctacca cagagctaca 240actccagcct ttagtaacag actttctcat tgaatctgga attggcaaga ttggctggtc 300cccgggcccc acctgtcccc acctccctag tactgggaat ccaggcacgt gccaccatac 360ccagcttctt acacggctgc tgaaactcag gccctcacgt ttgtgccacg tggagatgcc 420tcccnatncc catacactat c 441 154 425 DNA Homo sapien 154acaacaccaa ccacgaggct gacgactggt gcgtccccag cagagaaccc aaagacatga 60cgacgttccg cagtgcctag acacacttgg gacatcggaa aatccaaatg tggcttttgt 120attaaatttg gaaggtccgt aaaagccctg ggctcagcca gagcagggca gaggatgacg 180ggatgaccag ctgcagagag gagtactcta ctgataactg gagacgatgg gcgaccacct 240tcagagagaa actgttagca gagaggagct gccctctgct gagagcttca gagacctgca 300gacatctgaa tgacttgcct gcagagagga gccactcttt tcagggcctt ctctcagctg 360agagctgaac acccaatggg ataattgcct acagagagga gccacccact cctctgagct 420gttcc 425 155 428 DNA Homo sapien 155tgtatcagaa ccttaatgag ccaaccacgt ggagcttaac cagtgataga actagaaatt 60gggttcttca acagaaaata gaaggagaaa caaaagaatc aaactacgct aaattgattg 120aaatgaatgg aggaggaacc ggctgtaatc atgaattaga aatgatcaga caaaagcttc 180aatgtgtagc ttcaaaacta caggttctac cccagaaagc ctctgagaga ctacagtttg 240aaacagcaga tgatgaagat ttcatttggg ttcaggaaaa tattgatgaa attattttac 300aactacagaa attaactggc cagcaaggtg aagagcccag cttggtgtcc ccaagtactt 360cttgtggctc attgactgaa agactactga gacaaaatgc tgagctgaca gggcatatca 420gtcaactg 428 156 440 DNA Homo sapien 156gaagaagaaa cagatgatag tgacacttgg gaacctccac gacatgtgaa acggaagctg 60tctaaatcag atgactgaaa tctgcctaaa acgttgaagg agaatcaatt cttcaactca 120agatgtctga tttactgtga atttgcccaa tctttgatga cattgaaaac gttttggggc 180atacacactc aaaaagcagg atccaatacc caaaagaaat ggaacttaat gttgtgccaa 240agttaaacta ctgcagttgg tggaagttct gcaatgtaaa tagaacacta attaaaaaac 300aacttgtaaa aatgcaattt aaattttaat acagtacatt tttcttctaa tatgatggag 360acattctgaa tcttagactt tctgaggggg tttaatgacc actagagctt gtcctcatat 420tcagtccagt ttaatactgt 440 157 1031 DNA Homo sapien 157accagattgg cctgttagtt cagtgtagtg cagcacaaat cccagtgact aaacaccttg 60gaagtaagaa tccttgacct ggatttggaa gacctgggct gtgatctctg gcgttttgct 120tattggctct tcaaacttca acaggcccct aagttttcca agcattggtt tcttcttaca 180taaagtaaac catcatcaca agtgccctga agatggctga gatcatggaa tcaagtggtg 240tgcaacagag tgagctttgt ggtttctttt tgggcttaag ttcctggaag gcagggattg 300tgagtagctc acgcgaacgg gctttttagt gcctgcaaac tgaaactgag cagatggtca 360tggtgatttt cttcctagtg gaactgaaaa tctttgttct ttgtctaggt caatgctggc 420ccactagcat atgcgcgagc tttcttagat gatacaaaca caaagcgata tcctgacaat 480aaagtgaagc tgcttaagga agttttcagg caatttgtgg aagcttgcgg tcaagcctta 540gcggtaaacg aacgtctgat taaagaagac cagctcgagt atcaggaaga aatgaaagcc 600aactacaggg aaatggcgaa ggagctttct gaaatcatgc atgagcaggt gagggccgca 660ctggctccaa caacttggag ttcttggtta ggggtttcaa gtacacccta tcatgactta 720ggccgcctga tatccttcca gaactgtgac atctgaagga gaatgtagca taccacactc 780ctgccatgct ctagccccag gtcatttggg aacagctaac agattgccca tatgctgtta 840tctacggcaa gcaggggaga gcgggcccgc ctcctcgtgg ctctaagagg tggccatgtt 900tcctaagctt tctctctccc cacccccgtc tagccaaaaa gaaaagaaag gaaaaactca 960cacgaaaata tccatactgt tctgacaact ttattccttt aatcctttga aaaaagcagg 1020acttgccaac c 1031 158 445 DNA Homo sapien 158caaacaatac tatcttataa aatagtactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctaaaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttacttcagt catttcaaca cagaaaatgc ttctctagca tttttctttt gtagtgttaa 300cattttgaaa ttcatgtttc agaggcttca tcatcacaga atttactctt gctccatgaa 360aaaaaattaa ataccttcag aggaatattt aagttgtaaa ctatgaaact tgagaaatcc 420tcttgagata aaaggctgcc aaatc 445 159 1071 DNA Homo sapien 159tcatcaatcc tgacacctac cgcatcgacc ccaatgttct tctagatcca gctgatgaga 60aacttttgga agaggagatt caggccccca ccagctccaa gagatcccag cagcacgcga 120aggtggtgcc atggatgcga aagacagagt acatctccac tgagttcaac cgttatggca 180tctccaatga gaagcctgag gtcaagattg gggtttctgt gaagcagcag tttaccgagg 240aagaaatata caaagacagg gatagccaga tcacagccat tgagaagact tttgaggatg 300cccagaaatc aatctcacag cattacagca aaccccgagt cacaccggtg gaggtcatgc 360ctgtcttccc agactttaag atgtggatca atccatgtgc tcaggtgatc tttgactcag 420acccagcccc caaggacacg agtggtgcag ctgcgttgga gatgatgtct caggccatga 480ttaggggcat gatggatgag gaagggaacc agtttgtggc ctatttcctg cctgtagaag 540agacgttgaa gaaacgaaag cgggaccagg aggaggagat ggactatgca ccagatgatg 600tgtatgacta caaaattgct cgggagtaca actggaacgt gaagaacaaa gctagcaagg 660gctatgagga aaactacttc ttcatcttcc gagagggtga cggggtttac tacaatgagt 720tggaaaccag ggtccgcctt agtaagcgcc gggccaaggc tggggttcag tcaggcacca 780acgccctgct tgtggtcaaa catcgggaca tgaatgagaa ggaactggaa gctcaggagg 840cacggaaggc ccagctagaa aaccacgaac cggaggagga agaggaagag gagatggaga 900cagaagagaa agaagctggg ggctcagatg aggagcagga gaagggcagc agcagtgaga 960aggagggcag tgaagatgag cactcgggca gcgagagtga acgggaggaa ggtgacaggg 1020acgaggccaa gtgacaagag tggcagtggt gaggacgaga gcagcgagga t 1071 160 444 DNA Homo sapien 160actgaatgta acaacatgac cctcatcaac ttgctactta aagtccttgg gcccatacat 60gagagaaacc tcacattgct cctgctgctg ctgcaggtga ggatgggaat cgagtttata 120cctccgtgtc tccctttctg cgtgattctt actccagtcc atttctcctt gcagatcctg 180ggcagtgcca tcaccttctc cattcgatat cagctcgttc gactcttcta tgatgtctga 240gtcccttgat cattgtcctt tacctcacag tctctaggat tcctgactca ggctgacctc 300tctctctggt cccagactgc ctccttgccc aggcctctct cactcttcat actcctccag 360attttgttct cagcattttc ctttctctgt gatcattggc atcctgggcg tttcttgccc 420tctgctgact actgattgga tttt 444 161 444 DNA Homo sapien 161ccttcaacct gcatttcctc ctcctgcagg gcctccaggg aatccagggt cccaagggct 60tggatggagc aaagggagag aagggtgcgt cgggtgagag aggccccagc ggcctgcctg 120ggccagttgg cccaccgggc cttattgggc tgccaggaac caaaggagag aagggcagac 180ccggggagcc aggactagat ggtttccctg gaccccgagg agagaaaggt gatcggagcg 240agcgtggaga gaagggagaa cgaggggtcc ccggccggaa aggagtgaag ggccagaagg 300gcgagccggg accaccaggc ctggaccagc cgtgtcccgt ggagaatccc acgtgcggag 360gccggagagg ggcaccaggc tggcggggcc ctgcgagggg caatgggcca tgccctgcgg 420gccccgacgg gctgcctgtg cctg 444 162 435 DNA Homo sapien 162caccgacgtg tgtgacagcg actacagcgc cagccgctgg aaggcgtcgt cgggggcgcc 60attcctcgaa tgatgtaggg cctgtacggt ctcgcagtgg ccggaatgtt tgaagagtag 120aacatgtcca tgttgtacag ggaggggtcc gtggccgcgc agagcaacca caccgtgggc 180cccttgctgg cggctgcagc tggtgcccca gcccctctgt acctcggggg cctgcctgag 240cccatggccg tgcagccctg gccccccgcc tactgcggct gcatgaggag gctggcggtg 300aaccggtccc ccgtcgccat gactcgctct gtggaggtcc acggggcagt gggggccagt 360ggctgcccag ccgcctagga cacagccaac cccggcccct ggtcaggccc ctgcagctgc 420ctcacaccgc ccctt 435 163 437 DNA Homo sapien 163ggacagcgag gcgcactggg gcctcccagc gcggggccgg ccgcgccgtc cagcccgagg 60tctacggctt tgcgctccga gcccagagga agatgcctgc cggcaccgag ctcgggctgc 120ggggctgaac gcctgtcttc caggcgcagc ggcagcactg ccctcggccg gtgtcggtag 180cggcactcgg cgtgccccgg gcggacgaag agcgcaggct gggtacacct tgcccgaatc 240ggcggagttc gcagctagcg agggcgggcc ggccggcccg gatgggcgcg gggtttgcgg 300cccccgccgg gtgctccgga gcggcccggg caccgggggc acgctgagtg ccggagccgc 360ggccgcagag agaacttggg gcgggggcca tgccccggtg cggagtctag agccgagcgg 420agcgccccgc gggcccg 437 164 439 DNA Homo sapien 164aagatttcag ctgcgggacg gtcaggggag acctccaggc gcagggaagg acggccaggg 60tgacacggaa gcatgcgacg gctgctgatc cctctggccc tgtggctggg tgcggtgggc 120gtgggcgtcg ccgagctcac ggaagcccag cgccggggcc tgcaggtggc cctggaggaa 180tttcacaagc acccgcccgt gcagtgggcc ttccaggaga ccagtgtgga gagcgccgtg 240gacacgccct tcccagctgg aatatttgtg aggctggaat ttaagctgca gcagacaagc 300tgccggaaga gggactggaa gaaacccgag tgcaaagtca ggcccaatgg gaggaaacgg 360aaatgcctgg cctgcatcaa actgggctct gaggacaaag ttctgggccg gttggtccac 420tgccccatag agacccaag 439 165 361 DNA Homo sapien 165gctggggggt cgggatgctg ggcccctcct catctccctc aaggatggct acgtaccccc 60aaagagccgg gagctgaggg tcaaccgggg cctggacacc gggcgcagga gggcagcacc 120agaggccagt ggcactccca gctcggatgc cgtgtctcgg ctggaggagg agatgcggaa 180gctccaggcc acggtgcagg agctccagaa gcgcttggac aggctggagg agacagtcca 240ggccaagtag agccccgcag ggcctccagc agggtcagcc attcacaccc atccactcac 300ctcccattcc cagccacatg gcagagaaaa aaatcataat aaaatggctt tattttctgg 360t 361 166 326 DNA Homo sapien 166atcacgaagt gatatccaac tccccaagtt gcagtggttc ctggagccca ggaccacccg 60ccagcgggcc ctcttcctcc tccatatctg aggtcccagc ccgcaacacc agttcccggg 120ccgcagccgc catggtcgca gcggcggcca ttccccgcag cctcacttcc ggcaactgtc 180agtcccggcg agtccgttcc ccggagtgga gctacaagtc ccaaagggtc ttcctcagcg 240cgaaatcgtt cccagatatt tgagttaagt tgtttgactc cagctgtccc ctttcagctc 300taaccacttc acccaactgc aaatgg 326 167 471 DNA Homo sapien 167caaggccatg gcgatatcgg atccgaattc aagctcatca atcctgacac ctaccgcatc 60gaccccaatg ttcttctaga tccagctgat gagaaacttt tggaagagga gattcaggcc 120cccaccagct ccaagagatc ccagcagcac gcgaaggtgg tgccatggat gcgaaagaca 180gagtacatct ccactgagtt caaccgttat ggcatctcca atgagaagcc tgaggtcaag 240attggggttt ctgtgaagca gcagtttacc gaggaagaaa tatacaaaga cagggatagc 300cagatcacag ccattgagaa gacttttgag gatgcccaga aatcaatctc acagcattac 360agcaaacccc gagtcacacc ggtggaggtc atgcctgtct tcccagactt taagatgtgg 420atcaatccat gtgctcaggt gatctttgac tcagacccag cccccaagga c 471 168 438 DNA Homo sapien 168caaacctcct cacagcccac tggtcctcaa gaggtgccac gtctccacac atcagcacaa 60ctacgcagcg cctccctcca ctcggaagga ctatcctgct gccaagaggg tcaagttgga 120cagtgtcaga gtcctgagac agatcagcaa caaccgaaaa tgcaccagcc ccaggtcctc 180ggacaccgag gagaatgtca agaggcgaac acacaacgtc ttggagcgcc agaggaggaa 240cgagctaaaa cggagctttt ttgccctgcg tgaccagatc ccggagttgg aaaacaatga 300aaaggccccc aaggtagtta tccttaaaaa agccacagca tacatcctgt ccgtccaagc 360agaggagcaa aagctcattt ctgaagagga cttgttgcgg aaacgacgag aacagttgaa 420acacaaactt gaacagct 438 169 437 DNA Homo sapien 169ctcgcgcctg cagtttttgg ctttcacccc caaccagtga ccaaagactt gaccactcaa 60agtccagctc cccagaacac tgctcgacat ggacaccggt gtgattgaag gtggattaaa 120tgtcactctc accatccggc tacttatgca tggaaaggaa gttggcagta tcatcggaaa 180gaaaggagaa tcagttaaga agatgcgcga ggagagtggt gcacgtatca acatctcaga 240agggaattgt cctgagagaa ttatcacttt ggctggaccc actaatgcca tcttcaaagc 300ctttgctatg atcattgaca aactggaaga ggacataagc agctctatga ccaatagcac 360agctgccagt agacccccgg tcaccctgag gctggtggtc cctgctagtc agtgtggctc 420tctcattgga aaaggtg 437 170 435 DNA Homo sapien 170ccgtccggcc tccctgacat gcttccctct ggaccccgag gttggaccct actgtgacac 60acctaccatg cggacactct tcaacctcct ctggcttgcc ctggcctgca gccctgttca 120cactaccctg tcaaagtcag atgccaaaaa agccgcctca aagacgctgc tggagaagag 180tcagttttca gataagccgg tgcaagaccg gggtttggtg gtgacggacc tcaaagctga 240gagtgtggtt cttgagcatc gcagctactg ctcggcaaag gcccgggaca gacactttgc 300tggggatgta ctgggctatg tcactccatg gaacagccat ggctacgatg tcaccaaggt 360ctttgggagc aagttcacac agatctcacc cgtctggctg cagctgaaga gacgtggccg 420tgagatgttt gaggt 435 171 435 DNA Homo sapien 171cagatgtata gattgtgaag atgtttgctt attctgtggg tgtgaatgtt ataattaagg 60agatttgtag ggagattagt atagagaggt agagtttttt tcgtgatagt ggttcactgg 120ataagtggcg ttggcttgcc atgattgtga ggggtaggag tcaggtagtt agtattagga 180ggaggatgtg aaactcttaa gtatatctgg aaagcggtct gcccctggag gtggtagcaa 240ggttccacag aaaaaagtaa aacttgctgc tgatgaagat gatgacgatg atgatgaaga 300ggatgatgat gaagatgatg atgatgatga ttttgatgat gaggaagctg aagaaaaagc 360gccagtgaag aaatctatac gagatactcc agccaaaaat gcacaaaagt caaatcagaa 420tggaaaagac tcaaa 435 172 435 DNA Homo sapien 172gcacagcgag gcgctagggg gaacgctggc ctctgaaact agctctggga ccggggtctg 60cggccggccc ctagctggcc ccgtctccca tccccagaag ggtattcact ggggattctg 120agctttggct actccagttt cccacgacac gatgttccct ttctacagct gctggaggac 180tggactgcta ctactactcc tggctgtggc agtgagagaa tcctggcaga cagaagaaaa 240aaacttgcga cttggtagga gaaaagggta aagagtcaga gaaagagttg gctctagtga 300agaggctgaa accactgttt aataaaagct ttgagagcac tgtgggccag ggttcagaca 360catacatcta catcttcagg gtgtgccggg aagctggcaa ccacacttct ggggcaggcc 420tggtgcaaat caaca 435 173 450 DNA Homo sapien misc_feature (1)...(450) n = A,T,C or G 173attcaagagc aaatgaccaa nagccatgtg ggnggnggtt ggctaaagtt cggatgatga 60aaggagaatt ttatgtcatt gaatatgctg cttgtgacgc tacttacaat gagaatagtc 120acatttgaac gacttcggcc tgtcaatcaa aataaaactg tcaaaaaaaa taccttcttt 180aaatgcacag tggatgttcc tgaggatttg agagaggcgt gtgctaatga aaatgcacat 240aaagatttta agaaagcagt aggagcatgc agaatttttt accatccaga aacaacacag 300ctaatgatac tgtctgccag tgaagcaact gtgaagagag taaacatctt aagtgacatg 360catttgcgaa gtattcgtac gaagttgatg cttatgtcca gaaatgaaga ggccactaag 420catttagaat gcacaaaaca acttgcagca 450 174 307 DNA Homo sapien misc_feature (1)...(307) n = A,T,C or G 174cacgagcctg ttctgaaaat gtggacgtaa nacaaacacg tgctcgtcct ttaatggagt 60tcaccagcac acttgttaac cagtcctgtt tgctttcgtc tttttttgtg cgtaataaag 120tcaactgacc aagtgaccat gaaaaggggc tgtctggggc tcctgttttt tagctgctgt 180tcttcagctc cgaccatgtt gctgtgtgat tatctcaatt ggttttaatt gaggcagaaa 240ctgaanctnt accaatgaac tgnttanaaa caagacacac ttttgtatta aaattgcttg 300cagtaac 307 175 449 DNA Homo sapien 175gtttctgcgc gggctcccgg cgctgctact gctgctgctc ttcctcgggc cctggcccgc 60tgcgagccac ggcggcaagt actcgcggga gaagaaccag cccaagccgt ccccgaaacg 120cgagtccgga gaggagttcc gcatggagaa gttgaaccag ctgtgggaga aggcccagcg 180actgcatctt cctcccgtga ggctggccga gctccacgct gatctgaaga tacaggagag 240ggacgaactc gcctggaaga aactaaagct tgacggcttg gacgaagatg gggagaagga 300agcgagactc atacgcaacc tcaatgtcat cttggccaag tatggtctgg acggaaagaa 360ggacgctcgg caggtgacca gcaactccct cagtggcacc caggaagacg ggctggatga 420ccccaggctg gaaaagctgt ggcacaagg 449 176 443 DNA Homo sapien 176tggtgtctct caaaagcctg atcctgccaa aaccaagaat cgccgcaaaa ggaagccatc 60cacttctgat gattctgact ctaattttga gaaaattgtt tcgaaagcag tcacaagcaa 120gaaatccaag ggggagagtg atgacttcca tatggacttt gactcagctg tggctcctcg 180ggcaaaatct gtacgggcaa agaaacctat aaagtacctg gaagagtcag atgaagatga 240tctgttttaa aatgtgaggc gattatttta agtaattatc ttaccaagcc caagactggt 300tttaaagtta cctgaagctc ttaacttcct cccctctgaa tttagtttgg ggaaggtgtt 360tttagtacaa gacatcaaag tgaagtaaag cccaagtgtt ctttagcttt ttataatact 420gtctaaatag tgaccatctc atg 443 177 440 DNA Homo sapien 177gctgcacccg ccgggaaagt ggcgagagcc acctcggcgc ttgggcgctc agtcgcagga 60ggcgctcctt ggcggtgcct ggagcccggg cgcaccccac cgctcccggg acctgttggg 120ggctggcccg aaccgtcgtc gaagggagcc gctcggccac ccccgacgtt cctcgccccg 180cccgacgttc cctcaagtgg ccgaaccagc cggacgagcc aaactcgccg ggcctcccgg 240cggcagcagg tggccccgtc cttccaggga gggccctgcg ccccgcggcg ctccggagcc 300ctctcggccg cccccgccag gcgggatgga ggcggatggg gacggagagg agctggcccg 360gctgcgctca gtcttcgccg cctgcgacgc gaaccgctcg gggcgcctgg agcgcgagga 420gttccgggca ctgtgcacgg 440 178 442 DNA Homo sapien 178aggaagaaaa attaaagcca tttgaaaagt tcttgctgaa gctagaaggg caattactgg 60atggaatgat attccaggcc tgtatagaac aacaatttga ttctctcaat ggaggagtat 120ctgtgtcaaa aaatagtact tttgctgagg aatttgcaca tagtattcgg tcaatttttg 180caaatgtaga agccaaactt ggagaacctt ctgaaattga ccagagagac aagtatgttg 240gaatttgtgg actctttgta ttgcactttc agatttttcg aactattgat aaaaagtttt 300ataagtcttt attggacatt tgtaagaagg taccagccat cactctaact gctaatatta 360tttggtttcc tgataatttt ctgatccaga aaataccagc agctgccaaa ctgctagaca 420gaaaaagtct tcaagccatt aa 442 179 434 DNA Homo sapien 179ctcccaggag gtgatattat ttttagtgct cagctgaaat accaacccca ggaataagaa 60ctccatttca aacagttctg gccattctga gcctgctttt gtgattgctc atccattgtc 120ctccactaga ggggctaagc ttgactgccc ttagccaggc aagcacagta atgtgtgttt 180tgttcagcat tattatgcaa aaattcacta gttgagatgg tttgttttag gataggaaat 240gaaattgcct ctcagtgaca ggagtggccc gagcctgctt cctattttga tttttttttt 300ttttaactga tagatggtgc agcatgtcta catggttgtt tgttgctaaa ctttatataa 360tgtgtggttt caattcagct tgaaaaataa tctcactaca tgtagcagta cattatatgt 420acattatatg taat 434 180 440 DNA Homo sapien 180cgcaagcggc ctgggccgag cgccgtttcc aggccctcgc caggtctttg aactgcaggt 60aaagtggcag gaacgtcttc cgtctgctca gcgtttgggg atttagactc ctaaagccag 120tacctgcccc gtttcccccc caggttccgt cctgcccgcg cccggtctca gggtggcggc 180cccggacacg gcccgtcccc acagacgagg tctccggcct gagctgtcgc acctggcgcg 240gaggtcgccc ggggtgccct ggctgggtga gaggtggcct ggcgggcgga gcttgccaag 300aatcacggcc agtccttaag tggatggtgg ggcccagcag ctgctctgtc ccccttaaca 360aaccaggggg catggagggg cctagggcac cgccccccta ccaggctcag gccctccaag 420gagaacctgc tgagacccct 440 181 438 DNA Homo sapien misc_feature (1)...(438) n = A,T,C or G 181caaacaatac tatcttataa aatagtnttg ttgaattatt ccaagcctcc ctaggtttgt 60tctcaaatgt catttacaga ttgggctaac gacctggaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttacttcagt catttcaaca cagaaaatgc ttctctagca tttttctttt gtagtgttaa 300cattttgaaa ttcatgtttc agaggcttca tcatcacaga atttactctt gctccatgaa 360aaaaaattaa ataccttcag aggaatattt aagttgtaaa ctatgaaact tgagaaatcc 420tcttgagata aaaggctg 438 182 423 DNA Homo sapien misc_feature (1)...(423) n = A,T,C or G 182cagagaagga taaatatttg aaaggttttt gaggggaaga aactctccaa cactgggttt 60accaatttga caaagggaac aaggagaaaa aaaantatag gacaatttac agctttttgt 120ctatgtcatt aggtagatag tggtgacatt caaaaataag gaaataaaag caggaacaag 180actaaaggaa aattcataat tcaatttaga atacattgaa tttgtagagt ctatagacat 240gcgacttgac atcaaaaacc ccgataaatt accaaagaaa actcttttcc aactataatg 300cgataacttt ctaacagctt aatcatgagt aaaaatcaga gaaaggcatg gttatataaa 360atattttaca gaatgaatac caacaaaact aagattaaag tagactatta tagaattgaa 420taa 423 183 437 DNA Homo sapien 183catggctctg gacgggataa ggatgccaga tggctgctac gcggacggga cgtgggaact 60gagtgtccat gtgacggacc tgaaccgcga tgtcaccctg agagtgaccg gcgaggtgca 120cattggaggc gtgatgctta agctggtgga gaaactcgat gtaaaaaaaa gattggtctg 180accatgctct ctggtgggaa aagaagagaa cttggcttct gaagacacat tggaccttag 240ataagtatgg tattcaggca gatgctaagc ttcagttcac ccctcagcac aaactgctcc 300gcctgcagct tcccaacatg aagtatgtga aggtgaaagt gaatttctct gatagagtct 360tcaaagctgt ttctgacatc tgtaagactt ttaatatcag acaccccgaa gaactttctc 420tcttaaagaa acccaga 437 184 442 DNA Homo sapien misc_feature (1)...(442) n = A,T,C or G 184ccaaccacca gaggatcatt caccaatntc ccgaaaggaa tttgttcgat ttctgctggc 60cactccaacc aagtcagagc tgcgctgcca gtgtgcaaat ctccagggag tcaagatgct 120ctgctcaaac gcagaaggcg catccctgag gctctgtaat tttgaggatc cttcgggtct 180taaagccaac ttagagggtg ctaatctgaa aggtgtggac atggaaggaa gccagatgac 240agggattaac ctcagagttg ccaccttaaa aaatgcaaaa ctgaagaact gtaatctcag 300aggagcaact ctggcaggaa ccgatttaga aaactgtgat ttgtcggggt gtgacctcca 360ggaagccaac ctgagaggct ccaatgtgaa gggtgccata tttgaagaga tgctgacacc 420attacatatg tcccagagtg tc 442 185 433 DNA Homo sapien 185gaacctgctg tccttcactg ggagcactca ggtgggaaaa caggtgggcc tgatggtgca 60ggagaggttt gggagaagtc tgttggaact tggaggaaac aatgccatta ttgcctttga 120agatgcagac ctcagcttag ttgttccatc agctctcttc gctgctgtgg gaacagctgg 180ccagaggtgt accactgcga ggcgactgtt tatacatgaa agcatccatg atgaggttgt 240aaacagactt aaaaaggcct atgcacagat ccgagttggg aacccatggg accctaatgt 300tctctatggg ccactccaca ccaagcaggc agtgagcatg tttcttggag cagtggaaga 360agcaaagaaa gaaggtggca cagtggtcta tgggggcaag gttatggatc gccctggaaa 420ttatgtagaa ccg 433 186 422 DNA Homo sapien misc_feature (1)...(422) n = A,T,C or G 186cttccgagga agctaaggct gcgttngggt gaggccctca cttcatccgg cgactagntc 60cgcgtccggc agcgccagcc ctacactcgc ccncgccatg gcctctgtct ccgagctcgc 120ctgcatctac tcggccctca ttctgcacga cgatgaggtg acagtcacgg aggataagat 180caatgccctc attaaagcag ccggtgtaaa tgttgagcct ttttggcctg gcttgtttgc 240aaaggccctg gccaacgtca acattgggag cctcatctgc aatgtagggg ccggtggacc 300tgctccagca gctggtgctg caccagcagg aggtcctgcc ccctccactg ctgctgctcc 360agctgaggag aagaaagtgg aagcaaagaa agaagaatcc gaggagtctg atgatgacat 420gg 422 187 436 DNA Homo sapien 187attccaaaca atactatctt ataaaatagt actgttgaat tattccaagc ctccctaggt 60ttgctttcaa atgtcattta cagattgggc taacgaccta aaatctatat ataaagactt 120tctgaagaac tctgtattat agcaatacca aacgagtgct gtgtgtgcaa acagtctggc 180gttgcttttt atgttgatat ttatcctaga acactgaaag agaatatgcc agtgataact 240cactttactt cagtcatttc aacacagaaa atgcttctct agcatttttc ttttgtagtg 300ttaacatttt gaaattcatg tttcagaggc ttcatcatca cagaatttac tcttgctcca 360tgaaaaaaaa ttaaatacct tcagaggaat atttaagttg taaactatga aacttgagaa 420atcctcttga gataaa 436 188 436 DNA Homo sapien 188tcaagccctc aacctcacca gtcctgataa aacccaagag tgctggttat gcctagtatc 60gggaccccca tactacgagg gggttgccgt cctaggtacc tactccaacc atacttctgc 120cccagctaac tgctctgtgg cctctcaaca caaattgacc ttgtccgaag tgaccggaca 180gggactctgc ataggagcgg tccctaaaac ccatcaagtc ttgtgtaata ccacccaaaa 240gacaagcgat gggtcctact atttggccgc tcccacagga actacctggg cttgtagtac 300tggactcact ccctgtatct caaccaccat acttgacctc accaccgatt actgtgtcct 360ggtcgagctt tggccaaggg tgacctacca ttcccctagt tatgtttacc accaatttga 420aagacgagcc agatat 436 189 422 DNA Homo sapien 189ggaagatata acctcatcag atcagggaac ctccaatagc acaaagagga catcgctgag 60ccgagggatc tctgtcacat ccaacctgga agaatggcac gccctgttgg tcgagtccaa 120aacctaccta gaggaagagg aggatgagga aagcctggaa aaaatcattt tccaaactga 180caagcttcag agcattgaca gccactccat ggaggaagtt ggagaggtgg aaaacaaccc 240agtgagcaaa gcaatcgctc accacctggg cattgacatt tctgcagaag gccgcctggc 300caagaaccgg aaaggcatcg ccattatcat tcacgggaca cccttgtcag gaaagtcagc 360caatgccgtt agcgtggcca agtactacaa cgcagcctgc ctgagcatcg actccattgt 420gc 422 190 426 DNA Homo sapien misc_feature (1)...(426) n = A,T,C or G 190ggaagatata acctcatcag atcannttaa cctccaatag cacaaagagg acatcgcttt 60ccgagggatc tctgtcacat ccaacctgga agaccggcac gccctgttgg tcgagtccaa 120aacctaccta gaggaagagg aggatgagga aagcctggaa aaaatcattt tccaaactga 180caagcttcag agcattgaca gccactccat ggaggaagtt ggagaggtgg aaaacaaccc 240agtgagcaaa gcaatcgctc accacctggg cattgacatt tctgcagaag gccgcctggc 300caagaaccgg aaaggcatcg ccattatcat tcacgggaca cccttgtcag gaaagtcagc 360caatgccgtt agcgtggcca agtactacaa cgcagcctgc ctgagcatcg actccattgt 420gctgga 426 191 432 DNA Homo sapien misc_feature (1)...(432) n = A,T,C or G 191ccgagccggg gttctggcgg agcgcttngg ccctgaagga cgccgccgag caccgcgagc 60tgatggcctg gaaccaggcg gagaaccggc ggctgcacga gctgcggata gcgaggctgc 120ggcaggagga gcgggagcag gagcagcggc aggcgttgga gcaggcccgc aaggccgaag 180aggtgcaggc ctgggcgcag cgcaaggagt gggaagtgct gcagctgcag gaagaggtga 240aaaacttcat cacccgagag aacctggagg cacgggtgga agcagcattg gactcccgga 300agaactacaa ctgggccatc accagagagg ggctggtggt caggccacaa cgcagggact 360cctaggggcc cagtaaggac agtgcccgcc agggaccatg tatgtatcat ggcggaagag 420ttggccctga cc 432 192 440 DNA Homo sapien 192caagagcaga ggccgaactc gggatctgac aagatggccg ggctgccccg caggatcatc 60aaggaaaccc agcgtttgct ggcagaacca gttcctggca ttaaagcaga accagatgag 120agcaacgccc gttattttca tgtggtcatt gctggccccc aggattcccc ctttgaggga 180gggactttta aacttgaact attccttcca gaagaatacc caatggcagc acctaaagta 240cgtttcatga ccaaaattta tcatcctaat gtagacaagt tgggaagaat atgtttagat 300attttgaaag gtaagtgttg tttgtcaccc tgtgctttat taacgtgtcc tttttgtcct 360aagcattcta catttagaat gtaagcattg gaatctcact gtatgctaac agccccagag 420tgtgtgggag ggaagtgcag 440 193 477 DNA Homo sapien misc_feature (1)...(477) n = A,T,C or G 193cggcgacgac ccattcgaac gtctgcccta tcaactttcg atggtagtcg ccgtgcctac 60catggtgacc acgggtgacg gggaatcagg gttcgattcc ggagagggag cctgagaaac 120ggctaccaca tccaaggaag gcagcaggcg cgcaaattac ccactcccga cccggggagg 180tagtgacgaa aaataacaat acaggactct ttcgaggccc tgtaattgga atgagtccac 240tttaaatcct ttaacgagga tccattggag ggcaagtctg gtgccagcag ccgcggtaat 300tccagctcca atagcgtata ttaaagttgc tgcagttaaa aagctcgtag ttggatcttg 360ggagcgggcg ggcggtccgc cgcgaggcga gccaccgccc gtncccgccc cttgcctctc 420ggngccccct cgatgctctt agctgagtgt cccgcggggc ccnaancgtt nactttg 477 194 443 DNA Homo sapien misc_feature (1)...(443) n = A,T,C or G 194aagcctcatt ccaganaaag aggtagaagg tcntaggagc acatcaaaaa caagagacaa 60aaagaaagaa gacaaagaaa agaaacgttc taaaacacca ccaaaaagtt acagcacagc 120cagacgttct agaagtgcaa gcagagagag acgacgacga agaagcagga gtggcacaag 180atctcctaaa aagcctcggt ctcctaaaag aaaattgtcc cgctcaccat cccctaggag 240acataaaaag gagaagaaga aagataaaga caaagaaaga agtagggatg aaagagaacg 300atcaacaagc aagaagaaga agagtaaaga taaggaaaag gaccgggaaa gaaaatcaga 360gagtgataaa gatgtaaaac aggttcacgg gattatgtga agaggaacag gggtatgcag 420tgagaaagag aaaaaagaag aga 443 195 428 DNA Homo sapien 195aattcacatc tctcagaggt tcaccgtaga cagctttgga aactacgctt cctgtggaca 60aattgacttc tcctgaggtg gatcttggaa agcactagaa actaaacatc ttcaccaggt 120gctgaagaaa agtgtcttcg ttttaattgc caagcaggga tgtggacatt tggatggtga 180cttccctggg tggttcccca tagattcacc attgcctcta atggtgtcta cacccgtcat 240actaccagct gagatggtgg tgggcataag gagaatttgt gtctataacc cttagtgtgt 300tctggttttt tttcttttaa tttttaaatt gtcgtaaaat actcataaaa catactgtct 360tcaccatttt taagtgcaca gttcagtaac gttaactgtt aatacattca taatgctgtg 420tggccgtc 428 196 423 DNA Homo sapien 196aaaaagatac aagtttataa catcttataa aaactaccat ttaaaagtga tcttgtccat 60ttgatattcc cctcccccat agcaaaatat tatttaaaaa aaaaaaaaca aaaaacaggg 120tggagaggag gataggaagg ggacagttga taaaacccca gggccacagc agaggcaaag 180ggcatctggg gagagggttc gaagctgtgg cggactccac taatgtaacc ctccaatgtc 240aagccatggg cgtgatcagt agctaagtga tgacaaggct gttgggggtg gacggaaaag 300acttggggca aagcagactg tttatagcct gagctggtag ggcctggtgc agcagcctac 360ccggaactgg cactactctt tcccaggttc cctgactctc tatcctggtc tctgagagcg 420tgc 423 197 427 DNA Homo sapien 197caggcacctt cctggcagta gagttcacca ctttggcgga ctatttgcat ctgttgcagg 60ctgcggccca ggcactcaat ccgctaggcc cttctgcgat gttttacctg gctgcggctg 120tgtcagattt ctatgttcct gtctctgaaa tgcctgaaca caagatccag tcatctgggg 180gcccactgca gataacaatg aagatggtgc caaaactgct ttctcctttg gttaaagatt 240gggctcccaa agcatttata atttccttta agttggagac tgaccccgcc attgtaatta 300atcgagctcg gaaggctttg gaaatttatc agcatcaagt ggtggtggct aatatccttg 360agtcacgaca gtcctttgtg tttattgtaa ccaaagactc ggaaaccaag ttattgctat 420cagagga 427 198 427 DNA Homo sapien 198caaacaatac tatcttataa aatagtactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctaaaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttacttcagt catttcaaca cagaaaatgc ttctctagca tttttctttt gtagtgttaa 300cattttgaaa ttcatgtttc agaggcttca tcatcacaga atttactctt gctccatgaa 360aaaaaaatta aataccttca gaggaatatt taagttgtaa actatgaaac ttgagaaatc 420ctcttga 427 199 442 DNA Homo sapien 199actccacctt actaccagac aaccttagcc aaaccattta cccaaataaa gtataggcga 60tagaaattga aacctggcgc aatagatata gtaccgcaag ggaaagatga aaaattataa 120ccaagcataa tatagcaagg actaacccct ataccttctg cataatgaat taactagaaa 180taactttgca aggagagcca aagctaagac ccccgaaacc agacgagcta cctaagaaca 240gctaaaagag cacacccgtc tatgtagcaa aatagtggga agatttatag gtagaggcga 300caaacctacc gagcctggtg atagctggtt gtccaagata gaatcttagt tcaactttaa 360atttgcccac agaaccctct aaatcccctt gtaaatttaa ctgttagtcc aaagaggaac 420agctctttgg acactaggaa aa 442 200 353 DNA Homo sapien misc_feature (1)...(353) n = A,T,C or G 200ggcaggactg ggaggcgaca gatgggcccc tcttggcctc tgtcccagct ctctgcagcc 60agacggaaag gcggctgctt gcctctccat cctccgaaaa acccctgagg accccccccc 120atcctcttct aggatgaggg gaagctggag ccccaacttt gatcctccat tggagtggcc 180caaatctttc catctagggc aagtcctgaa aggcccaagg ccccctcccc agnntagcct 240tggcctccag cctggagaag ggctaacatc agctcattgt caaggccacc cccaccccag 300aacagaaccg tgtctctgat aaaggttttg aagtgaataa agttttaaaa act 353 201 443 DNA Homo sapien 201actaagaggt gcttagacaa gggctggtgc ccggcccagg gtgcccagcg gggccatgcc 60atggcagata aagctcagga cgtcaaaaac tcaccatgga ccccaaggca gaaaccaaga 120actgtctgca ggcaaataag cacccagcac ccatcctggc tgccggtgcc ccgtaccctg 180tatttattct tttaacaata acaaaagcca tttatttatt ccatctagaa aggaaaccct 240gtttcagtcc cctctctctg gctgttctgt tactttcctt ccacctgtgc cctccctggg 300atatgtatgc ctcgcccgcc ctccctgggc acatgtgcac acgtgcccag gcacaagtat 360gtctctgggt cccttgccct gcagtttcca gggggctctg ctccaagttc cctagcgggc 420ccctcaggga gaaatagcct cac 443 202 443 DNA Homo sapien misc_feature (1)...(443) n = A,T,C or G 202cccgcggtaa ccagcgtgag ctcgcccncc agaagaatat gaaaaagcag agcgactcgg 60ttaagggaaa gcgccgagat gacgggcttt ctgctgccgc ccgcaagcag agggactcgg 120agatcatgca gcagaancag aaaaaggcaa acgagaagaa ggaggaaccc aagtagcttt 180gtggcttcgt gtccaaccct cttgcccttc gcctgtgtgc ctggagccag tcccaccacg 240ctcgcgtttc ctcctgtagt gctcacaggt cccagcaccg atggcattcc ctttgccctg 300agtctgcagc gggtcccttt tgtgcttcct tcccctcagg tagcctctct ccccctgggc 360cactcccggg ggtgaggggg ttaccccttc ccagtgnttt tttattcctg gnggggctna 420ccccnangtn ttaaaagtng ctt 443 203 432 DNA Homo sapien 203taccagaggt aaaaggagga gctggtacca ttccttctga aactattcca atcaatagaa 60aaagagggaa tcctccctaa ctcatttttt gaggccagca tcatcctgat accaaagctg 120ggcagagaca caacgaaaaa agagaatttt agacgaatat ccttcatgaa cattgatgca 180aaaatcctca ataaaatact ggcaaaccga atccagcagc acatcaaaaa gcttttccac 240catgatcaag tgggcttcat ccctgggatg caaggctggt tcaacatatg caaatcaata 300aatgtaatcc agcatataaa cagaaccaaa gacaaaaacc acatgattat ctcaatagat 360gcagaaaagg cctttgacaa aattcaacaa aattcatgct aaaaactctc aataaatgag 420gtattgatgg ga 432 204 230 DNA Homo sapien misc_feature (1)...(230) n = A,T,C or G 204cgagtatgga gcagaaacga ttgcagggtt tnaccaggat ccacctctga tgttcactga 60agagnaccag aaaagnctgc tagagcagtn ccatctgggt ctngatccca aacgcagaaa 120atacntggtn ggagagctna nntggaatac tantgatttc atgactgaac agtcaccgac 180tagagtgctg gggntggcaa acnggatctt cactcggcag agacaacctt 230 205 431 DNA Homo sapien 205ggaaattaca atgattttgg aaattataac cagcaacctt ctaactacgg tccaatgaag 60agtggaaact ttggtggtag caggaacatg gggggaccat atggtggagg aaactatggt 120ccaggaggca gtggaggaag tgggggttat ggtgggagga gccgatactg agcttcttcc 180tatttgccat gggtaagtag cttttgagtt ttacaattat tattatcttg ggagacatag 240ctgcaggagt aaaagctttt taggatcatg ttatctttcc ttaaaatctg gttagatgga 300taatttcata acctattttt tttttactct ttacttctgt tgaaacaggc ttcactgtat 360aaataggaga ggatgagagc ccagaggtaa cagaacagct tcaggttatc gaaataacaa 420tgttaaggaa a 431 206 427 DNA Homo sapien 206ggaaagaaga agataaaaag agcaagaaag aaaatataaa ggatgagaag acaaaaaaag 60aaaaagagaa aaaaaaagat ggtgaaaagg aagaatccaa aaaggaggaa actccaggaa 120ctcctaaaaa gaaggaaact aagaaaaaat tcaaacttga gccacatgat gatcaggttt 180ttctggatgg aaatgaggtg tatgtatgga tctatgaccc agttcacttt aaaacatttg 240tcatgggatt aattcttgtg attgcagtaa tagcggccac cctcttcccc ctttggccag 300cagaaatgag agtaggtgtt tattacctca gtgtgggtgc aggctgtttt gtagccagta 360ttcttctcct tgctgttgct cgatgcattc tatttctcat catttggctc ataactggag 420gaaggca 427 207 432 DNA Homo sapien misc_feature (1)...(432) n = A,T,C or G 207acaagcacca agagattgaa acaaaagaaa tttatgctca aaggcaactt ttactaaaag 60atatggattt gctaagagga agagaagcag agctgaagca aagagttgaa gcttttgaat 120tgaaccagaa gctccaggaa gaaaaacata aaagcataac tgaggcactt aggagacagg 180agcagaatat aaagagtttt gaggagacct atgaccgaaa gctcaagaat gaacttctaa 240agtatcaact tgaactgaag gatgactaca tcattagaac taatcgactg attgaagatg 300aaaggaagaa taaagaaaaa gctgttcatt tgcaagagga gctcatagct attaattcaa 360aaaaggagga actcaatcaa tctgtaaatc gtgtgaaaga acttgagctt gaattagaag 420tctgtcaaan cc 432 208 431 DNA Homo sapien 208cgcggaggcc gcacgatgcc tggagttact gtaaaagacg tgaaccagca ggagttcgtc 60agagctctgg cagccttcct caaaaagtcc gggaagctga aagtccccga atgggtggat 120accgtcaagc tggccaagca caaagagctt gctccctacg atgagaactg gttctacacg 180cgagctgctt ccacagcgcg gcacctgtac ctccggggtg gcgctggggt tggctccatg 240accaagatct atgggggacg tcagagaaac ggcgtcatgc ccagccactt cagccgaggc 300tccaagagtg tggcccgccg ggtcctccaa gccctggagg ggctgaaaat ggtggaaaag 360gaccaagatg gcggccgcaa actgacacct cagggacaaa gagatctgga cagaatcgcc 420ggacaggtgg c 431 209 427 DNA Homo sapien 209ctggtactgt ggccctccgt gaaatcagac gctatcagaa gtccactgaa cttctgatcc 60gcaagctccc ctttcagcgt ctggtgcgag aaattgctca ggacttcaaa acagatctgc 120gcttccagag tgcagctatt ggtgctttgc aggaggcaag tgaggcctat ctggttggcc 180tttttgaaga taccaatctg tgtgctatcc atgccaaacg tgtaacaatt atgccaaaag 240atatccagct agcacgccgc atacgcggag aacgtgctta agagtccact atgaggggaa 300acatttcatt ctcaaaaaaa ttttttttcc tcttcttcct gttatcagta gttctgaatg 360ttagatattt tttccatggg gtcaaaggta cctaagtata tgattgcgag tggaaacata 420ggggaca 427 210 427 DNA Homo sapien 210atttatacct acaaaaagaa aacaagatga tggtatcaaa aggacaattt acaaactaag 60aatagtaaca tagctttcag catcctgtgc ctgaacatca cacatctaca agtctttcaa 120gtcttaatgc aacaggaatg tgtctggaga ccagcaagaa catcaataga gagcactgat 180cccaagcaaa agccactaac cttttagatg agaagtccac acaacgaatt gttagggagg 240attggggaga agcagcccat tgcttaatac attggaaccc tttccctaag ttgagtttca 300accatgaatg caataactag cataaaacga ttcttctgct catgttctga agccaacagc 360agaacctgaa ttataagtga cagacatgga ggcagaagag ttaaactctg ctagatttca 420gctgtgc 427 211 429 DNA Homo sapien 211tgtatcagaa ccttaatgag ccaaccacgt ggagcttaac cagtgataga actagaaatt 60gggttcttca acagaaaata gaaggagaaa caaaagaatc aaactacgct aaattgattg 120aaatgaatgg aggaggaacc ggctgtaatc atgaattaga aatgatcaga caaaagcttc 180aatgtgtagc ttcaaaacta caggttctac cccagaaagc ctctgagaga ctacagtttg 240aaacagcaga tgatgaagat ttcatttggg ttcaggaaaa tattgatgaa attattttac 300aactacagaa attaactggc cagcaaggtg aagagcccag cttggtgtcc ccaagtactt 360cttgtggctc attgactgaa agactactga gacaaaatgc tgagctgaca gggcatatca 420gtcaactga 429 212 426 DNA Homo sapien 212agaacatctg tttctgggcc cccatccacc gtggccttcc agttgtccac ggtgtcctaa 60gagcctcgcc atttctgatg ttcccgtgtt cctcccccag atgtctccca cgtcttcccc 120gagttcccag cgcccgacct gggcagcttc ctgctgcagg acggcgtcac actgcacgac 180gtcaaggccc tgcagctggt gtacagacgg cactgcgagg tgaccgcccc agcccaggca 240ggcagctcct gcgtgtccct cccgggaacc gccagcgctc aggccaggcg tccccgggtg 300acgctgagga gctggagccc cgagcccccc aacaagcatc ctctctgaag cagcagcccc 360tccgcatcca tgtccatcgc ctgctcctct cctctctgtg gcctcccttg ggattccagg 420gcaccc 426 213 430 DNA Homo sapien misc_feature (1)...(430) n = A,T,C or G 213gctcaagatc tgccgagtaa accggaactc tnggagctgc ctcggtgggg atgagatctt 60nttgctgtgc gacaaggtgc anaaagaana cattgangng tatttcacgg gaccaggctg 120ggaggcacga ggctcctttt ctcaagctga tgtgcatcgg caagtggcca ttgtgttccg 180gactcctccg tacgccgacc ccagcctcca ggctcctgtt cgagtctcca tgcagctacg 240gcggccttct gatcgcgagc tcagtgagcc catggagttc cagtacttgc cagacacaga 300tgatcgccac cggattgaag agaagcgcaa aaggacctat gagaccttca agagtatcat 360gaagaagagt cctttcaatg gaccaactga accccggcct ccaacccggc gtattgctgt 420gcctacccga 430 214 431 DNA Homo sapien 214gttccctggg ctccccccat cacatcccag cccctctggg ctgaccctgt ctagagatgc 60atctgtcccc tccttggact gggagctcca aggacagggc caggggtcgt ctccccatcc 120cagtgattct ggaattgtcc agggcagggc cgggcgcagg acagacgttt tgtggaacta 180atgcaggggt gaattagtgg attcatgggg ccaaagatgt ggcgtcagcg cagatgaggg 240tggcgcttcc ccacctctgt cctggtcgct ccccaacctg ctcacacctc tctctctctc 300tctccctgac agcatttctt cacttccttt ggggcccgtg accgctgctt cctcctcatc 360ttccgcctct ggcagaatgc actgcttgaa aagacgctga gtccccgcga gctctggcac 420ctggtgcatc a 431 215 436 DNA Homo sapien 215tcatcatagt tgggagccat tggatgcccc agagggtaag ctgcaaggct ctaggtgtga 60caacagcagt tgcagcaagc tccctccaca agaaggaaga ggcattgctc aagaacagct 120gttccaagaa aagaaggatc ctgctaaccc ctccccggtg atgcctggaa tagccacctc 180tgagaggggt gatgaacaca gcctaggctg tagtccttca aattcatcag ctcagcccag 240ccttcccctg tatagaacct gccaccccat aatgcctgtt gcttcttcat ttgtgcttca 300ctgtcctgat cctgtgcaga aaactaacca atgcctccaa ggccaaagcc tcaaaacttc 360attgacttta aaagtggaca gaggcagtga ggagacctat aggccagagt ttcccagcac 420aaaggggctt gtccgt 436 216 427 DNA Homo sapien 216gatatgttga atacaccttt gtgtccttca cacagcagtt tacatccagt gctgttacct 60tcagatgtat ttgaccaacc acaacctgta ggtaacaaaa gaattgaatt ccatatatct 120accgacatgc cagctgcatt taagaaagat ttagaaaagg aacaaaattg tgaggaaaaa 180aatcatgatt tacctgctac tgaagttgat gcatccaata taggatttgg aaaaatcttc 240cccaaaccta atttggacat cacagaggag attaaagaag actctgatga aatgccttca 300gaatgtattt ctagaaagga attggaaaag ggcagaattt ctagagaaga aatggaaaca 360ctttcagttt tcagaagtta tgaaccgggt gaaccaaact gtagaattta tgtaaagaat 420ttagcta 427 217 399 DNA Homo sapien 217acccaacctc cgagcagtac atgctaagac ttcaccagtc aaagcgaact actatactca 60attgatccaa taacttgacc aacggaacaa gttaccctag ggataacagc gcaatcctat 120tctagagtcc atatcaacaa tagggtttac gacctcgatg ttggatcagg acatcccgat 180ggtgcagccg ctattaaagg ttcgtttgtt caacgattaa agtcctacgt gatctgagtt 240cagaccggag taatccaggt cggtttctat ctacttcaaa ttcctccctg tacgaaagga 300caagagaaat aaggcctact tcacaaagcg ccttcccccg taaatgatat catctcaact 360tagtattata cccacaccca cccaagaaca gggtttgtt 399 218 426 DNA Homo sapien 218cgcggaggta cgctgagtgg agctcggggc tgcgtagggg agctgagccg agcggctggg 60cgggcctggc cgggccagcg gaggggagac gtcggttgag cggcggcgaa catgcgcttt 120tgacacattg gaggctttct tgatcatgga tggtgaagat ataccagatt tttcaagttt 180aaaggaggaa actgcttatt ggaaggaact ttccttgaag tataagcaaa gcttccagga 240agctcgggat gagctagttg aattccagga aggaagcaga gaattagaag cagagttgga 300ggcacaatta gtacaggctg aacaaagaaa tagagacttg caggctgata accaaagact 360gaaatatgaa gtggaggcat taaaggagaa gctagagcat caatatgcac agagctataa 420gcaggt 426 219 427 DNA Homo sapien 219cggcggcggc tgcggcccaa tatagccagc agccagcttc gggtgtagcc tattctcatc 60caactacagt tgctagctac actgtccatc aggctccagt agctgctcac acagttactg 120ctgcctatgc accagcagcc gccacagttg cagttgccag gcctgctcca gtagctgttg 180cagctgctgc aacagctgct gcttatggag gctaccccac tgcacacaca gcaactgact 240atggttatac tcagaggcaa caagaagcac caccaccacc acccccagct actacacaaa 300actaccagga ttcatactca tatgtaaggt ccacagctcc tgctgtagct tatgatagta 360agcaatacta ccaacaacca acagcagcaa cagaagcagg cagcagcagc agctgctgct 420gctgctg 427 220 428 DNA Homo sapien 220ctctgtcgaa gattataaag cccttcagaa atacgaaaag gagaaatttg aagagatgat 60tcaacaaatt aaagagactg gtgctaacct agcaatttgt cagtggggct ttgatgatga 120agcaaatcac ttacttcttc agaacaactt gcctgcggtt cgctgggtag gaggacctga 180aattgagctg attgccatcg caacaggagg gcggatcgtc cccaggttct cagagctcac 240agccgagaag ctgggctttg ctggtcttgt acaggagatc tcatttggga caactaagga 300taaaatgctg gtcatcgagc agtgtaagaa ctccagagct gtaaccattt ttattagagg 360aggaaataag atgatcattg aggaggcgaa acgatccctt cacgatgctt tgtgtgtcat 420ccggaacc 428 221 422 DNA Homo sapien 221aaaagcctga agaatacaat tctgagaaat ataaaaaaat tttaatggta tactcatgtt 60gaaagataaa tgttgctaag tcctggtatg atggtgtgag cttccttggg gaagtacttc 120ttgagttatg taactaacag gatgttttac tacagatctg gatggctatt cagataacat 180ggcaaaaaat gatagcagaa gatcattaaa aacttaaaat atattttatt agaaaacatt 240tatctatgaa tgaatatttc cttgatgctg gtctctgcac acatatgctt ggttacttgc 300atgcattcat tggttgttca ataagtgaga tgattacaga taacttaata ctgtattttc 360cttatatgga aaaccgttat agacccaata acaactaaac ctttcaaaag aaaatatttt 420ct 422 222 47 DNA Homo sapien 222aagccgcccg gccagccgcc ccgtccggga gggaggtggg ggggtca 47 223 432 DNA Homo sapien 223ctgcaggccc gtgcccgtgt ggatgagtac ctggcatggc agcacacgac tctgcggaga 60agctgcctcc gggccttgtg gcataaggtg atgttccctg ttttcctggg tgagccagta 120tctccccaga cactggcagc caccctggca gagttggatg tgaccctgca gttgctcgag 180gacaagttcc tccagaacaa ggccttcctt actggtcctc acatctcctt agctgacctc 240gtagccatca cggagctgat gcatcccgtg ggtgctggct gccaagtctt cgaaggccga 300cccaagctgg ccacatggcg gcagcgcgtg gaggcagcag tgggggagga cctcttccag 360gaggcccatg aggtcattct gaaggccaag gacttcccac ctgcagaccc caccataaag 420cagaagctga tg 432 224 428 DNA Homo sapien 224cccagcccat ccattaggct gggggaaggg ggtgggacag gggctggagg aggggctctg 60gggtccatca cggcacagga acaacacgca tggtgttggt gaagccggag ccagggcgcc 120atccggtcag cacaatgacc acatctccct tcttgaagaa gcctcgggcc ttgccaacat 180tcatggcaaa gttcacccgg aggtccacgt cctcagccca tccattaggc cagcaacgct 240tgtagaactc actctgggct gtaacgtggc actggtaggt tgggacacca gggaagaaga 300tcaacgcctc actgaaacat ggctgtgttt gcagcctgct ctagtgggac agcccagagc 360ctggctgccc atcatgtggc cccacccaat caagggaaga aggaggaatg ctggactgga 420ggcccctg 428 225 428 DNA Homo sapien 225ggccagcaac gacgaatacg acagcaacgc ttgatctcta taggcaaatg gattgctgat 60aatcagccaa ggctgattca gtgtgaaaat gaggtaggga aattgttgtt tatcacagaa 120atcccagaat taatactgga agaccccagt gaagccaaag agaacctcat tctgcaagaa 180acatctgtga tagagtcgct ggctgcagat gggagcccag ggctaaaatc agtgctatct 240acaagccgaa atttaagcaa caactgtgac acaggagaga agccagtggt taccttcaaa 300gaaaacatta agacacgaga agtgaacaga gaccaaggaa gaagttttcc tcccaaagag 360gtaaaatccc agacagaact aagaaagact ccagtgtctg aagccagaaa aacacctgta 420actcaaac 428 226 249 DNA Homo sapien 226cttgctgcct gcagcataca gagctgtgtc caaggctccc agcgccacca gggctaggga 60gtcggtttct aagtggagct tcacggactc cccgttccgg tactgcttgg caccgtccac 120gctgagctcc agcttgccct cgcaggcccc agcctggaca tccactcgca gggagttggc 180cactgggtgg tctccatggt agtagaaggc cacaaagtag aaggagggtg ccaggtgatg 240gtccacccc 249 227 433 DNA Homo sapien 227agcaacagat gatacgctta actttttgga cacctgtgat ttgcatactg agcatataaa 60gccatcttta cgcacgtcca tcggtgaaag aaaacggtct ctttcaccac taattaagtt 120ttctccagtg gaacaaagat tgagaaccac aatagcatgt agtcttggag aactacctaa 180tttaaaggaa gaagacattt tgaataagag ccttgatgca aaagaaccac cgtctgactt 240gacaagatga agacgtaccc atttaatata actatgatgc acttaaattg aagctatgcc 300acaggataga aaatgaatta caacttaaat acatgttgga agtgtaacac tgtttttcaa 360ggtttaaaaa aattcctaat gccttttagc cttctttaat atttttaggt aaggaaagta 420tgtttggatt ttt 433 228 428 DNA Homo sapien 228ccccttcgcc cggctgcacg agtgctatgg ccaggagatc cgggccctgc gtggccagtg 60gctcagcagc cgggtccagc cctgaggcca ccagggcgcc tgttttaggg ggacacaagc 120tctatgccct ctgggacagg ccgggtcctg gagagactgg gggagcagat cctgagggaa 180atcatgggca aggctggccc ccaggccctg agtggcctgg ttttggggga tgcaggctct 240gagaaggtgc tggattctga gtgggccttt aggaccatgt gacccagaag gcctaccctt 300gaggggaacg tcacgtgcaa cactaaggag aatccagggc ctgaggggga ggtttcctga 360gaactccggc cccaggctgg cctgagctgc cgggcagagg cctgtgctgg caacaggcat 420tgccgggc 428 229 422 DNA Homo sapien 229gtttcagaaa atgttcagac acccaagtca tgtacagctg aaggtagttg ctggaaacca 60tgacattggc ttccattatg agatgaacac atacaaagta gaacgctttg agaaagtgtt 120cagctctgaa agactgtttt cttggaaagg cattaacttt gtgatggtca acagcgtggc 180gctgaacggg gatggctgtg gcatctgctc tgaaacagaa gcagagctca ttgaagtttc 240tcacagactg aactgctccc gagaggcacg tggctccagc cggtgtggac ctgggcctct 300gctgcccacg tctgcccctg tcctcctgca gcattatcct ctgtatcgga gaagtgatgc 360taactgttct ggggaagacg ctgctcctcc agaggaaagg gacatcccat ttaaggagaa 420ct 422 230 431 DNA Homo sapien 230tccagacatt aataattttg accctaggaa agctatccat ttatggaatg caagaacacc 60gtcttcaact ggtgacacaa gatctaattc agattgctca tcaaactcag aaaatgaaag 120tgattagcaa tatgcaaatg ttgacatttt tgttgcttag caatgtagct cttttgcata 180gtaaaaaata aaataaaata aatggtttcc agaagcctgg aatttaaaag taaaacagta 240acttctcttc acatcaaaca aaaggcattt ggcttcttcc aaacatacag agtaaaaagc 300ccaagattgt ttcttctata gctttctaac ttcacttatg tattcctgtg ttctttcaca 360ctcttttggt ggagctgtat gctgctacac aatggtgtta ttttgatgtc atttttttca 420gttattccta a 431 231 435 DNA Homo sapien 231gcctttgccg ctaccgcttt cttaccctcc gcacccgtta agttctccgg tcgggcggca 60gtctctgaac acttagccgc gccatccggg gtcacaccgc ctggaaggag gtgacggggg 120cggcgcgggg cgcggacact ccccgctgag agtccgcctg ccatggactc ggaatattac 180agcggcgacc agtcagatga tggtggtgct accccagtac aggatgaacg ggattcaggg 240tcagacggtg aggatgatgt aaatgagcaa cactccggat cagacactgg aagtgtagaa 300cgtcattcag agaatgaaac tagtgatcga gaagatggcc tccccaaagg acatcatgtg 360acagactctg agaacgatga gcccttaaat cttaatgcta gtgactctga aagtgaggag 420cttcacaggc aaaag 435 232 452 DNA Homo sapien 232gtcccgggat gcccctgccc gagcccagcg agcaggaggg tgagagtgtg aaggccagcc 60aggagccatc ccccaagcca ggcacagaag tcatcccggc agcccccagg aagcccagaa 120agttctccaa actggtcctg ctcacagcct ccaaagacag caccaaggtg gcgggggcca 180agcgcaaggg tgtgcactgt gtcatgtccc tgggggtgcc cggccccgcc acccttgcca 240aggccctcct ccagacccac cccgaggccc agcgggccat tgaggcagcc cctcaggagc 300ctgagcagaa acggagcagg caggacccag gcacagacag aacagaagac agtggattag 360cagcggggcc tcctgaggct gctggggaga actttgcccc ctgctctgtg gcgcccggca 420agtccctgta accttgacaa caggcgcatc ct 452 233 452 DNA Homo sapien misc_feature (1)...(452) n = A,T,C or G 233ggcgcgggag cagctcggcc ggctgggtct tcatcctcat tgtactccct tggcatntca 60tggtgacgtg acttaaaagg tggtgcagag acgtttgaaa ctattgcttt gctgaaaaca 120tctgactgcc aggctaggat gtgacactta agggaccagg gatcatttac atactgnggn 180cttgcattac tgcgatgaaa tcttccacca ctcccaccac ccactacaag agatggaatt 240aattgaaact acagccttca agagacattt ggagcaatac tcttccagtt ctttcttcca 300cattttattt gtgggtacag cgtctcccag gatgtagtgt gctgtaatta ttcttccacc 360cttttatttt ctgggagttt ctctatctga atagcacaga aatattagtg gataggaagg 420gaatataata ttctatccat ctgaaaatta ac 452 234 434 DNA Homo sapien 234caaacaatac tatcttataa aatagtactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctagaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttacttcagt catttcaaca cagaaaatgc ttctctagca tttttctttt gtagtgttaa 300cattttgaaa ttcatgtttc agaggcttca tcatcacaga atttactctt gctccatgaa 360aaaaaattaa ataccttcag aggaatattt aagttgtaaa ctatgaaact tgagaaatcc 420tcttgagata aaag 434 235 312 DNA Homo sapien 235tgggcttcaa gaagcgtgca cctcgggcac tcaaagagat tcggaaattt gccatgaagg 60agatgggaac tccagatgtg cgcattgaca ccaggctcaa caaagctgtc tgggccaaag 120gaataaggaa tgtgccatac cgaatccgtg tgcggctgtc cagaaaacgt aatgaggatg 180aagattcacc aaataagcta tatactttgg ttacctatgt acctgttacc actttcaaaa 240atctacagac agtcaatgtg gatgagaact aatcgctgat cgtcagatca aataaagtta 300taaaattgcc tt 312 236 427 DNA Homo sapien 236cgcccacaag ccacagagcc tagacactga tgaccccgcg acgctgtacg ccgtggtgga 60gaacgtgccc ccgttgcgct ggaaggaatt cgtgcggcgc ctagggctga gcgaccacga 120gatcgatcgg ctggagctgc agaacgggcg ctgcctgcgc gaggcgcaat acagcatgct 180ggcgacctgg aggcggcgca cgccgcggcg cgaggccacg ctggagctgc tgggacgcgt 240gctccgcgac atggacctgc tgggctgcct ggaggacatc gaggaggcgc tttgcggccc 300cgccgccctc ccgcccgcgc ccagtcttct cagatgaggc tgcgcccctg cgggcagctc 360taaggaccgt cctgcgagat cgccttccaa ccccactttt ttctggaaag gaggggtcct 420gcagggg 427 237 452 DNA Homo sapien 237gtgatttttc catcccattc ccccaaaaat gtgcctcata cactggacaa gacttctact 60gtgactattc ttggcacaag aaaaaaactt caaacaattc ccaaaaaaaa gcactcactc 120caaaaaaaaa aaaaaaaaaa aaaggatgtc cctcacccct aagctgaaaa gcagtctctc 180tcttcagctt agggatgtcc ctcacccctt tcacagcacc aaagttgaag agagagactg 240cttttcactt cttcagttct gccatcttgt tttcaaaggg ctccagcctc actcagtccc 300taattatggg actgagaaaa gcttggaaag aatcttggtt tcatataaat tcttgttgtt 360aggccttact aagaagtagg aaagggcatg ggcaaaaggt agggataaaa accaccagca 420tatacatgga catacacaca cacccacaca ca 452 238 453 DNA Homo sapien misc_feature (1)...(453) n = A,T,C or G 238agccgaccgt gattccctct actacanata ttatgtcttg taagttagca tttttagcac 60acaggagaaa tnttatgtaa taaaattact gtatcttttg gatttaacaa atttgtattt 120gaaacacatt ctatgtctga taattcttaa tggcactttt actaatttat ttggggatct 180tgggtacatt cttaatttgt gtttattctt cacgcttgac ttgcaagtgg gatattcccc 240tgccacaagt gtcaaacagt gatattcttc ctgtgttgtg actggacagt tttccagatc 300ttttttggga gattttccta cagcttggtt gtatgtnttg agataacacc accaaacagc 360tctcagaaat tcttttttga ttgatcagna gctatgatga ttctcctcca tgacactaag 420gattagttta tatatnnnag agaaanangg gct 453 239 453 DNA Homo sapien misc_feature (1)...(453) n = A,T,C or G 239cgtgtttgtg tgcctgctgg agtacccccg ggggaagagg aagaagggct ccaccatgga 60gcgctgggga cagaagcaca tgaccgccgt ggtgaagctg ttcgggccct ttaccaggaa 120ttactatgtt cgggccgtcc tgcatctcct gctctcggtg cccgccggct tcctgctggc 180caccatcctt ggggccgcct gcctggccat tgcgagcggc atctacctac tggcggctgt 240gcgtggcgag cagtggacgc ccatcgagcc caagccccgg gagcggccgc agatcggagg 300caccatcaag cagccgccca gcaacccccc gccgcggccc ccggccgagg cccgcaagaa 360gcccagcgag gaggaggctg cggcggcggc ggggggaccc ccgggaggtc cccaggncaa 420ccccatcccg gtgaccgacg aggncgtgtg acc 453 240 453 DNA Homo sapien 240ggctcatctt cgcagacggg ctcctctact gtcccgtggc cttcctcagc ttcgcctcca 60tgctgggcct cttccctgtc acgcccgagg ccgtcaagtc tgtcctgctg gtggtgctgc 120ccctgcctgc ctgcctcaac ccactgctgt acctgctctt caacccccac ttccgggatg 180accttcggcg gcttcggccc cgcgcagggg actcagggcc cctagcctat gctgcggccg 240gggagctgga gaagagctcc cgtgattcta cccaggccct ggtagccttc tctgatgtgg 300atctcattct ggaagcttct gaagctgggc ggccccctgg gctggagacc tatggcttcc 360cctcagtgac cctcatctcc tgtcagcagc caggggcccc caggctggag ggcaagccat 420tgtgtagagc cagaggggaa ccactttggg aac 453 241 453 DNA Homo sapien misc_feature (1)...(453) n = A,T,C or G 241aagcaacggc aagggccgca gccagcnccg ggcggagagg gctaccatgg ggaaaatcgc 60gctgcaactc aaagccacgc tggagaacat caccaacctc cggcccgtgg gcgaggactt 120ccggtggtac ctgaagatga aatgtggcaa ctgtggtgag atttcggaca agtggcagta 180catccggctg atggacagtg tggcactgaa ggggggccgt ggcagtgctt ccatggtcca 240gaagtgcaag ctgtgtgcaa gagaaaattc catcgagatt ttaagcagca ccatcaagcc 300ttacaatgct gaagacaatg agaacttcaa gacaatagtg gagtttgagt gccggggcct 360tgaaccagtt gatttccagc cgcaggctgg gtttgctgct gaaggtgtgg agtcagggac 420agccttcagt gacattaatc tgcaggagaa gga 453 242 441 DNA Homo sapien misc_feature (1)...(441) n = A,T,C or G 242tcctatggcn cgncntnnaa gcggcggcgg nnatnagncn aaagcactac cttgaggctg 60cagcgcgggg actgcacgac agctgcccgg gccaagcccg ntacctnctc tgggcctaca 120cttngncgca cgatgataag agcacttttg aagaaacgtg tccatactgt ttccagctgt 180tggttctgga taactctcga gtgcgtctca aacccaaagc caggttgaca cccaaaatac 240agaaacttct taatcgagaa gcgagaaact atacactcag ttttaaagaa gcaaaaatgg 300tgaaaaagtt caaagactcc aaaagtgtat tgttgatcac ttgtaaaaca tgcaacagaa 360cagtgaaaca tcatggtaaa agtagaagct ttgtgtcaac attgaagagc aatcctgcca 420ctcctgcaag taaactcagc c 441 243 429 DNA Homo sapien 243gaaaaaggaa aaaaagaaga aacggaaggc agagaaacat cgtggccgaa ttgggatcga 60tgaagatgat aaggggccta gggcacctcg cccacctcag cccaagaaat ctaagaaagc 120aggtggtggg ggtagcaatg ctactacact cagccatcct ggctttggga cttccggagg 180aagtagcaac aagctaccta aaaagtctca aaagacagct ccacctgtcc ttcccactgg 240ctatgattct gaggaggagg aagaaagcag gcccatgagt tatgatgaga agagacagtt 300aagcctggat atcaataagt tacctgggga aaagctgggt cgagtagtac atatcatcca 360agccagggaa ccctctctac gtgattcaaa tccagaagaa attgagattg attttgaaac 420actcaagcc 429 244 433 DNA Homo sapien misc_feature (1)...(433) n = A,T,C or G 244caaacaatac tatcttatan aatagnactg ttgaattatt ccaagcctcc ctaggtttgc 60tctcaaatgt catttacaga ttgggctaac gacctaaaat ctatatataa agactttctg 120aagaactctg tattatagca ataccaaacg agtgctgtgt gtgcaaacag tctggcgttg 180ctttttatgt tgatatttat cctagaacac tgaaagagaa tatgccagtg ataactcact 240ttacttcagt catttcaaca cagaaaatgc ttctctagca tttttctttt gtagtgttaa 300cattttgaaa ttcatgtttc agaggcttca tcatcacaga atttactctt gctccatgaa 360aaaaaattaa ataccttcag aggaatattt aagttgtaaa ctatgaaact tgagaaatcc 420tcttgagata aaa 433 245 430 DNA Homo sapien 245gatgcccctt ggagtggcaa ggaagctgga cagggcaggc ctctggggac gggacacagg 60gaagcccgaa ggggcgcctt ggccaggtct gccatctcct ccagcgaggc tctggccagc 120actgggtgag agtggggagg gggcactggc ctttgcagca cagtaaaaca tggtccagac 180aacctgtggc cccggcctca tgagcacccc ctgcacaggc ccagcccaag ccaggcgcta 240gaagggctgg ttgtggagtg cttatccttg acaggtatgg ggccaggtga gggcagggga 300caaggtgcag ctgaggccga gcccaactag gtcctgggca cccctgcagg tgggagtggt 360ccttgtcctc ctggtatcca gcagacaccc ccctctcccc accagcccca ttctcaggtc 420ctttcctctt 430 246 428 DNA Homo sapien 246cctgcccagc aaggacatct gtccagggtg gcacatggac atgttgagcc cccgcagcag 60gggatggtgc cccatggcct gcaccagggg gtcatgtccc ctccacaagg cctcatgacc 120cagcagaatt tcatgctgat gaagcagcgg ggcgtggggg gcgaggtcta cagccagccg 180ccccacatgc tctccccgca gggctccctc atgggccccc cgccccagca gaacctcatg 240gtgtcccacc cccttcggca gcgcagtgtg tccctggaca gccagatggg ctacctcccg 300gcaccaggcg gcatggccaa cctgcccttc tagaagtcgc tgccagggct ggagccgggg 360caatgttgca aatacgataa ccttaacaaa gttcttcccc tcaatgttgg gatggcctgg 420gtcgtggg 428 247 428 DNA Homo sapien misc_feature (1)...(428) n = A,T,C or G 247gacaagtcgg acaggggcca tgacntntcg gaccgcagcc atgagaaact agacaggtgc 60cacgacaagt cagaccgggg ccacgacaag tctnacaggg atcgagagcg tggctatgac 120aaggtagaca gagagagaga gcgagacagg gaacgggatc gggaccgcgg gtatgacaag 180gcagaccggg aagagggcaa agaacggcgc caccatcgcc gggaggagct ggctccctat 240cccaagagca agaaggcagt aagccgaaag gatgaagagt tagaccccat ggaccctagc 300tcatactcag acgccccccg gggcacgtgg tcaacaggac tccccaagcg gaatgaggcc 360aagactggcg ctgacaccac agcagctggg cccctcttcc agcagcggcc gtatccatcc 420ccaggggc 428 248 430 DNA Homo sapien misc_feature (1)...(430) n = A,T,C or G 248ggctgtgaat ccatctggtc ccggactntt tttggttggt aaactattga ttattgccac 60nttttcagct cctgttattg gtctattcag agatacncct tcttcctggt ttagtcttgg 120gagagtgtat gtgtcgagga atgtatccat ttcttctaga ttttctagtt tatttgcgta 180gaggtgtttg tagtattctc tgatggtagt ttgtatttct gtgggatcgg tggtgatatc 240ccctttatca ttttttattg tgtctatttg attcttctct ctttttttct ttattagtct 300tgctagcggt ctatcaattt tgttgatcct ttcaaaaaac cagctcctgg attcattgat 360tttttgaagg gtttttgtgt ctctatttcc ttcagttcct gctctgatnt tagtnatttc 420ttgccttctg 430 249 425 DNA Homo sapien misc_feature (1)...(425) n = A,T,C or G 249gtcgccgccg ccgccaccgc taccgtcgcc gccgccgccg ccgaggtgac tgaggagaga 60ggcgcctcct cgctcccgcc accgccggac ttcnatgccc agtccccagc tcgccagcgt 120ttttcgttgg aatatacgtt gcacatttat ggcgattctg agtgtgaggg cagacttctg 180ccaggctcag cacagcattt tcgctgacaa gtgagcttgg aggttctatg tgccataatt 240aacattgcct tgaagactcc tggacaccga gactggcctc agaaatagtt ggcttttttt 300tttttttaat tgcaagcata tttcttttaa tgactccagt aaaattaagc atcaagtaaa 360caagtggaaa gtgacctaca cttttaactt gtctcactag tgcctaaatg tagtaaaggc 420tgctt 425 250 424 DNA Homo sapien misc_feature (1)...(424) n = A,T,C or G 250gttctggtcc acaataaaat gccatngatg gctcaagcaa agcacattaa agccttctta 60agcttttaaa tgcattccac tattcatttt caanttacct ttaaaatttc catttttacc 120atgttcacac aagtatgaca cttaatcgcc tcaggttata acaagagata ctgtgaaatc 180attgaaactt taagagggga aaccctaaaa taagtcaaca tacacatttt ccttctcacc 240tttttcagga tgttctggtt ctggctgatt actactgctt gagctcacac tggcatcaaa 300acctgctggc gagctattcc cttcagactg gaggtcttgg agctccccag caacactatc 360cacctcaatt gtgctatcag tttcactctt gatacttcga acctcttctt ggtttggagc 420cagt 424 251 426 DNA Homo sapien 251attttgatct gtatctacac cacccaaagt taggcctcct ataatgtcca aaacattcct 60tttagccttt ttatttctta ctgtactgtc tcttactgta ctgtctatct gcagtaattg 120aggacccata aaatttagat aactacatgt ctttgctctt agaattgtca ctcagcataa 180tgagcattta acatacaaag gcaatgtact gttttgtgtt gatctatgta aaagaataca 240attctttttt acataattag tgaaatttta ttttttatta ggaaacacta aatagtgtaa 300tatttctttt gcttttaaaa aaattcctgg tagcaaatca agataaataa ttgcttcatt 360ttcttgagca atactgaagc aggatgaagt aagaggaatg cattcattta aacatgcttt 420gcttta 426 252 429 DNA Homo sapien misc_feature (1)...(429) n = A,T,C or G 252ttcaaagaac tacttgaaaa tgcagagant tccctgaatg atatgtttgt gaagacatat 60ggncatttat acatgcaaaa ttctgagcta tttaaaganc tcttcgtaga gttgaaacgt 120tactacgtgg tgggaaatgt gaacctggaa gaaatgctaa atgacttctg ggctcgcctc 180ctggagcgga tgttccgcct ggtgaactcc cagtaccact ttacagatga gtatctggaa 240tgtgtgagca agtatacgga gcagctgaag cccttcggag atgtccctcg caaattgaag 300ctccaggtta ctcgtgcttt tgtagcagcc cgtactttcg ctcaaggctt agcggttgcg 360ggagatgtcg tgagcaaggt ctccgtggta aaccccacag cccagtgtac ccatgccctg 420ttgaagatg 429 253 436 DNA Homo sapien misc_feature (1)...(436) n = A,T,C or G 253agcgaattgg tagcaaaaag ggtggaggnt ngaactggag aaaaggaagg atgaaattga 60acnagaagtt ctccgaaggg tggaggaagc caaacgcatc atggaaaagc agttgctcga 120agaactcgag cgacagagac aagctgagct tgccgcacaa aaagctagag aggaggaaga 180acgtgcaaaa cgtgaggagc tagagcgaat actggaagag aataaccgaa aaattgcaga 240agcacaagcc aaactggccg aagaacagtt gagaattgtt gaagaacaaa gaaagattca 300tgaggaaagg atgaaactag aacaagaacg acaacgtcaa caaaaagaag aacaaaaaat 360tatcctgggc aaggggaagt ccaggccaaa actgtccttc tcattaaaaa cccaggatta 420aattgcaaac tctgaa 436 254 430 DNA Homo sapien misc_feature (1)...(430) n = A,T,C or G 254ccaagatggt caactagaag tagctngtgt ttgtggctct cacagaaaca aatggaagga 60gagagtaaat aacagcacct tcaactgaaa catgccggta gtcactttgg gaataatcaa 120ggaaacaacc cacaaagaac agagaaaagc aaggcaggaa aatggcccat ctggaagcag 180cacagagcca agggagcctc ccctgcccag ggaagtggtg aatgagtgtg tcaccccggg 240aacccacact tctctcacag atctttgcaa cccttgggtt gggagatcct gtcgtgaacc 300catttcacca gggctttcag tctgactgac acacagagct acagggagtc tcagcagagg 360ccccacaaag ggacacatgg agacttggga gccttagata ctagatggct ttctgggcat 420cccagcaaaa 430 255 436 DNA Homo sapien misc_feature (1)...(436) n = A,T,C or G 255ttcatcccct ccccgcgcgt tccttcgcac antgtgattt tgccctcctg cccacgcaga 60cctgtngcgg gcaaagagct cccgaggaag cacagcttgg gtcaggttct tgcctttctt 120aattttagag acagctaccg gaaggagggg aacaaggagt tctcttccgc agcccctttc 180cccacgccca cccccagtct ccagggaccc ttgcctgcct cctaggctgg aagccatggt 240cccgaagtgt agggcaaggg tgcctcagga ccttttggtc ttcagcctcc ctcagccccc 300aggatctggg ttaggtggcc gctcctccct gctcctcatg ggaagatgtc tcagagcctt 360ccatgacctc ccctccccag cccaatgcca agtggacttg gagctgcaca aagtcagcag 420ggaccactaa atctcc 436 256 442 DNA Homo sapien misc_feature (1)...(442) n = A,T,C or G 256gaattnccaa ccccacgagc tgctccctct ttccgcaaac ctcctaaccc cggggttttt 60ccataagggn gtttacttcg tccacgccag cctgcgaagt tccaaaatgg agtctgggcc 120acgccggcgt tctgggcacg actacggtct cttgaaaaga tttggaattg accatgtaga 180taatctctga gagcagttct taaagtgtaa tccagaaccg gtggaacttg ctagaaacgc 240atattcttcg gaccccctcc aaatctgctg aatctgagat tgtggaggcc attcaatgtc 300ccttcttcag gaatttggaa aaaggatgga gagatctctc tgagctagac tcttcagtgg 360aggaaatgtt acaactcatg gacagtggca ttaccatctg ccttaggaac ggagcagcct 420ctgtcttcaa agaaaaaaga at 442 257 436 DNA Homo sapien misc_feature (1)...(436) n = A,T,C or G 257gcggccaccc tccgccgtcc agggcccctc cgtctcggcc ccgggacccc ggctccccgc 60cagccccggc cccggccccg gcaccatgtc ngataaaagc gtggaggcag cggccgagtt 120gagcgccaag gacctgaagg agaagaagga gaaggtggag gagaaggcaa gccggaaaga 180gcgaaagaaa gaagtggtgg aggaggagga gaacggggct gaggaggaag aagaagaaac 240tgccgaggat ggagaggagg aagatgaagg ggaagaagaa gatgaggaag aagaagaaga 300ggatgatgaa gggcccgcgc tgaagagagc tgccgaagag gaggatgaag cggatcccaa 360acggcagaag acagaaaatg gggcatcggc gtgagcccct gccaacaggc tggggttggg 420aggcctctct gggcct 436 258 436 DNA Homo sapien 258ggccagggga cgggggcgga gccggagccg gagccgacgg gcggtggccg cactgggacc 60ccggaatccc gcgcgctgcc cacgattcgc ttctgaggaa cctataaaga ttgtacaatg 120aatggtgatt ctcgtgctgc ggtggtgacc tcaccacccc cgaccacagc ccctcacaag 180gagaggtact tcgaccgagt agatgagaac aacccagagt acttgaggga gaggaacatg 240gcaccagacc ttcgccagga cttcaacatg atggagcaaa agaagagggt gtccatgatt 300ctgcaaagcc ctgctttctg tgaagaattg gaatcaatga tacaggagca atttaagaag 360gggaagaacc ccacaggcct attggcatta cagcagattg cagattttat gaccacgaat 420gtaccaaatg tctacc 436 259 341 DNA Homo sapien misc_feature (1)...(341) n = A,T,C or G 259aaaaaatcta gagagaatat aaagaaattt aaagattgaa aagtgaaata ctctcaccta 60ctcntcagtt aacaaatatt aactcatatg aagtgaatat tatgtagcac atgttattct 120gtacactgaa gatataggga tgacaaagaa attagagttc tggcctaaag gagtttacat 180attttaaaag gatacagata ttaaccattt atacataaac acataagatt tcttgttctg 240agtgctaaga acaagagtct aaggaggcat ttgactgaga gtggctaatg agagatttct 300cctttagcta gcgttgtcag gaagataaaa ccctaatgat g 341 260 313 DNA Homo sapien 260aaaccaagat ctgggtaccc gacgacgacg acaaggccat ggcgatatcg gatccgaatt 60caagcgaccc catggaccct agctcatact cagacgcccc ccggggcacg tggtcaacag 120gactccccaa gcggaatgag gccaagactg gcgctgacac cacagcagct gggcccctct 180tccagcagcg gccgtatcca tccccagggg ctgtgctccg ggccaatgca gaggcctccc 240gaaccaagca gcaggattga agcttcggcc tccctggccc tgggttaaaa taaaagcttt 300ctggtgatcc tgc 313 261 446 DNA Homo sapien 261gaattctgtc cagtctcaga gagttggaaa gtgctttgca acaaatttta gaaaaagtaa 60aaactcctgc ttcacccatt cctctggccc caaaaactag ttagcagtat gccttgtggg 120gaggagccaa gatggccgaa taggaacagc tcccgtctgc agctcccagc atgagcgatg 180cagaagatgg gtgatttctg catttccaac tgagctttga agagagtagt ggttctccca 240gcatgtagct tgagatctga gaacgggcag actgcctcct caagtgggtc cctgacccga 300gtagcctaac tgggaggcac cccccagtac gggcggactg acacctcaca cggccgggta 360ctcctctgag acaaaacttt cagaagaacg atcaggcagc agcatttgcg gttcaccaat 420atacactatt ctgcagccac cgctgc 446 262 453 DNA Homo sapien 262ccggatccga attcaagcgg cggcagcagt cgacagcgcg atggaggtgg tgccggcgct 60ggcggaggag gccgcgccgg aggtagcggg cctcagctgc ctcgtcaacc tgccgggtga 120ggtgctggag tacatcctgt gctgcggctc gctgacggcc gccgacatcg gccgtgtctc 180cagcaactgc cggcggctgc gcgagctgtg ccagagcagc gggaaggtgt ggaaggagca 240gttccgggtg aggtggcctt cccttatgaa acactacagc cccaccgact acgtcaattg 300gttggaagag tataaagttc ggcaaaaagc tgggttagaa gcgcggaaga ttgtagcctc 360gttctcaaag aggttctttt cagagcacgt tccttgtaat ggcttcagtg acattgagaa 420ccttgaagga ccagagattt tttttgagga tga 453 263 403 DNA Homo sapien 263gaattcaagc acccacgcgt gacccgggcc aagtacttca ttcgagacga gtttctgagg 60atcagcactg ccagtggaga tgggcgtcac tactgctacc ctcatttcac ctgcgctgtg 120gacactgaga acatccgccg tgtgttcaac gactgccgtg acatcattca gcgcatgcac 180cttcgtcagt acgagctgct ctaagaaggg aacccccaaa tttaattaaa gccttaagca 240caattaatta aaagtgaaac gtaattgtac aagcagttaa tcacccacca tagggcatga 300ttaacaaagc aacctttccc ttcccccgag tgattttgcg aaaccccctt ttcccttcag 360cttgcttaga tgttccaaat ttagaaagct taaggcggcc tac 403 264 446 DNA Homo sapien 264gaattcattc gtgcacaatt cattaaatga acgtctcaaa aattaaaaaa attataagat 60acgtatttct ttaggccttt gtgtttttaa attaaaacca acaaaaagaa gtctccctct 120ccactccacc cagcagcaag ggcagccgga acgcttcgct ccagctacct ggcctcccgc 180aagagggttc ccccatgaga ccgttagtct ctctttgcct ggctgactac ctgcatacag 240taggcactca ctgctggagt gaggcactga ctcctccaaa gattgcaggg ggcggaggag 300ggaaccacga aggcctggga gggggcatct ttggccccca ctaaccatct ccctatttct 360gcatcctggt gaccgtcagc aagagatgag tcggggagac cctctcctgg agttctagcc 420cctaattctg ggctttctat atgaga 446 265 245 DNA Homo sapien misc_feature (1)...(245) n = A,T,C or G 265cagggctccc tcatgggccc cccgccccag cagaacctca tggtgtccca cccccttcgg 60cagngcagtg tgtccctgga cagccagatg ggctacctcc cggcaccagg cggcatggcc 120aacctgccct tctagaagtc gctgccaggg ctggagccgg ggcaatgttg caaatacgat 180aaccttaaca aagttcttcc cctcaatgtt gggatggcct gggtcgtggg gtggggtgga 240ggggg 245 266 1238 DNA Homo sapien 266caaaaaccca tctgtacatc accatcatca aagaccaaaa gtagataaaa ccacaaagat 60ggggaaaaaa cagaacagaa aaactggaaa ctctaaaacg cagagcgcct ctcctcctcc 120aaaggaacgc agttcctcac cagcaacaga acaaagctgg atggagaatg attttgacga 180gctgagagaa gaaggcttca gacgatcaaa ttactctgag ctacgggagg acattcaaac 240caaaggcaaa gaagttgaaa actttgaaaa aaatttagaa gaatgtataa ctagaataac 300caatacagag aagtgcttaa aggagctgat ggagctgaaa accaaggctc gagaactacg 360tgaagaatgc ataagcctca ggagccgatg cgatcaactg gaagaaaggg tatcagcaat 420ggaagatgaa atgaatgaaa tgaagcgaga agggaagttt agagaaaaaa gaataaaaag 480aaatgagcaa agcctccaag aaatatggga ctatgtgaaa agaccaaatc tacgtctgat 540tggtgtacct gaaagtgatg tggagaatgg aaccaagttg gaaaacactc tgcaggatat 600tatccaggag aacttcccca atctagcaag gcaggccaac gttcagattc aggaaataca 660gagaacgcca caaagatact cctcgagaag agcaactcca agacacataa ttgtcagatt 720caccaaagtt gaaatgaagg aaaaaatgtt aagggcaacc agagagaaag gtcgggttac 780cctcaaagga aagcccatca gactaacagc ggatctctcg gcagaaaccc tacaagccag 840aagagagtgg gggccaatat tcaacattct taaagaaaag aattttcaac ccagaatttc 900atatccagcc aaactaagct tcataagtga aggagaaata aaatacttta tagacaagca 960aatgctgaga gattttgtca ccaccaggcc tgccctaaaa gagctcctga aggaagcgct 1020aaacatggaa aggaacaacc ggtaccagcc gctgcaaaat catgccaaaa tgtaaagacc 1080atcgagacta ggaagaaact gcatcaacta atgagcaaaa tcaccagcta acatcataat 1140gacaggatca aattcacaca taacaatatt aactttaaat ataaatggac taaattctgc 1200aattaaaaga cacagactgg caagttggat aaagagtc 1238 267 1664 DNA Homo sapien 267attgatgaac tcccagaggg ccggccagtg cgggtagccc ggattgatga actcccagag 60ggcgctgtga agcctccagc aaacaagtat cctatcttct tttttggcac ccatgaaact 120gcatttctag gtcccaaaga cctttttcca tataaggagt acaaagacaa gtttggaaag 180tcaaacaaac ggaaaggatt taacgaagga ttgtgggaaa tagaaaataa cccaggagta 240aagtttactg gctaccaggc aattcagcaa cagagctctt cagaaactga gggagaaggt 300ggaaatactg cagatgcaag cagtgaggaa gaaggtgata gagtagaaga agatggaaaa 360ggcaaaagaa agaatgaaaa agcaggctca aaacggaaaa agtcatatac ttcaaagaaa 420tcctctaaac agtcccggaa atctccagga gatgaagatg acaaagactg caaagaagag 480gaaaacaaaa gcagctctga gggtggagat gcgggcaacg acacaagaaa cacaacttca 540gacttgcaga aaaccagtga agggacctaa ctaccataat gaatgctgca tattaagaga 600aaccacaaga aggttatatg tttggttgtc taatattctt ggatttgata tgaaccaaca 660catagtcctt gttgtcattg acagaacccc agtttgtatg tacattattc atattcctct 720ctgttgtgtt tcggggggaa aagacatttt agcctttttt aaaagttact gatttaattt 780catgttattt ggttgcatga agttgccctt aaccactaag gattatcaag atttttgcgc 840agacttatac atgtctagga tccttttatc aaggcagtta tgatcatcgt tttcctgcct 900tgaccccacc atcatcaaac actcagttaa atataaatta acatttttta gatgaccact 960caacataatg cttaagaatg gaatttcctc tctgtgacag aacccaggaa ttaattccta 1020aatacataac gttggtatat tgaagacgaa attaaaattg tccttcagtt ttgaggccat 1080gtgtaaagtt tacccatatt gtaaaatatc tattccggta ttagaaatag ctagttgaca 1140gcttatactt ctcaaaattc atattgttat gtacacaaac taagtttcta tatgtgaagt 1200tagtgagtct ttttgtgtta ctccaaaata aaggcaatga tttatttttt tcccagtgcc 1260aatacaattt tgagctaagc actcaaggtg gatactttac attttaaagc tggaatcagc 1320aacagcccta tgggaaacca gacaaagcat tgacttttaa atgtagactt ttaaaataaa 1380ctgttttctt ttggaactac aattagaata gttaatattc atccttaaac cattattatg 1440tgtacattat tgttgctatt gtgataatag agaattttat ttatttttat gccagcttat 1500attgtgagaa cacatttagt cagtttgggt tttatcaatc ctgttaatgc ttgtccttgg 1560aacatctttc gcgtattcac ggtttgtagt tgaaaagttt actgtaaaaa aatcaaaaac 1620aaaaaaatgt attgttttta cagaataaat ttattggaat gtgt 1664 268 436 DNA Homo sapien 268cggtcacccc gtcatccacc acctcttcca cccgtgccac cccagcccct tctgctccag 60cagctgcctc agcaactagc ccgagccccg cgcccagttc cgggaatgga gccatcacca 120gcgagtccag tcccggcaag cgggaaaagg acaaagagaa agacaaagag aagcggttca 180gcctttttgg caaaaagaaa tgaactcctt tccttcacct cctgcccttc tcttaccttt 240tcagtgaaat tccagcatgc aagctcagaa ccaacacatt actctctgtg cctaatgttc 300ctcaatgtgg ttgatttttt ttttttttaa tttatagagc atttcggggg gggtggggga 360aacacaccta aacactttat ctccaagtta caaaagtttg aggtgcagag ggaaggccag 420attttttttt taatga 436 269 439 DNA Homo sapien misc_feature (1)...(439) n = A,T,C or G 269ggctgtgaat ctatctggtc ctggactctt tttggttggt aagctattga ttattgccac 60aatttcagat cctgttattg gtctattcag agattcaact tcttccttgt ttagtctttg 120gagggtgtat gtgtcaagga atttatccat ttcttctaga ttttctagtt tatttgcgta 180gaggtgtttg tagtattctc tgatggtagt ttgtatttct gtgggatcgg tggtgatatc 240ccctttatca ttttttattg cgtctatttg attcttctct ctttttttct ttattagtct 300tgctagcggt ctatcaattn tgttgatcct ttcaaaaaac cagctcctgg attcattaat 360ttttttgaag ggttttttgt gnctctattt ccttcagttc tgctctgatt ttagttattt 420cttgccttct gctagcttt 439 270 418 DNA Homo sapien 270ggaggacctc cgctgcaaat acatctccct catctacacc aactatgagg cgggcaagga 60tgactatgtg aaggcactgc ccgggcaact gaagcctttt gagaccctgc tgtcccagaa 120ccagggaggc aagaccttca ttgtgggaga ccagatctcc ttcgctgact acaacctgct 180ggacttgctg ctgatccatg aggtcctagc ccctggctgc ctggatgcgt tccccctgct 240ctcagcatat gtggggcgcc tcagtgcccg gcccaagctc aaggccttcc tggcctcccc 300tgagtacgtg aacctcccca tcaatggcaa cgggaaacag tgagggttgg ggggactctg 360agcgggaggc agagtttgcc ttcctttctc caggaccaat aaaatttcta agagagct 418 271 438 DNA Homo sapien 271cctagatggg ctaggatgga gataacccac cctggtcccc catcccccat acccccaact 60ccctgtcctc tgtccccatt cccctccctt ccccatcctt aaacttagct tagcagcctg 120ggtacccccc tcacagtggg gcccagccag ggcagaggag gagcatggtg tctatgtgta 180tgacctgatg gctactgtgg tacacatcct ggactcacgc acagggggca gcctggtggc 240tcacatcaaa gttggagaga cctaccacca gcgcaaggag ggcgttactc accagcagtg 300gtatctgttc aatgactttc ttattgaacc tattgataag catgaagctg tgcagtttga 360catgaattgg aaagtacctg caatccttta ttatgtcaaa cggaatctca attccagata 420caacctgaac atcaagaa 438 272 443 DNA Homo sapien misc_feature (1)...(443) n = A,T,C or G 272taaagataat gattgataag ctagaacttt ctgatgtagt cattacatga aaccccttgt 60cactggtttg tgtgttcaga ggaagccatg gccgagatag ctttcctgaa ataaaccagt 120agcttttcag attgacgttc ttgctacaat tgtaccatct ggtaattcct gaaaatgtca 180atttttttgt gttaatattt ttggtttcaa acaaataaca aatgtctcta gaaagaaaat 240tttaagaaag cttaattaat agtaaaaatg cctttcctga aataattctt ggaaaatttt 300ttaaatgtca aaatgatgag tcatgctaaa tacatttgag gggttggttt tttggttggt 360tggttggttg gtttttgaga cagagtttcc ntcttggttg cccaggctng gagtggcaat 420ggggcccgaa ccttnaanng tta 443 273 439 DNA Homo sapien 273gaattggtag caaaaagggt ggaggaagaa ctggagaaaa ggaaggatga aattgaacga 60gaagttctcc gaagggtgga ggaagccaaa cgcatcatgg aaaagcagtt gctcgaagaa 120ctcgagcgac agagacaagc tgagcttgcc gcacaaaaag ctagagagga ggaagaacgt 180gcaaaacgtg aggagctaga gcgaatactg gaagagaata accgaaaaat tgcagaagca 240caagccaaac tggccgaaga acagttgaga attgttgaag aacaaagaaa gattcatgag 300gaaaggatga aactagaaca agaacgacaa cgtcaacaaa aagaagaaca aaaaattatc 360ctgggcaagg ggaagtccag gccaaaactg tccttctcat taaaaaccca ggattaaatt 420gcaaactctg aacttttta 439 274 445 DNA Homo sapien misc_feature (1)...(445) n = A,T,C or G 274aaaggagacg agtcagccaa ccacagctac atttcaggct ttctcccctg acacttttac 60agttatcttg gacttcgtat attctggcaa actgtctctt actggtcaga atgtcataga 120agtgatgtcg gctgctagct tccttcagat gactgatgtc ataagtgtat gtaagacttt 180tattaaatct tccttagaca ttagtgagaa agaaaaagat cgcntatttc agtctctcag 240ataaagatgc caattctaat ggtgtagaac cgttcctctt tttatagtgg tggctggcaa 300gaaggaagca gttctccacg ttctcaccta agcccagagc aaggaacagg tataataagt 360ggaaaatctt ggaataagta taattatcat ccancctccc anaanaatac tcaacaaccc 420ttggccaagc atgaaccaag gaaag 445 275 441 DNA Homo sapien 275ggctcccaag aacatggcga cttccacacc tgtggctcgt ggtggtggtt tgccagctac 60gttcaacaaa aacactccta agacctttac tcctgaatgt gaaaatcaga aggacccttt 120ggtcaacact gttgttgttt atgattgtga tgtttgttcg tttgcaagcc ccaacatgca 180ttctgtcttg gttcattatc agaagaaaca ccccgaagaa aaggcttcct actttaggat 240ccagaaaact atgcgaatgg tgtctgtgga caggggctct gccctttctc aattatcatt 300tgaggtgggt gctccaatgt ctcccaaaat gtccaacatg ggttccccac ccccccccca 360caacccccgc caccagacct cagtactgag ctttactact gcaaacactg ttcctacagc 420aatcggtcag ttgtgggagt g 441 276 436 DNA Homo sapien 276gaaacgccca gtattctcag agtgccatat gaaccatcca ggaaagctgg caaattctct 60aacagttaat aaagccaatt gtattgtatt gataattgga caaagagaga gaaagaaaga 120aggaaggaag gaaaaacttg ttactgaaag agactacact atcaggtttc attacatatt 180ctccttcatt gagaatctgg cccattttca atttaagctt gcggccgcac tcgagcccgg 240gtgaatgatt gagtttaaac cgctgagcaa taactagcat aaccccttgg ggcctctaaa 300cgggtcttga ggggtttttt gctgaaagga ggaactatat ccggataacc tggcgtaata 360gcgaagaggc ccgcaccgat cgcccttccc aacagttgcg cagcctgaat ggcgaatgga 420cgcgccctgt agcggc 436 277 440 DNA Homo sapien misc_feature (1)...(440) n = A,T,C or G 277caaatcttcg tgaagacact cactggcaag accatcaccc ttgaggtcga gcccagtgac 60actatcgaga acgtcaaagc aaagatccaa gacaaggaag gcattcctcc tgaccagcag 120aggttgatct ttgccggaaa gcagctggaa gatgggcgca ccctgtctga ctacaacatc 180cagaaagagt ctaccctgca cctggtgctc ccgtctcaga ggtgggatgc agatcttcgt 240gaagactctg actggtaaga ccatcaccct cgaggtngag cccagtgaca ccatcgagaa 300tgtcaaggca aagatccaag ataaggaagg catccctcct gaccagcaga ggctgatctt 360tgctggaaaa cagctggaag atgggcgcac cctgtctgac tacaacatcc anaaagagtc 420caccctgcac ctgntnctcc 440 278 306 DNA Homo sapien misc_feature (1)...(306) n = A,T,C or G 278gagcgngcgg ccgcnctaaa gattcnctcg cacacacaat aagnctttct ctccgaaacc 60ggaagtaaat ntatatctgt tagaaataat gtagccaaaa gaatgtaaat ttgaggattt 120ttttgccaat agtttataga aaatatatga accaaagtga tttgagtttg taaaaatgta 180aaatagtatg aacaaaattt gcactctacc agatttgaac atctagtgag gttcacattc 240atactaagtt ttcaacattg tgttcttttt gcattcattt tttactttta ttaaaggttc 300aaaacc 306 279 450 DNA Homo sapien misc_feature (1)...(450) n = A,T,C or G 279gagcgggcgg ccgngctccg ggccggggtc ccgggggagc agatcctcan aatggccctt 60ggtgctgcag gcgcggtggg ctccgggccc aggcaccgag ggggcactgg atgactctcc 120aggtgcagga ccctgccatc tatgactcca ggtcttcagc acccacccac cgtggtacag 180cgccccggga tgccgtctgg agcccggatg ccccaccagg gggcgcccat gggccccccg 240ggctccccgt acatgggcag ccccgccgtg cgacccggcc tggcccccgc gggcatggag 300cccgcccgca agcgagcagc gcccccgccc gggcagagcc aggcacagag ccagggccag 360ccggtgccca ccgcccccgc gcggagccgc agtgccaaga ggaggaagat ggctgacaaa 420atcctccctc aaaggattcg ggagctggtc 450 280 435 DNA Homo sapien 280gcagctccga gtggcggcgc gcgggccagg gccggggccg gggccggggc cggagccgga 60gccggggccg ggcggcgcgc ctgtggagcg ctgggggcgg cctggggctg agcatggagc 120agcgcggcgg aggtcgcctg cgaggccgct ggccaggcct gagcctctgc caccatggcc 180attgtgcaga ctctgccagt gccactggag cctgctcctg aagctgccac tgccccacaa 240gctccagtca tgggtagtgt gagcagcctt atctcaggcc ggccctgtcc cggggggcca 300gctcctcccc gccaccacgg ccctcctggg cccaccttct tccgccagca ggatggcctg 360ctacggggtg gctatgaggc acaggagccg ctgtgcccag ctgtgccccc taggaaggct 420gtccctgtca ccagc 435 281 443 DNA Homo sapien 281ttttagaaag ggattagaat tttactctgc tagttacaag ttttaaagtc acgctacggc 60attatcaccc tggcaggtag gttttgttat tgttttacat tttgtgaaaa aaagttttgt 120agaagttaca gctagtggtc ttttccctcc agagccagtg atgagtgtgg gagcacttca 180gctctgtaag gggccagcgt tctgaccttt aaccacatga actaacctgc gtcagcagtt 240gcagaaagta gcctgttagg acagcagctg ctaagcgttg cctggtattt tagtggggag 300aaggctggga ctcttcatgg catcaacact tgcatgctct gaatctttga tcagagatga 360ggtgccattt ttggcatttc caccccgtct cgtggtagcc tttaaaagtg gtagaagatg 420ctgccctaat tccccgagga tga 443 282 435 DNA Homo sapien misc_feature (1)...(435) n = A,T,C or G 282gacactcaag ccgaacatca gacnttaaga tgcagcaggt ctcgggacca caaaaggtca 60cgaagtagag aaagaaggcg gagcagaagt agagatcgac gaagaagcag aagccatgat 120cgatcagaaa gaaaacacag atctcgaagt cgggatcgta gaagaattaa aagaaaagtt 180aaggaaaaga accgaagaac ctgatcgtga tgagcgtcta aaaaaggaga agcaagaaag 240agaagaaaga gaaaaagaac gggagagaga aagggaagaa agagaaagga aaagacgaag 300ggaagaggaa gaaagagaaa aagaaagggc tcgtgacaga gaaagaagaa agagaagtcg 360ttcacgaagt agacactcaa gccgaacatc agacagaaga tgcagcaggt ctcgggacca 420caaaaggtca cgaag 435 283 437 DNA Homo sapien 283agaaaaaaat ttaaactgct ttttcggaag aacaacaaca aaaaagaggt aaagacgaat 60ctataaagta ccgagacttc ctgggcaaag aatggacaat cagtttcctt cctgtgtcga 120tgtcgatgtt gtctgtgcag gagatgcagt ttttgtgtag agaatgtaaa ttttctgtaa 180ccttttgaaa tctagttact aataagcact actgtaattt agcacagttt aactccaccc 240tcatttaaac ttcctttgat tctttccgac catgaaatag tgcatagttt gcctggagaa 300tccactcacg ttcataaaga gaatgttgat ggcgccgtgt agaagccgct ctgtatccat 360ccacgcgtgc agagctgcca gcagggagct cacagaaggg gagggagcac caggccagct 420gagctgcacc cacagtc 437 284 174 DNA Homo sapien 284caattcccta ctgaagactg gagcgctcag cctgccacgg aagactggtc tgcagctccc 60actgctcagg ccactgaatg ggtaggagca accactgact ggtcttaagc tgttcttgca 120taggctctta agcagcatgg aaaaatggtt gatggaaaat aaacatcagt ttct 174 285 440 DNA Homo sapien 285gagaagaaag agaaaaagaa cgggagagag aaagggaaga aagagaaagg aaaagacgaa 60gggaagagga agaaagagaa aaagaaaggg ctcgtgacag agaaagaaga aagagaagtc 120gttcacgaag tagacactca agccgaacat cagacagaag atgcagcagg tctcgggacc 180acaaaaggtc acgaagtaga gaaagaaggc ggagcagaag tagagatcga cgaagaagca 240gaagccatga tcgatcagaa agaaaacaca gatctcgaag tcgggatcga agaagatcaa 300aaagccggga tcgaaagtca tataagcaca ggagcaaaag tcgggacaga gaacaagata 360gaaaatccaa ggagaaagaa aagaggggat ctgatgataa aaaaagtagt gtgaagtccg 420gtagtcgaga aaagcagagt 440 286 242 DNA Homo sapien 286aagcggtaaa aaggggtcac tatggagttc aaaggacaga actcctgcct ggtgaccggg 60acaacctggc cattcagacc cggggtggcc cagaaaagca tgaagtaact ggctgggtgc 120tggtatctcc tctaagtaag gaagatgctg gagaatatga gtgccatgca tccaattccc 180aaggacaggc ttcagcatca gcaaaaatta cagtggttga tgccttacat gaaataccag 240tg 242 287 429 DNA Homo sapien 287tttcagggtt gcattatgca accagtaaat gacctcttga aaggacagag tcgtctgatt 60tttacttacg ggctaaccaa ttcaggaaaa acatatccat ttcaagggac agaagaaaat 120attggcattc tgcctcgaac tttgaatgta ttatttgata gtcttcaaga aagactgtat 180acaaagatga accttaaacc acatagatcc agagaatact taaggttatc atcagaacaa 240gagaaagaag aaattgctag caaaagtgca ttgcttcggc aaattaaaga ggttactgtg 300cataatgata gtgatgatac tctttatgga agtttaacta actctttgaa tatctcagag 360tttgaagaat ccataaaaga ttatgaacaa gccaacttga atatggctaa tagtataaaa 420ttttctgtg 429 288 436 DNA Homo sapien misc_feature (1)...(436) n = A,T,C or G 288tcaagcctca gagcttcaaa gagcaggact antcctaaga actgtctgtg atatttgacc 60agaggtgcag cctagctgcc attcttcctc accctgtgga agacattaaa gggagaatga 120aagtagctgt agaattacct ttgggggaag aagccacttg gtgaacttgg caaacacccg 180tgtttgaggg gtcacccagg gtgtcatgag ctgggccgga ggggatggat tgattacttg 240tcttgtttgc ttgtttctgt tgtaagtcag ggcccctcag cagaaggcag aacagaaccg 300agttccttta gaatgctggt ttttgtgtgg agtgaggaag gaccgtgagt gtggtcagtt 360tccaacctga caggacctgc tcccgttggc caggactgca gcttgttact ttgaccctgg 420gaagaaggta agtgtt 436 289 425 DNA Homo sapien 289tataagagct tgaccaatga ctgggaagat cacttggcag tgaagcattt ttcagttgaa 60ggacagttgg aattcagagc ccttctattt gtcccacgac gtgctccttt tgatctgttt 120gaaaacagaa agaaaaagaa caatatcaaa ttgtatgtac gcagagtttt catcatggat 180aactgtgagg agctaatccc tgaatatctg aacttcatta gaggggtggt agactcggag 240gatctccctc taaacatatc ccgtgagatg ttgcaacaaa gcaaaatttt gaaagttatc 300aggaagaatt tggtcaaaaa atgcttagaa ctctttactg aactggcgga agataaagag 360aactacaaga aattctatga gcagttctct aaaaacataa agcttggaat acacgaagac 420tctca 425 290 426 DNA Homo sapien misc_feature (1)...(426) n = A,T,C or G 290gctcccggag gcgaggctcg cgcgntcgcc cccgccctgg ccccagcgcc cacccggttn 60gccccggccc agccatgatc aaggccatcc tcancttcaa caaccacggg aagccgcggc 120tctccaagtt ctaccagccc tatagtgaag acacgcaaca gcaaatcatc agggagactt 180tccatttggt gtctaagcgc gatgagaacg tttgtaattt cctagaagga ggattattaa 240ttggaggctc tgacaacaag ctcatttaca gacattatgc aacactatat tttgtcttct 300gtgtggactc ctcagaaagt gaacttggca ttttagatct aattcaagta tttgtggaaa 360cattagacaa atgttttgaa aatgtttgtg aactggattt aatattccat gtagacaagg 420ttcata 426 291 426 DNA Homo sapien misc_feature (1)...(426) n = A,T,C or G 291gagaagcaag aaagagaaga aagattttaa gaacgggaga gagaaaggga agaaagantt 60tggaaaagac gaagggaaga ggaagaaaga gaaancnnaa agggctcgtg acagagaaag 120aagaaagaga agtcgttcac gaagtagaca ctcaagccga acatcagaca gaagatgcag 180caggtctcgg gaccacaaaa ggtcacgaag tagagaaaga aggcggagca gaagtagaga 240tcgacgaaga agcagaagcc atgatcgatc agaaagaaaa cacagatctc gaagtcggga 300tcgaagaaga tcaaaaagcc gggatcgaaa gtcatataag cacaggagca aaagtcggga 360cagagaacaa gatagaaaat ccaaggagaa agaaaagagg ggatctgatg ataaaaaaag 420tagtgt 426 292 426 DNA Homo sapien misc_feature (1)...(426) n = A,T,C or G 292ctgggacgtg gaagtggcga ggtgcntgct gccccaggaa gccccctcag cactaggcna 60tgggctgcaa ggggtaaggc gctcttcacc tganaacgtt ccctcaagct gcacagcctt 120tcagagcagc aggaccctgc ggtgacatcg aaatgaaaca gaaatagaac ttctgcggtg 180ggtgagtgat gtgctgggcc tgaaggtgga ctggccaggg accccacagt ggactcgtga 240ggagggctcg acagacactg gcccagaggg ggctcttgcc tggtggtggg ctgcatgcag 300cgggaggtca cctaggagca gggtggcccc agccaggctg atgccgtaga aaggactgca 360ggctctaact ttgagcattt tctcgtgctt gggcatgggt gctgattttg cctgtcaatg 420ctgatg 426 293 436 DNA Homo sapien 293ggaagaaata gttgaaggtt gtaccggagc ccttcacatc ctagctcggg atgttcacaa 60ccgaattgtt atcagaggac taaataccat tccattgttt gtgcagctgc tttattctcc 120cattgaaaac atccaaagag tagctgcagg ggtcctctgt gaacttgctc aggacaagga 180agctgcagaa gctattgaag ctgagggagc cacagctcct ctgacagagt tacttcactc 240taggaatgaa ggtgtggcga catatgcagc tgctgttttg ttccgaatgt ctgaggacaa 300gccacaagat tacaagaaac ggctttcagt tgagctgacc agctctctct tcagaacaga 360gccaatggct tggaatgaga ctgctgatct tggacttgat attggtgccc agggagaacc 420ccttggatat cgccag 436 294 439 DNA Homo sapien misc_feature (1)...(439) n = A,T,C or G 294ccggctcaca agcgcctcct tctggacacc ctgcagctca gcaagtgata gcggaggcac 60cacgaagctg tgaactcaga gcccctccct gctaccaagg cccagctatg gccccagggt 120tgaaaagtta tgagggtcag ggcagtatct ctctgcctat ttattggggt gcctatttat 180tggggatctg cattccccgc tgcccaatca ntttgcaatg ccctaattag ggcatcctgc 240ccctcgcctt ttaggctcag gacggaaggt cagttgccat ggttaccgag gaccctggtt 300actctggtgc tgtcctcttt tactggaccc cgcctcccag ccccaggggt gcctgtgggg 360gtccatntgg gtacgtctgg gcccccactt tcaccagttt ctgcggcctt ccaccgggcc 420tgaaccacan cggaggagc 439 295 434 DNA Homo sapien 295cactacaccg acccccaccc agttcttgtg ccccaagaac gtgaccgacg agcaggaggg 60cttcgccgag ggcttcgtgc gcgccctggc tgaactgcat agccagaaca cgcttcccag 120tgtcacctcc gcggcacagc cggtcagcgg ggcgggcatg gtggctcccg cggtggcctc 180agtagcaggc gctggcggcg gtggtggcta cagcgccagc ctgcacagtg agcctccggt 240ctacgccaac ctcagcaact tcaacccggg tgcgctgagc agcggcggtg gggcgccctc 300ctatggcgcg gccgggctgg cctttccctc gcagccgcag cagcagcagc agccgcctca 360gccgccgcac cacttgcccc aacagatccc ggtgcagcac ccgcggctgc aagccctgaa 420ggaagagccg caga 434 296 433 DNA Homo sapien 296caaatacgaa atcttaacaa agaaaaacca aactataaaa aaggaccaac tgaaaattct 60agaaaaagtg caatatctac tatttttaaa aaattggaga gtttaacaac agagtaaaga 120tggcataaga aaaaaatcag tataagtaaa agtagatcaa gactagttat gcaattaaaa 180aacagaggaa taaaaagact ttccagaatt gcctgtacaa cagtaatctc ctttctgtcc 240tggtgtagat tttttaacca gcttgttggc cctggtcatt ttggccacat ttgtgaccat 300cataaaagct aagtggtatt tctgtgtagt ttccgtctgg aactgctttc ccattcccgg 360gaacccatag ccgggccagc cagggtcccg aacacaggcc caaagtttat taaaccccga 420tcataacctc cag 433 297 440 DNA Homo sapien misc_feature (1)...(440) n = A,T,C or G 297ctgcggcggc gcggggactg tgaggctgcc gagcggacag cgactcccgg ggaagcccgc 60gctccgggag cgggagcggg agcaggagca ggagcagcgc cgtcccaggc cagaggcgag 120cgccgggcgc cgggagagcg gagagcccgg gcagctgccg gagcgcgggg gcgcggcccg 180aggaaaccac agagcgagcc caggcctggg ggagggcgcc gaacatctga ggcggcttcg 240cgggagacaa agccgcgcgt agagacgcga tgccccgccg atcgcgagcc cggccggcga 300gggcgcgggg actgcggcgt ctgagcgcgc caagccgtgc gcccgcgggg acgccgagcc 360ccggggccgg tgcgggcggc ggcgggcggg gcccangtgc gcccggccgc gtcgggcccg 420tgactgctcg gggggcggnc 440 298 435 DNA Homo sapien misc_feature (1)...(435) n = A,T,C or G 298gctggccaat aaggtgccag ctgctgcccg tgctggtgcc attgccccat gtgaagtcac 60tgtgccagcc cagaacactg gtctcgggcc cgagaagacc tcctttttcc aggctttagg 120tatcaccact aaaatctcca ggggcaccat tgaaatcctg agtgatgtgc agctgatcaa 180gactggagac aaagtgggag ccagcgaagc cacgctgctg aacatgctca acatctcccc 240cttctccttt gggctggtca tccagcaggt gttcgacaat ggcagcatct acaaccctga 300agtgcttgat atcacagagg aaactctgca ttctcgcttc ctggagggtg tccgcaatgt 360tgccagtgtc tgtctgcaga ttggctaccc aactgntgca tcagtacccc attctatcat 420caacgggtac aaacg 435 299 441 DNA Homo sapien 299aatgaatatg ccaaatcgta cttatttcag agtaagtttt tcattttttt aggttgtagg 60gagttttttt cctactgagt gttattagat tattttaatg ttactattgt tattaggcaa 120ttaaaatgtt tttaagcaag ctttaaggca ttaacctccc ccttcagata agtatacata 180aattggttct aaaagttaat aagaagtttt ctgaaaccag ggaacttttt ttttcctgaa 240acatttttag tagtttccca aggcatattt tttggaactg agttctttta ggcatctctg 300atgttggtga gatgctttat taactgaatg gatgtaggct tccttttacg ttgaagttga 360ttacatggag taagtttttg ttttctattt gaaattaaat ggaatctgtt ggagggttat 420caaaattgtt tgcatcacaa a 441 300 434 DNA Homo sapien 300aaaagaagaa agaacctgca attacatcgc agaacagccc tgaggcaaga gaagaaagta 60cttccagcgg caatgtaagc aacagaaagg atgagacaaa tgctcgagat acttatgttt 120catcctttcc tcgggcacca agcacttctg attctgtgcg gttgaagtgt agggagatgc 180ttgctgcagc tcttcgaaca ggggatgact acattgcaat tggagctgat gaggaagaat 240taggatctca aattgaagaa gctatatatc aagaaataag gaatacagac atgaaataca 300aaaatagagt acgaagtagg atatcaaatc ttaaagatgc aaaaaatcca aatttaagga 360aaaatgtcct ctgtgggaat attcctcctg acttatttgc tagaatgaca gcagaggaaa 420tggctagtga tgag 434 301 434 DNA Homo sapien 301agaaaggaaa agacgaaggg aagaggaaga aagagaaaaa gaaagggctc gtgacagaga 60aagaagaaag agaagtcgtt cacgaagtag acactcaagc cgaacatcag acagaagatg 120cagcaggtct cgggaccaca aaaggtcacg aagtagagaa agaaggcgga gcagaagtag 180agatcgacga agaagcagaa gccatgatcg atcagaaaga aaacacagat ctcgaagtcg 240ggatcgaaga agatcaaaaa gccgggatcg aaagtcatat aagcacagga gcaaaagtcg 300ggacagagaa caagatagaa aatccaagga gaaagaaaag aggggatctg atgataaaaa 360aagtagtgtg aagtccggta gtcgagaaaa gcagagtgaa gacacaaaca ctgaatcgaa 420ggaaagtgat acta 434 302 437 DNA Homo sapien 302caaattctcc ttatttaaaa gtaagaagca tttgcctttc ggtgaagagg cttcggcctc 60tgcctctcct tccagagagc ccaggcaaat tctccttatt taaaagtaag aagccacggc 120accgctcaaa ttcattcagt gatgaaagag agttctctgg accttccacc ccgacgggga 180cgctggagtt tgaaggtggg gaagtgtctc tggaaggtgg gaaagttaaa gggaaacacg 240ggaagctgaa attcggtacc tttggtggat tggggtcaaa gagcaaaggt cattatgagg 300tgactgggag cgatgatgag acaggcaagt tacaggggag tggggtgtcc ctggcctcta 360agaagtcccg actgtcctcc tcttctagca atgacagtgg gaataaggtt ggcatccagc 420ttcccgaggt ggagctg 437 303 436 DNA Homo sapien 303agactttcca tgagacgctc aactgttgtg gctccaacgc actgaccaca ctgactacca 60ccatactgag gaacagcctg tgtccctcag gcggcaacat actcaccccc ttactgcagc 120aagattgtca tcagaaaatc gatgagctct tctctgggaa gctgtacctc attggaattg 180cagccattgt ggtagctgtc attatgatct ttgagatgat tctgagcatg gtgctgtgct 240gtggcatccg gaacagctcc gtgtactgag gccctttgca ttgcaccaga ggatccctgg 300agtgaccaga ggccaccttg ggggacatgg cctgtgtata taatatttct gtatcactct 360gctacactta gtctttttac ttttgagttt tttgttttgt tttgttttgt ttttgtttta 420gttttttttt tgtcct 436 304 440 DNA Homo sapien 304ctcagaggag gttcgattaa aactggaaga gaccagagag gtacagaact tgaggaagag 60gcccaacggg gtgagtgctg tggccttgct ggtgggagag aaggtacaag aggagaccac 120tctagtggat gatccctttc agatgaagac aggtggtatg gtggatatga agaaactgaa 180ggaaaggggc aaagataaga tcagtgagga ggaggacctg cacctgggga catcgttttc 240tgcagaaacc aaccgaaggg atgaggatgc agacatgatg aagtacattg agacagagct 300aaagaagagg aaagggatcg tggaacatga ggaacagaaa gttaagccaa agaatgcaga 360ggactgtctt tatgaacttc cagaaaacat ccgtgtttcc tcagcaaaga agaccgagga 420gatgctttcc aaccagatgc 440 305 440 DNA Homo sapien 305aggagacgag tcagccaacc acagctacat ttcaggcttt ctcccctgac acttttacag 60ttatcttgga cttcgtatat tctggcaaac tgtctcttac tggtcagaat gtcatagaag 120tgatgtcggc tgctagcttc cttcagatga ctgatgtcat aagtgtatgt aagactttta 180ttaaatcttc cttagacatt agtgagaaag aaaaagatcg ctatttcagt ctctcagata 240aagatgccaa ttctaatggt gtagaacgtt cctcttttta tagtggtggc tggcaagaag 300gaagcagttc tccacgttct cacctaagcc cagagcaagg aacaggtata ataagtggaa 360aatcttggaa taagtataat tatcatccag cctcccagaa gaatactcaa caacccttgg 420ccaagcatga accaaggaaa 440 306 437 DNA Homo sapien 306ctcagaggag gttcgattaa aactggaaga gaccagagag gtacagaact tgaggaagag 60gcccaacggg gtgagtgctg tggccttgct ggtgggagag aaggtacaag aggagaccac 120tctagtggat gatccctttc agatgaagac aggtggtatg gtggatatga agaaactgaa 180ggaaaggggc aaagataaga tcagtgagga ggaggacctg cacctgggga catcgttttc 240tgcagaaacc aaccgaaggg atgaggatgc agacatgatg aagtacattg agacagagct 300aaagaagagg aaagggatcg tggaacatga ggaacagaaa gttaagccaa agaatgcaga 360ggactgtctt tatgaacttc cagaaaacat ccgtgtttcc tcagcaaaga agaccgagga 420gatgctttcc aaccaga 437 307 426 DNA Homo sapien 307cagactgaga aaacccatag ttaaagctct tggggtttct gagagctcag ctggaagtga 60ctgggtgaca aggcgcacag gctcagccgt ggaagctcca tcatgattcc acaagtagtg 120accagtgaga ctgtcacagt gatttcacca aatggaatca gctttcccca aacagacaaa 180ccccagcctt cccaccagag ccaagacaga ctgaagaaac atctaaaggc tgagatcaaa 240gtgatggcgg caatccagat catgtgtgct gtgatggtgt tgagtctggg aatcattttg 300gcatctgttc cctccaatct acactttacc tcagtgtttt ccatcctgtt agaatctggc 360tacccatttg taggagcttt gttttttgcc atctctggaa ttctgtctat tgtcacagag 420aaaaag 426 308 439 DNA Homo sapien 308gctgctcgag gagctgctgc ccaaagggag caaggaggaa cagcgggatt acgtcttcta 60cctggccgtg gggaactacc ggctcaagga atacgagaag gccttaaagt acgtccgcgg 120gttgctgcag atagagcccc agaacaacca ggccaaggaa ctggagcggc tcattgacaa 180ggccatgaag aaagatggac tcgtgggcat ggccatcgtg ggaggcatgg ccctgggtgt 240ggcgggactg gccggactca tcggacttgc tgtgtccaag tccaaatcct gaaggagacg 300cgggagccca cggagaacgc tccaggaggg cctgtccatc ctcgctgtcc tttccctgtt 360ctccccctgc cccccgtctc tatcctctgt ggccttcagc taatttctgc tcccctgaga 420ttcgtccttc agccccatc 439 309 347 DNA Homo sapien misc_feature (1)...(347) n = A,T,C or G 309tcgtgactgg ccagttttgt gcacccagcg aaacttcatc catgctctgg caggacagga 60aagcacccgg ccccttggga atatacaaat atttgccata ttctctttgc ttgttacaaa 120aaacagttaa gaaagcttac agcagattat ttacaaacag tatcctggga tatgatgaag 180gcagaggtgg gctggcttgg aggataggat ctgtgggggc agaggagcca cagcagccca 240gagggtccca ggctgggcct tctccccagg cttcaggctc tgcaaggcac tggactctgc 300tactgagaag gaggcttaat tcttcttgtg gagaaacttc nttttgt 347 310 438 DNA Homo sapien 310ctccgtctgg gccgccgtcc ccgggaaaac gttcgtcaac atcacgccag ctgaggtggg 60tgtcctggtt ggcaaagacc ggtcaagttt ttacgtgaat gggctgacac ttgggggcca 120gaaatgttcg gtgatccggg actcactgct gcaggatggg gaatttagca tggatcttcg 180taccaagagc accggtgggg cccccacctt caatgtcact gtcaccaaga ctgacaagac 240gctagtcctg ctgatgggca aagaaggtgt ccacggtggt ttgatcaaca agaaatgtta 300tgaaatggcc tcccaccttc ggcgttccca gtactgacct cgtctgtccc ttccccttca 360ccgctcccca cagctttgca cccctttcct ccccatacac acacaaacca ttttattttt 420tgggccatta ccccatac 438 311 440 DNA Homo sapien 311ctcagagctt caaagagcag gactagccta agaactgtct gtgatatttg accagaggtg 60cagcctagct gccattcttc ctcaccctgt ggaagacatt aaagggagaa tgaaagtagc 120tgtagaatta cctttggggg aagaagccac ttggtgaact tggcaaacac ccgtgtttga 180ggggtcaccc agggtgtcat gagctgggcc ggaggggatg gattgattac ttgtcttgtt 240tgcttgtttc tgttgtaagt cagggcccct cagcagaagg cagaacagaa ccgagttcct 300ttagaatgct ggtttttgtg tggagtgagg aaggaccgtg agtgtggtca gtttccaacc 360tgacaggacc tgctcccgtt ggccaggact gcagcttgtt actttgaccc tgggaagaag 420gtaagtgttc ccaagaaaag 440 312 268 DNA Homo sapien 312tgaaaacaca accataaatc atagttggtt tttctgtgac aatgatctag tacattattt 60cctccacagc aaacctacct ttccagaagg tggaaattgt atttgcaaca atcagggcaa 120aacccacact tgaaaagcat tttacaatat tatatctaag ttgcacagaa gaccccagtg 180atcactagga aatctaccac agtccagttt ttctaatcca agaaggtcca aacttcgggg 240aataatgtgt ccctcttctg ctgctgct 268 313 439 DNA Homo sapien 313ctgccccccg tttcccttcg tctataccac cctccacctc ggaagcgagg tcgcagtcgc 60ccactggaca gtttgaagga gaccgcagat ttgcacccgt ttcccatggg cccagacacg 120gcaggagttg cccaggccac tcctgcagac attggggcgt gggcgtgggg tccctgagcc 180aggccatccg ctgggcctcc cgtggggttc cctgtgacct gatcggaggt gcctttgcct 240cacaccagcc ccttggccaa ctgggaaggc cccgagtgca tttaatccca ctggctgtgc 300gctaacaggt gtgtccagtt tctgttctgt ggattttacc acgataaaaa aaaaattggg 360ggagaaaaag aatttttgta atatgacttt catacttaac acgtgttaca gattcgttta 420attccctcag tgatagaac 439 314 439 DNA Homo sapien 314agttgatgag cggcgtgtcc cctctgcagc gcgcaccccg gcggggcttt ggctgtgacg 60cggtcggggc gcggggctgg gctgtggccc cgcggcgccg cctcctccct ggtccctcga 120aatcgtggca tctcacttct gagaacgaaa tctcgcttca gtcactctgc cgaaggcgct 180gacggcatcg cggccggaac ctctgggccc ggcccctccc agggccgccg ctccgtggga 240aaaaacagct cctccatttc cttgaaaact gaacgattat taaaaataga ttaaacttcg 300ctggaaatga gtagccagga agttcagggg agggtgccgg gtccttcccg ggcctggcgt 360gtcggagcca cccaggtccc gcagctgccg ctgagaaaat gcaaatattt gttgtgacaa 420gaatcacata catttactt 439 315 437 DNA Homo sapien 315tcttgaagtc tggtgatgct gccattgttg atatggttcc tggcaagccc atgtgtgttg 60agagcttctc agactatcca cctttgggtc gctttgctgt tcgtgatatg agacagacag 120ttgcgtgggt gtcatcaaag cagtggacaa gaaggctgct ggagctggca aggtcaccaa 180gtctgcccag aaagctcaga aggctaaatg aatattatcc ctaatacctg ccaccccact 240cttaatcagt ggtggaagaa cggtctcaga actgtttgtt tcaattggcc atttaagttt 300agtagtaaaa gactggttaa tgataacaat gcatcgtaaa accttcagaa ggaaaggaga 360atgttttgtg gaccactttg gttttctttt ttgcgtgtgg cagttttaag ttattagttt 420ttaaaatcag tactttt 437 316 434 DNA Homo sapien misc_feature (1)...(434) n = A,T,C or G 316cccggacgca ccggcccagg cgcgcggggc cccgcggctg ctgttgctcg cagtcctgct 60ggcggcgcac ccagatgccc aggcggaggt gcgcttgtct gtacccccgt ggtggaggtg 120atcgaggaaa gtctgtcatt ctggactgca cccctacggg aacccacgac cattatatgc 180tggaatggtt ccttaccgac cgctcgggag ctcgcccccg cctagcctcg gctgagatgc 240agggctctga gcggtcggtc acaatgcacg acacccgggg ccgcagtccc ccataccagc 300tggactccca ngggcgcctg gtgctggctg angcccangt gggcgacnag cgagactacn 360tgtgcgtggt gagggcangg gcngcaggca ctgctgaggc cactgcncgg ctcaacgtgt 420ttgcaaagcc anan 434 317 435 DNA Homo sapien 317aaagggagta ttatgaccat ttcaacttga gagatcgaaa cttgagaggt ttgataatat 60cttggttaag atttttattt tgtatatgtg ggtgactggg tgggtgtggg tgtccacaga 120aggagaaaag ggtattagat tcccgagagc tggagttaca ggcagttgtg agccactcgg 180cattggtgtt gagaactgaa cataggccct ctggaagagc agcaagtact ctgagtgctg 240agcagtctct ccagaagctt attgggtagc ccaggctggc tcacggctcc tcctcagctt 300ctcctgtgtg cctccttttt ggttaataca actgaagaac ctttcaagtg tggggggaaa 360ttacagaaga aaagaaaaat taccacttct aacaaccact gtaccatcgt gattctattc 420ttagtgtctc tttat 435 318 436 DNA Homo sapien 318gtggagcctg atgccatcaa gcctgtggga atccgacgaa tggatgaaag acccatccac 60gctgagcccc agtatccggt ccgatctgca gccccacacc ctggagactt ggggacttca 120ttatgagggc cttaaagcgg ctgacaatga ccccacagct ccaccatatg actccctgtt 180agtgtttgac tatgaaggca gtggctccac tgctgggtcc ttgagctccc ttaattcctc 240aagtagtggt ggtgagcagg actatgatta cctgaacgac tgggggccac ggttcaagaa 300acttgctgac atgtatggtg gaggtgatga ctgaacttca gggtgaactt ggtttttgga 360caagtacaaa caatttcaac tgatattccc aaaaagcatt cagaagctag gctttaactt 420tgtagtctac tagcac 436 319 442 DNA Homo sapien misc_feature (1)...(442) n = A,T,C or G 319cgccgacccc gccactctca cccgacccgt gcacgacgct gcccgggagg gcttcctgga 60cacgctggtg gtgctgcacc gggccggggc gcggctggac gtgcgcnatg cctggggccg 120tctgccgtgg acctggctga ggagctgggc catcgcgatg tcgcacggta cctgcgcgcg 180gctgcggggg gcaccagagg cagtaaccat gcccgcatag atgccgcgga aggtccctca 240gacatccccg attgaaagaa ccagagaggc tctgagaaac ctccggaaac ttagatcatc 300agtcaccgaa ggtcctacag ggccacaant tggccccgcc acaacccacc ccgctttcgt 360agttttcatt tagaaaatag agcttttaaa aatgtcctgc cttttaacgt agatatatgc 420cttcccccac taccgtaaat gt 442 320 451 DNA Homo sapien misc_feature (1)...(451) n = A,T,C or G 320aaccggaaac ccggaaaccc ggnaaaccaa aagggggncc cccattgggg ggcccggaaa 60ttaatttccc gggggnaatt ccccggaaaa tttncaaagn aattaattta aaaccctnca 120aaaggccctt tgggtntnaa gnaagngggn cctttttttt ttaaaaaaaa attananana 180agggntttgt atntncccgt ggncaaaagn agnagncaag nttacntggc tggctttacc 240gttcagnaga cttacaggtg cttgcctgca ttgcaataaa ggactcattt attgagcaag 300acttatattt atctcttcat tttggagagc ctaataaact gttattacag tttctctact 360gactttcaaa agttttgaag tttgaaagac ctttgcaatt aaaacagcat gagcacggcc 420agaacagaga accctgttat aatgggtctg t 451 321 440 DNA Homo sapien 321aagtgtgatc cccatgaagc aacgtgctat gacgatggga agacctacca tgtaggagaa 60cagtggcaga aagaatatct cggagccatt tgctcctgca cgtgtttcgg aggcagcggg 120gctggcgtgt gacaactgcc gtagacctgg ggctgctgaa cccagtcccg atggcaccac 180cggccacacc tacaaccagt atacacagag atacaatcag agaacaaaca ctaacgtaaa 240ttgccccatt gagtgcttca tgccgctaga tgtgcaagct gacagagacg attctcgaga 300gtaatctttc cagccccacc ctacaagtgt ctctctacca aggtcaatcc acaccccagt 360gatgttagca gaccctccat ctttgagtgg tcctttcacc cttaagcctt ttgctctgga 420gccatgttct cagcttcagc 440 322 440 DNA Homo sapien misc_feature (1)...(440) n = A,T,C or G 322aatctcttga cccatggncg ngtccgcctg ctactgagta aggggcattc ctgttacaga 60ccaaggagaa ctggagaaag aaagagaaaa tcagttcgtg gttgcattgt ggatgcaaat 120ctgagcgttc tcaacttggt tattgtaaaa aaaggagaga aggatattcc tggactgact 180gatactacag tgcctcgccg cctgggcccc aaaagagcta gcagaatccg caaacttttc 240aatctctcta aagaagatga tgtccgccag tatgttgtaa gaaagccctt aaataaagaa 300ggtaagaaac ctaggaccaa agcacccaag attcagcgtc ttgttactcc acgtgtcctg 360cagcacaaac ggcggcgtat tgctctgaag aagcagcgta ccaagaaaaa taaagaagag 420gctgcagaat atgctaaact 440 323 373 DNA Homo sapien 323tctgtatact ttaaaggaga agcaaataga aataaagaga gagggtgata aaatctagat 60tcatagaatt gtggaaacct tacttcattt taagagtgaa gaacccagtc tgattaaagg 120aagttccgtg tttaaggcaa catgttgctt gtggcagatc tagactcaaa actgagattc 180ctgcctctgt ccagtgcttt tttcacttca ttacattacg agccatctta actccattca 240tgcaattctg gggtaagggg ttttgtcaga attccacctg accttcccta gagcagggtt 300tggacaggat gagagacccc aatctctcag atttgaggct tcttttcaag atatctgttt 360ttcccttttc ctt 373 324 439 DNA Homo sapien 324atacaaaaaa ctaggagcat actaggaact tgaaaaggaa gattgtaaga ttatagccat 60ctttggtagg atcttggaag ctgattgcat ttaagccttg taactactat gtaaatcaag 120tgtccaactt ggtaaactct gaggttggct ttgtttttta aagagcagat tataatagtt 180ttgtctggga aagtgattta aacggcctct tcgttaagcc aaacgtgtga tttagggtag 240agggaggctg ccaagcgcgt cgggtaagca ggggccccac gctcggcccc gcccaggtaa 300cgctgccttc cgggctttgt taactcgcgc gcgctgcgtc gccaactcag cggcgggcag 360ggggcggagc cgcagggcgg ggcggtgcgc gttgatgtga cgtccctgcg cgcgccgctt 420tctgttgccg ggcgcaatg 439 325 442 DNA Homo sapien 325ttttagaaag ggattagaat tttactctgc tagttacaag ttttaaagtc acgctacggc 60attatcaccc tggcaggtag gttttgttat tgttttacat tttgtgaaaa aaagttttgt 120agaagttaca gctagtggtc ttttccctcc agagccagtg atgagtgtgg gagcacttca 180gctctgtaag gggccagcgt tctgaccttt aaccacatga actaacctgc gtcagcagtt 240gcagaaagta gcctgttagg acagcagctg ctaagcgttg cctggtattt tagtggggag 300aaggctggga ctcttcatgg catcaacact tgcatgctct gaatctttga tcagagatga 360ggtgccattt ttggcatttc caccccgtct cgtggtagcc tttaaaagtg gagaagatgc 420tgccctaatt ccccgaggat ga 442 326 433 DNA Homo sapien 326cgacaggcca gagccccttg gggaggagcg gcggctggag gcgcgaggct cctccggatg 60cccggagagc cgcttgcgac ttaactcccg cctctttccc agatgccgcg tcactgctcc 120gccgccggct gctgcacacg ggacacgcgc gagacgcgca accgcggcat ctccttccac 180agacttccca agaaggacaa cccgaggcga ggcttgtggc tggccaactg ccagcggctg 240gaccccagcg gccagggcct gtgggacccg gcatccgagt acatctactt ctgctccaaa 300cactttgagg aggactgctt tgagctggtg ggaatcagtg gatatcacag gctaaaggag 360ggggcagtcc ccaccatatt tgagtctttc tccaagttgc gccggacaac caagaccaaa 420ggacacagtt acc 433 327 436 DNA Homo sapien 327cggctgctgg tcgtggaccc cgagacagat gaacacttca agcggcttcg ggtcacaccc 60accgaggagc acgtggaagg tcctctgccg tcacccgtca ccaatggaac cagccctgcc 120cagctcaatg gtggctctgc gtgctcgtcc cgaagtgacc tgcctggttc cgacaaggac 180actgaggatg gcagtgcctg gaagcaagat cccttccagg agagcggcct ccacctgagc 240cccacggcgg ccgaggccaa ggagaaggct cgagccatgc gagtcaacaa gcgcgcgcca 300cagatggact ggaacaggaa gcgtgaaatc ttcagcaact tctgagcccc ttcctgcctg 360tctcgggacc ctgggacccc tcccgcacgg accttgggcc tcagcctgcc ccgagctccc 420ccagcctcag tggact 436 328 440 DNA Homo sapien 328ggtaaacgta ggaggcgtag agctccaggt tgatctggcg gttgatggcg gcctctgagt 60cctggtggta gttctggcgc acctgcgagg tggacgcggt cgtcatggcg gcgactaagg 120agaggcggcg gcggcggcgg tggctgcgcg gcgctggagc ggcggcgggg gccttggggc 180tttgaagaac tttgccaaat actttcttca ccaatctcat gaggagaggg aacatgctga 240gaaactgatg aagctgcaga accaacgagg tggccgaatc ttccttcagg atatcaagaa 300accagactgt gatgactggg agagcgggct gaatgcaatg gagtgtgcat tacatttgga 360aaaaaatgtg aatcagtcac tactggaact gcacaaactg gccactgaca aaaatgaccc 420ccatttgtgt gacttcattg 440 329 438 DNA Homo sapien 329cgcgacgctg ctgcgcacag attccccaaa ggcacatgtg acccatcacc ccagatctaa 60aggtgaagtc accctgaggt gctgggccct gggcttctac cctgctgaca tcaccctgac 120ctggcagttg aatggggagg agctgaccca ggacatggag cttgtggaga ccaggcctgc 180aggggatgga accttccaga agtgggcatc tgtggtggtg cctcttggga aggagcagaa 240ttacacatgc cgtgtgtacc atgaggggct gcctgagccc ctcaccctga gatgggagcc 300tcctccgtcc actgactctt acatggtgat cgttgctgtt ctgggtgtcc ttggagctat 360ggccatcatt ggagctgtgg tggcttttgt gatgaagaga aggagaaaca caggtggaaa 420aggaggggac tatgctct 438 330 443 DNA Homo sapien misc_feature (1)...(443) n = A,T,C or G 330tgttccaact aactcagcac aacagggcca taacagtcct gacagccccg tcaccagtgc 60cgccaagggc atcccaggct ttggcaatac tggcaacatc agtggtgccc ctgtgaccta 120cccgtctgcc ggagcccaag gagtcaacaa cacagcttca gggaataaca gccgagaagg 180gactgggggc agcaacggga aaagagagag atatactgag aaccggggca gcagccgtca 240cagtcacgga gagactggca atcggcatag cgatagncca cgtcacggag atggtggtcg 300ccatggagat ggataccgcc atccagaaag cagcagccgt nntactgatg gncatcggcn 360cggggagaac agacatggag gaagcgcagg ccggcatggg gagaaccggg gtgcaaatga 420tggtcggaat ggggaaagca gga 443 331 176 DNA Homo sapien 331gctggtggga aaaaaagcag aggccgcagc ctcagcccta gctgatgctg atgcagacct 60ggaggaacgg cttaagaacc tgcggaggga ctgagtgccc ctgccactcc gagataacca 120gtggatgccc aggatctttt accacaaccc ctctgtaata aaagagattt gacact 176 332 437 DNA Homo sapien 332tcctgatgtt acgcatgatc atggagggcc agtaccagtt cagttccccc gagtgggatg 60accgttccag cactgtcaaa gacctgatct ccaggctgct gcaggtggat cctgaggcac 120gcctgacagc tgagcaggcc ctacagcacc ccttctttga gcgttgtgaa ggcagccaac 180cctggaacct caccccccgc cagcggttcc gggtggcagt gtggacagtg ctggctgctg 240gacgagtggc cctaagcacc catcgtgtac ggccactgac caagaatgca ctgttgaggg 300acccttatgc gctgcggtca gtgcggcacc tcatcgacaa ctgtgccttc cggctctacg 360ggcactgggt aaagaaaggg gagcagcaga accgggcggc tctctttcag caccggcccc 420ctgggccttt tcccatc 437 333 440 DNA Homo sapien 333tacaattaca aagaaacaaa caaacaaaat ttgaccaacc caggcggtta aatttaaact 60cttcaggaaa aatttaagct gttaaaatta ttctttttct aaatttctaa agtggaggga 120cagaattttt cagatttaaa agggcctcct aggtgcccag aaaattagtg gaaagaacca 180cgtctagacg catctttgat gtgtcagagt tccaaggata aaaagaaact tttaaagtct 240tctatactca gccaggttat caatcaaata tgagggcaaa ataatatttt cagacagatt 300ttaggcagtt tatcttccat atatcctttt ctttaagggt atttgtagat acactccaga 360aaaacaagag tgaaatatga aggaagttgt ggggtccagc aaacagtgct tccaaatcag 420acccctgata gaggtggaaa 440 334 439 DNA Homo sapien 334attcgtgcac aattcattaa atgaacgtct caaaaattaa aaaaattata agatacgtat 60ttctttaggc ctttgtgttt ttaaattaaa accaacaaaa agaagtctcc ctctccactc 120cacccagcag caagggcagc cggaacgctt cgctccagct acctggcctc ccgcaagagg 180gttcccccat gagaccgtta gtctctcttt gcctggctga ctacctgcat acagtaggca 240ctcactgctg gagtgaggca ctgactcctc caaagattgc agggggcgga ggagggaacc 300acgaaggcct gggagggggc atctttggcc cccactaacc atctccctat ttctgcatcc 360tggtgaccgt cagcaagaga tgagtcgggg agaccctctc ctggagttct agcccctaat 420tctgggcttt ctatatgag 439

Claims

1. A method for determining the presence or absence of a cancer in a patient, comprising the steps of:(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide sequence selected from the group consisting of: (i) a polynucleotide recited in SEQ ID NO:87; and (ii) complement of the foregoing polynucleotide; (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and (c) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

2. A method according to claim 1, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.

3. A method according to claim 1, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.